var title_f31_18_32032="DHR assay";
var content_f31_18_32032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Flow cytometric measurement of neutrophil respiratory burst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Neutrophils stimulated with phorbol ester stimulation generate reactive oxygen radicals that cause oxidation of the fluorescent dye DHR123. Defective oxidation is observed in individuals with CGD. Bimodal expression pattern of DHR123 oxidation indicates carrier status.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32032=[""].join("\n");
var outline_f31_18_32032=null;
var title_f31_18_32033="Bimalleolar fracture";
var content_f31_18_32033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bimalleolar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 471px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHXAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5zpaaaUVIDhSjrTacKAJ4+tWU6CqaGrUZpDPSPhy+Yyvoa9St/wDU/QV5D8OJcXDr7167bE+UPeqQMrz/AHunSqx4yB1NWrghMnqelVSfm96Qh2MY9R2pyjpimZDEilThuTQMsw/eGKvQnkexqijAEGrcDAc+9MLlu8AaA/SvH/Fcfl6m5x1r2CY7oG9a8o8bx7b1W9qmQI5WQ81LpL7NSiOepxVeQ/Nikt32XcTZ6MKhFHpGpDdpDfga5WDicDHeurnPmaO5H90GuSjGLkHP41TEdRb82xBrzXxcuy/r0azkzB+FefeNRi7U+tJjOYamZpWPNMJqhCmmn3pCaCaAFzQKbnigGgQ8VIh5qEHmpEPNA0et+DB/xJYPxrpU6Vzfg/8A5Atv9K6OOkgZYUVIKjTrUgphcXp1xTSKcR6UxuKAKc44YivEdaOdTuT/ALZ/nXt1yfkb6V4bqrZv5z/tn+dAFMnmimk0ZoAeppwNRqaeKAJkPNe5/CI/8SVPqa8JQ817j8Im/wCJKn+8aS3BnpN0R5YrHmPz+2c1qXLBkwfSsecjfg/nWgiMnbkEVJGcoMVXkJzxmnRvjHakBbjb5hVyM8ms+M5bir0XvTEWLgfuCe2K858UDFwDXo0pzAa878W8SqR60MaMDtSdFpueMZpC3FQMXPNejeFONPj/AN2vNAa9I8KN/oEXP8NNbktl2flD9aLLqB702Q5VqdYjLLViKev8Qse+K8Q1Q/6XMf8AaNe2+Iz+5cjsDXh2pNm6lP8AtGlLYpGfMetUJjyauTE4qjKeTUDK7Gih6KZJBmlBptAPFMB4NOBpgpwpASJ1qzGaqpU8ZpDR2nw+k26ntz1Fe02J/civCfBEmzWIvevctOOYFOaaBkd3yTVViMHmp7kkyNnpUBX5ST3xQIM469TQGOR+lI231+gpB1PegC0hOcVci68VRTjmrUDYIznNAGmOYiPWvNPH0eGRvfFelRHKH0rgPiEn+ilvRqJDPOnPJNV2bDg+9TSHg1Vc81mUeqaa3n6Qecgx/wBK5eQFJfqcVv8AhGTztITP93BrDvQVnI9Cap7CNfT2Bhzn1rivHKkSIfeus05sAKDXMeOBmNW9GoA4pzTCaVqYTTEGaQmgmmnrQA7NGabRQA8GpY+oqEVJGfmFAHr/AIQ/5Alv9K6SPtmub8I8aLbf7tdGnbFCAsIRTxUS/nUo6UAKDTGORTqa3WmBRuziKT6GvC9RObyY+rGvcL84glP+ya8LvTm5kP8AtGkMgJozSUlMQ8Gng1EDT80gJUPNe2/CFv8AiTL/ALxrxBTzXtXwj/5A45/iNHUGej3LHjisudsyH0xird05AIzway5XO8g8gjrVCFZto96EcnrUBPGTkDoPenIQB1+lAF6JueKuxOS3Y1mQH5ueauREBgR0zTA02bMGe9efeMOMfWu+HMRxXBeMRhCfehgcxnimE8YpgPHXmjNQMdnFeieE3zYx/SvOCc16D4RP+hxj2poTNYg/P6Utj/rsDoKV8rupLMFXH1qxGd4mb/R5Poa8OvzmeT03Gva/FjFbSQ98GvELtv3jfU0pFIpTtwaoyGrU54qnIagCNjRSNRTEQUUUd6YDgaUGminUgHqeamjNQCpYzQB0XhOTZrVt7nFe86Uf3INfPnh99mq2xz/GK+gdGO62X6UIbEuPvnjvzVZ2wTVu5JLMCOe1Us/eJ+lAhGGcYODQuR9KaegoJPDCgCzGfxNWoT1qjEev+c1bibOQB2oA1bZ/1rjvH6btPlOOnNdXasMj1rB8aR79Pm6/dND2A8ekPWqr9anl4Jqsx5rMo9B8ATbtOZP7rGq2sALeOAONxqD4dTfPcxH2NW/Eihb1zj3qnsHUjsHwaw/GfzWpPoa07OTBx9BWb4sG6yekBwjmmGlamHrViCmmikJ5oELmlpuaM0APzUkZ+YVCDUsf3hQM9j8Jf8ga2/3a6GPoK5/wp/yBrb/droE7UkBOhqUevrUS1IDQAtMc8U48cVGx4OKAM3Uj/oc5/wBg/wAq8LuT+/f6mvcNXOLC5PpGf5V4ZOcyt9aAI6KTNGaYhwNOFRg04UgJVPNe0/CbjSVHua8VTrXtHwsO3SVoGd1eybcD8azpTh89eKt3B3gBu561nSOPMI71QgMmeTyR0pUbjnr6VC7Y5BANKsmBuPJpAaFs/tV+E59Ky4HyQAa0bdgep5piNGM/IQD2rh/GY/ct9a7WE/KSea43xmP9Hc0xo4rd703dxTN2MimhvesxkpNd/wCEm/0SMe1ee13fhJv9GjHtTW5LOmm6tmm25y9LMwyw9qZAQCvXk1oBi+MmxZSn/ZNeH3LZZj717V43bGnS/wC6a8RuG5NKQ0VJTyaqv+tTymq7mpGRmikY0UCI6TNLSGmAoNOpgpwoAeOakQ81EKep5pAamlNtvoD6OK+hNCb/AERSPQV862TYuIj/ALQr6H8NMG0+Pn+EfyoQ2PvGJkY9AKgIOMD8TVi7/wBa/HGaqqT8zHPPFIkbuHUflTc4JApMY6Gkzz2zQMsREFhjr6Vbib5lwPyqlGc81YiOFyP50wNO3I3gVn+Jo99jL/ukVbhPTaabrQ32jj1FDA8IuvlkcehIqmTxV3VRsu5l7hjVAmsykdL4Bl26w6E8MldH4pAEwOOorj/BkmzxDAOm4EfpXZ+KR8qP7YqugMwLdsEVW8RANZP9KfETkAVHq53WZ+lSBwDZyaYakl4dh71EaskQ0lBpKoBaWm0tIBRUsfUVDUsX3hQB7P4WH/EmtuP4BW9GawvDA/4lFr/uCt2M4GKkCdak7YqNaeOfWmAueOlRt0qQ1E54xQBja6caZdH/AKZn+VeHzffP1r23xEcaNdn/AKZmvEZT8xoGMpKM80maYhwpwpmacOlAEida9p+GXy6TGa8UHUV7X8PPk0iP0wKQHT38hBB9ziqjuHIfPzd6l1FsuoxweaoK+CxXOOtMCWRgQM8Gnq4IAqryxB9akU7iPT1oA0LZuB65rTtjyvrWRbuDjHWtK2JKrmhCNiLhTjFcd4y5tJPpXW25wpzzXKeMP+PWXiqGjz0NSBuaaTSKfmrMCXdzXb+EX/cJ61wZPeu18HMTCvNNCZ2MwO7Oe1MhYZx1p8vQHHao4yNwrQRzvjo40yU+qmvE5zya9n+IJxpcv+7Xis55qZFLYrSGq7GpZD1qF+lICMmikNFMBKQ0tJQAUo6UlKKAHCpFqMU9TSYFu3OJFPvX0L4SbdpkJ/2RXzvAfmH1r6D8Etu0mE8fcFA+ho3QzK3PAHSqTkbgSTg1bvcCV2Bz64qi3BzyfrSJEYgZ9TTBgEZ6Uq/Mf5U0gBRnmgZYjB3DI4qxEw59KrR46Z4HQVOnJAPHFAFyFscHpU96N9sR7VX3bQpA+tWHbfbtkUwPC/EaeXqtwv8AtGshjXQeNI/L1ybjGea55zzUFI0PDMnl69aHP8eK9C8Uj/RYyPWvM9IfZqtq3pIP516d4m505D70xM5CNgrd6bqR/wBFIqIsd1Ovjm0/A1IHD3PErfWoSanu+JmquetaIQhpKDSUwFooooAUVLD94VCKli+8KQHtfhsY0i1/3BW2nSsXw5xpVrz/AACtuOpGTLnFPBpicU/mmIKY5+U08+1RS/cOKAMDxQduhXh/2DXicn3q9n8WtjQLw5/grxdz8xoQDTRSUZqgFHWnCmCnCkBInUV7d4HXbo8ePQV4lFy6j3r2zwn+70uLIxxSA2NRc7QQewrNWQBiQeCasX0qscgnJ6+lZqMMsud3P5UAWyQD3IFTxkYGapFwVXK/N35qcNwCfTpQBpxABhzmtO1JyD2xWPbE8E//AKq1rQ+p9/pTQjUhYha5jxf/AMesufSulgPyciua8X/8esv0pjR5sWpqtUbNyaUHioAkY12fgs5hHPeuIY8V2fgo4jH1poTO5kJ2r34qGI5Ycc5qSVvyxVWBv3o9M1YjnviIf+JVJ/u14tMck17L8SGA0uQ14vKetKRSIHNQvT396iakA09aKQ9aKYBSUGigAoBpKUdaAHCnr1pgp4pATxHBFfQHgVj/AGLCf9gV8/RdRXvvw/O7QoP9wUD6GvMhLE5HJzVJuCMjpwK0L3CcLgN/Ss6Q/OBg570hDY+Qf85pAOcj7p5pQOvYd6UDkc8CgCVTg9f0qVDnocVCmMHGeanHPA4AoAnJygqxbnKMvPPSq5J2kDpipbcnIBPJ4oA8o+I8Xl6wrY+8lce1eg/FOEie1lx2K1561IaHWbbb2A+jj+der6+N2ig+wrySI4uI/ZhXruqDd4fDDsgNAHAyEqaW7ObQ5ps5+b6mkmO60I71Izkr3iU1VNW78YlqmTWiJEIpKcab3pgFKKSlFABUsP3xUQqaD74+tID2zw9xpdt/1zFbSDgVj+H1/wCJZbZ/uCtmOpGSrzUnP40xKeB60xCe/NRS/dNTEYqGbG0mgDmPGZx4eu/oP514y/WvYvHBx4duffH868dfvQgGUUUVQBTxTKeKAJrYZnjH+0K9s8PqfsES+1eLWAzdxf7wr2jR38q0iOP4eKnqBNdFVbD9Ae1Z0Z2ynrjOKvXkg2K3GT1+tZ6sAG5Lc457UDLGTnJBI/WrUDAHJGBiqEZAIPJNWozlwSTj0oA1oTjr161pWxJwe2KybcbvbjOa07bsATTQjZgb9wR2rmvF3/HlKfaujgOIR6Vzvi3myk9QKYI8sc8mlUgio3PJpUPFQMeeTXbeDOIVPvXD55ruvBwxCg9aaEzspztQZPaqUL4lWrV190e3FZyP/pAHQc1YjD+JhxpLH1rxmXrXsfxN/wCQNke1eNyGkyuhA9QnvUjGozSENoo70UwENJTjSGgBKKKKAHCnrUYp4oAniPNe9/Dk/wDEjtyemwV4HH1r3n4bkDQISem2kPobd8wM5YdqpM2fmJ5NWLwlpWJ6HoBULx55xxnikIaeAQeppQM8e1GCSAMf1pwAYdOgoAE53CplyqjqeKhQjd82fap1XAyOnagCVifLGM5Ip0JIK56VGCdmfQ0KSpHcdeaAOX+J9uX0xJB/A9eVSV7X42t/tGhXA4ztyPwrxSXrSGiEHEin3Fev3A3+GlOesY/lXj54bNeuq27wohP/ADyFMGcHc/6wjPSmSEGFgD2p9wP3pqN8bTUDOa1EYkqia0dTHzVmmtEJiUhp1N70xBS0lLQAVNB99frUXWprf/WL9aTA9v0MY062H+wP5VroOKytEGNPt/8AcH8q1oxUgSr0FP8A5U1f5U7NMBGNQzfdNTt/OoJvuGgDkvHpx4dn+o/nXj79a9c+IRA8Pye7D+deSN1poBlJS96KYAOtOFN604UAXdJXdqEI/wBqvX7ZxHawK2cY615JoK51SEe9eqSFsKnHAFQ9xkt3JiHDdjkGqSyjacD5m7k1JO+UAPbiqqgsQSelDAt274fafu1eB3KOTnHWqEQ+Y4C9O3arkbnPbHrTEa9u3HvjFaNuMYI4xWVa5wM961Ic5HPYUwNi2IK4JxxWF4qXNhL9K27YkHnHSsfxWu3T5cf3TTEjyBz8xHvTl4FMc/OR708YxUFCjtXoXhBcQpmvPV+8BXpPhRMQJ6YFNCZv3uNh71lqwE2cjOK1L37hyOKxs/vuRViMj4ktnQj68V47LXr3xDO7Qz9BXkEnekyuhA3WozUjVGaQhKKSimAGkPWlJpDQAlFLSUAKKcKaKetAEsfWvefhuf8AinYu/wAteDR9a93+HGf+Ebjx/dpD6GzL8zE8+uajJBVBng/zp0hKvgnimR+noaQhNuWHp606Pcd2fXrSKBuZfxpyqQDjOOlAAQT0AzmpAPl55pCvB44qVBlcmgBJDtQ4784pin7o5IxSycr7Y4pEByuOmKAJNUj8/TnUjIKkV4PfRGG5ljPVWIr33BeB1xjFeK+L4PI1u5GOGOaQ0c+3WvXbP5vB8ZP/ADyFeRPXr2kAP4NiyePKoBnC3OFmIqEg4+tWbwYmPHQ1HgYJFSM5zVVwTWWRW1rC4zWMatCYw0hp3ekxVCG0tGKXFAAKmt/9Yv1qECp7cYlT6ikB7jowAsLf02D+VaydKy9I/wCPGAf7A/lWpH0FSMlX9KeDTBTu1AgbFQT8qcVMfpUM/K89aAOK+IzY0E+7ivJ2r1X4lN/xJVHrIK8qbrTQxppKU0lUIUcUoNIKUUAbXhZN+rw+1ejXMoEoUj615/4NXdqyn0FdxM26XJ6GoYyZnJicHp1GarqAFGOmcGn5/dfN+VJEF6IDyOaQFiLlmI61cgB6HsKpRKdx5B9OavQPk7ufemI07Z2CqMVqQH5VxWRESvLEg9q1rbk8HODyKYGvb/eyRx2NZ3idN2nSf7prQt+uB3NQeII86fIPY1SBHiEnErD3p2elFwMTuD60i9fYVAyaJcyqPcV6f4aTFug9q81s13XEY969R0NdtuuB2oiJl28P7psfTmsVifPyT61r3mdpGeKyJRtcntzViMbx5zop9CK8hlHWvXvG2G0nGe1eRTDBNDK6FZqYakbpUZoEIKKKKAEpDS0lACUv0pMUtAAKetMFPFAE0fWvd/hzx4ajz/drwiLrXvHgABfC0Wf7opD6GrOGLc9PUUiDnPc9acCXLLgDmmqrKOmD61IgC5OQePWnAFWwB+dKq/LnBOeKkCjafmJOe1ADYwc4PQ1IwwpwTj37UqKAeecGlcYAx3pgQnBTA/OgAquOenWgrhBnsabvAI3dDnpSAmt3JchjnIrzD4i2+zUFlA+9xXpKkLIPQmuR+ItrvtfMA5BoBHlz9K9d8N4fwZEO/l15E9eu+Efm8IRj/YNAzi7/AP4+G571GgPKk1NqAJunA9aiAyOPSpAxtbTg/SufNdRrafuc1zJFVEGRmkNONJVCG0lKetGKYAKntv8AWr9agFT2v+tT6ikwPc9K4soR/sj+VaaVmaZ/x6wj/ZH8q00wDx0qQJlzThTBTxQAHpVa44SrB71WuRx70AcJ8S2/4lUS+sleYNXpfxNb/QIF/wBs15metUhidqSlpKYhaWkFKKAOm8FL/pbvjoK6qRtrlckHrx2rmvB42Qyye9dHA3mO5ftWb3GWcExJnOCOvvTolC4IPNJMARHgnAAFSouHGP5UwJUID4J/SrUL4GM4qpGAWOfXHNXIwoOM8nigRfhOdv1xWvaEqT055rKtxwg+vIrUtM9R0NMDYtOnToadq6b7F8dMGo7N+ATnirl8u+0kxyMVSEeCX4xeTD/aNRoKt60mzUbgejmqyDgVD3KL2kruvYx2zXqWjqRD6cV5poSbr9DXqGlgrCKaExLtflY81jyKWI9jW7dAFDj1rHflqoDB8ZDOnYHpXkc/3zXrnisf6Cwz615Jdf6xvrSY+hVaozT2plAhBRRiimAlJTu1JQAhpKdSUAAp60wdaetAE8X3hXvfgweX4WtwR1UZrwSH7wr37Q/3Phq1HT5Aalj6FyPG7pnnNPLcLjg9RUcABY4PJHOfrUi/NjP8IxgUhE8a5Y9QOuBSooGTjg0qfdBHA71Ki7RgEHI4NMBoj5wSeRQ6kJ0B4qRc56dOpNG0Hp/OgCmwIPoBzURUheTyOasOvytwDUf8DNyD0pANyMEntWT4nh+0aY4IBOK1WGQc88VUuVEtvJGepXigDw+4QpKykdDivVfBZP8AwiagnoprznxBbmDUJF9TmvRfBX/IqjPYGgfQ5nUlxOx5zmq6g49eKu6qn7/I6VVjXJzngVIGdrKH7NnFcm3U12usKDatjt61xbD5jVIBhpppxpKoQ00lKaSmAtT2n+vT/eFQCrFn/wAfEf1FJge5abxbRf7orSjrN07/AFEY/wBkVpJUgSr708dKaM5pw/GgBDnFV7jpVhqr3HQUAeefE8/6PbD/AGjXm7V6H8UD8tqPrXnbVSATFJRRTAWlFJSigDsPDYEWn7j/ABHpW9ABk+pXNYlgmywgQDk81tWx2nccYAxWYy2xwhXoRz0qWNvmHJyBUTgl+SQM1JDlUUnPHfrQBLHySdxPc59auW44JPWqy/OM5AHoKtQK23nHpj8aYjRhIJAAAA55rTtclQOD71nQjDjPYelaMI+XgAdhTA0LT72M4BNauN8DccFaybbAbjnmte2G5CAeCDTQjxHxTH5erzj1NZyD5BW745iMWuyLjqM1hqPlAqXuUbHhld1+or06wGIiPavNPCYzqigehr060GFANOJLGX3AOM4rKTkmta/YBjWZEuSM9cGqAwPFa/6C3SvILwYmf617J4rXNmfpXjl7/r3+tJlFNutMNPbrTDQISilopgJTSKU9aKAEooooAO9PWmCnrQBatF3Txr6sBXvUQEekW0fQBBXhmjJ5mpWy+sg/nXudywESRj7yoMCpY+hPayHerAcEdatRjJIIHFVrVSQMZ4q4i7T70hFlQAoyMg8HNTKBhhnBx6UyDmNBg/jViMEqTjjvTAjIGRnp3pFUgHtkcVK2MZxQ+Wx1z3oEUWXpzkc9KjOdm0gZ7GrUq4xxxiqzjJ56Z9aBkbDch3fL6EVnMxDD16Vok8ANnvWZdnEnsQDSA888c2vl3IkA7811fg3H/CLkfhWf4uh+02bN1Iq/4LBXw4Q1A+hjamAZj7VTiXGeO2K1NTjzM49aoxDkjvUgVdSjLWTmuElGHYe9eiXQ32kg9q89uhidx71UQITTTmnGkNUIZSUppDTAUdatWX/HzH/vCqoqzY/8fUX+8KTA9ysMCGMd9orQTFULIZhTtwKvp06VIEynjFPFMXin55oAQ1WnNWWqtcdRQB5n8UG/e2o9jXANXdfFA/6ZbDP8J/nXCE81SASiiimAop8S7nUepplWtOTzLyJcdWFAHYxceUgB+VRWlEvysrDGR1qhDnzjx3wM1s24BYZXr3FZjFdenz81NCvJUHJweahcdxnr2FWLZWDksMY9aAJoUJTPy9c1ctwNp6YzjNRRoBEAB19KnhGFA9TzTEXrcEtnPHetG3bcowCee9UYQCQPpmtG1wIxk+tNAWrYcZPBra0xsnB7GsaBieCx45xWrp4+ccnPWmI80+KFt5Wsxvj7ykfrXIpgrXonxegImtHA4Of6V55GMLmk9yjc8Gru1pB2wa9PhADDPpXnPgiM/wBqF8cAYr0iJcsQewpxJZT1EZHfNUYF/eMO2OlaF+AScfSqFvnzWJPWmBi+Kl/0Nvp0rxq+/wCPiT617R4rX/QmOfWvF7//AI+JPqaGV0KTetM/CntTKQgNFFFMBpo+lFJQAtJiiigBcUoFIKctAG94Oh87X7RewbJr1sy+bMzA5PIrzP4foP7WeY9I4ya9C05wZH9vXvUMZvWPGAw3Aj1q+yjGOB34qlbgeWpxwev0q9GdyqQM49aBFq3yYgRngd6sxLjdxxjjmo7ZSq7R0znNWohtUE/eGelMBgViu0kDHI4pqrwDnv8AnU+wHB74pu0gYwcUCKMyYU4bGOMVUC/NhunrWjJFjIYdT1qoqDfg9MnkUAVnTEJx2znNY2ocSYx6dDW83KOBzxWFfZ88D6UDMfVIy0RGOD2rS0m2+y6OF7N2FUNWbayg5xXT2kAbSojjIwMUgOP1WPExPqM1lR5EhHBroNdjxOxPp0rBOBJ+NIYrRboXJ/iHSvPNSTZeSj3r0dOQR2rgfEEezUZPfmmgMo00080w1QhpptONIaYAKt6d/wAfUX+8Kpirumf8fkP+8P50gPcbIfuk+lX09qpWY/dp9KvJ0qQJR2zTx6U1fand896YCHpVW56irRqrcfeoA8r+JrZ1KEeif1riDXZfEps6ug9EFca31poGNpRRRTAUc1reHYt+oK3ZOayhXQ+G02RSykc9BSewG9EPnBPrWpEGU7gOF5NZNp+8fDdB61rJnJC5wM/yqBkq53nPTO4VdgOWcnOffpVCPGAFPQYzWjDvBdj0GM/WmItxZCHkc+1SIuSMgMT07U1YQUCs3LYqeFV8tMH8xTAtwDA469PwrVhT5N3GBVCIDLAD+L061oIAsXA4B9KYE0AwzdD9a0bA/vlG3oao269WPBq/pxBuFB65NAjnvi5GDp9q2OQ1eVR88V7L8VId+gKwHKtmvHIvvUSK6HWeBIybtq9DgUGRj2zXD+AYtsk0h78Cu+t0JT6miJJmX6/OcVVtVGDmr96MNxxwap2q/MxOOAKYGJ4uULYnHoa8Rvv+PiT6mvcfFq5sW+leHX3+vk/3jQylsUmpppzU00hCUUUUANoxQaKYCUUGigBR1p69aYOtSJSA7LwYohsrqY8GRhGDXcaTESFHXnrXF6Mvl6fbRd2O812+i/cQ7icnJFT1GdFaKRGu7kL2I61pW6cEgDHTiqdowUAHOTWjAhDcnIwMY5xQInhUsuSe2cetXYgwfIwOOgFRQg7SD1B6VcjT5RlufQUwIwCc8YGfSm+XkDngHmrbICwHQkcVGy7TgDigCi6jHXnpVFgBxzxmtZ1B7cg81UZTuIK0CM9kyxP8q53UhslYkEf0rqnjOCRxmsDWYcJJjrQBz+qfMgOCSOOa7XTI86TEo/ujj8K4y5UyIBnJJArudHwLdYz/AAgYpDOS8URGO5rk2JEhHvXfeK4N0jnH3elcLcYDEj9aTAfEcR9Otcb4sj23oYdxXZxj92D+Nc14yj+WJ8e1CGck1MNPamNViGmmmnGkNMAFXNK/4/Yf98VSq9pI/wBPgH+2P50gPc7T/Vr9KvJiqNqPkXntV5MVIEq9KcKRRxTvpQA0mqlwfmq4eao3H36YHkvxGbdrh9kFcia6n4gtnX5B6AVyxNNAJQKKWmA5Rmup05BHYxp3bmucs4jJMqgd66uBMBOPlFTIaL1iMkevateDcGOSCpJzVC1iK7D/AAmtS3jJwRx3x+NSAi/KQAMAjv61oW4QqxYkj1WqxUmZl28DgZq9CgCEbVwCDTQFtI/lGHUge1WI1Ab5euKhXaBkHAHX3q3GoDA9T7UxFq3QZySMc1oRodgB5HXr15qlCnHI7Gr0QKr60AWY1OWx9cVZ04Hzwx6VEinyxwPrVmyXbISO/amIZ8QIRN4fdfXB4rwwYDkdwcV9A+II1m0vYwGCK8Hv7cwX80ZHRqHsPodv4Ji22wc8ljmu7VCscfHvXI+B4z9iiLDntXbEHaM9cUIRjagn745JwB2qrbLkyHGOgq9fKWkYg9aqjbHGzNwB1JPAqgMHxfgae2O+eK8Ivj/pEn+8a958XLmwbFeD6gMXUv8AvGkxrYpN1php7Uw0gEooopgIabTyKQigBtLRR3oABVi2QySog5JOKgFamioPtHmN91eRSYHUWpAmVMHA/pXceH4+3AA71wemtvcHGWY+legaFgQAgdecmoQzobdSFYDqCOfxzWpagJg8c9eOtZ1qPkIwOecitK0HyqOc57UxGjEvHqT6dqsogPBBzjNRQoewIzVqP5Rk0wFEZyDn8aVlABJ7VJgYGR3oK5BxwaBFMrkkZH+NUXjw5GeP51rOoyM9O9UJF+dj09qAKLpxj+H61j6zDgkf3hmuglRfMXOcHtVDXbf/AEdXBxjigZwxyLoZPGeK7XTuFUrkkr+dchgfbMZ4BrsdPOQozg9aQFLWv3jujDvwa4HUbXypWxyMmu21K4BmkXqQayLy3Se3dtoye1AHMQg/dxntWT4uiL6dvxyjc1tfNFOVxketVdTTz7C6jPORkUhnmrCozUjjDEUw1YhhpDSmkNMBKv6P/wAhCD/fH86od60dFH/Ext/98fzpMD3G1+6v0q8nSqNvwq1eTrUgSr0xzTh096atO6DNADW/SqNyfnq8ao3J/eHFAHjnjpt3iC49sCubPWt/xod3iC6/3sVgGqQCUtFPjXcwFMDW0ODdI0hHCiuktYyzAAZY1b8E+D9Z16xuTolhJdm2CyTLGRuUNnGATk9DwKnWyuLC4e3vIJbe4H3o5UKMv1B5qGMngjBlRfTtWiNq8oOlZ0OfNUY5xzWnCoKsG4xzmkgG/ebg5zyTirkP+rHB65zVeMADBxk9quWuWABHB/SmItKPl4weauwqPMAAOD3qpEmRgHGK0IF3FcjBHemBZiU4C4z3rQVQBjAx161UhJAGBV+FRt2n7wPQ0xE0a/JyoqeHCEMAMZqLb8h6k09OV9DmmBe1AF9P6en4V5F4sstt80yjG7rXsUpzZNn+6D+tcDr1oJ9645OaBot+CUP2OLINdhKBtJ64Fc/4Sg8i0RSDmuilXK4HTpQhGRdoMkk8msbWVxoeonOf9Gk/9ANbl1wT6DNZGtgDQNRJ4zbSEf8AfJrWl/Ej6ozqfA/QyfFQxpwyeua8J1MYvJh/tGvefFgH2Ee3avCNWH+nzf71ZM2WxnNTT1pzUw0hCUUUUAHtSHpSmk/CmAhoH0oNKKAFUZNatqdqqi8DOazoRk1p2iEnPpUsaOi0hQzqAQK77SCMBc5CjFcBo52yDPftXcaMxYjk9qlAzqrEkL+eK2rTJVO4H61jWAyoGSRntW/YQEN39hVIReiBABP51aRSPkxkGiOBh05zUoifqAaBCMMseTgU/bwSBx6UpU5AIpwQ4ytMCFlzk4FUJ0yxPfFapiwhNUZ425IBNIDPmTnP6U2WIT2MqdWxmppY2KnFPtY2BZPUGmB5pfL5V2DjHzV1di220d+4Fc/r9tIbyQqBgNW/pkLPYlepZBSGZFzGGLv3JzUEZUpyeSOlbN7a+VERtG4/pWIxEWSBj60Ac7qhEN4F6EjvVKXYspUnhxin+JWCXIdzk4/KsK4kadCY94VR29akZyWpReTeSp78VTPFauqW0oUXDg7W9azovK8wefv2d9mM1pFc1kKTsrkJpp966nTv7O4+zbPM/wBr736/0rDvFtTdzHzZR87cCMEdf96u6tgXSpxmpp37P9TkpYtVJuLi1YpCtHRP+Qlb/wC+P51VCW3/AD2m/wC/Q/8AiquaGB/atvg5HmDr9a45Qcd/zOqMkz3C3HA5q4owKp2/3R61cTtmshkopaRevtTgCc0AMfpVGfG48VeeqM3LHmgDxTxa27Xrw/7ZrFNa3ic7tbuz/wBNDWTVIDR0XULbT5ZHu9HsNUV1ACXbzqE9x5UiHP1JrpNK1vS7m5Vf+EK8PqOpImv+P/JmuLUV0nh6DZA0pHL8A0Nge+/Bf4i+H/Dya42pada6SJRD5S2Qnkafbv4PmSPjG7j7o5PXin+O/i9beIYGtbTw9aNB0Wa/QSyL7qBwp/E143Eg3AelTBWBIXrU3ewy8r7mQ45B7Voh8hyB26VQtI2ODjB9a1rW3yGPU+hpICJPvAnitC1znAwc5pps3IHBH0q5b2jZHbHtTESR4Eg2447VowgE8CqotW3EAEDd+daUEAwMLj2pgTRAhjzwetXYccYBxg5qsincRtxV2CPaPmPOOlMRLkYBAPt7U5UOCM8UqoSOBweamiQ5P4UwLSqv2NhnluK5PUI8TE9Dnv2rrmG2x3BScGueuofNuQx5GeRQBt2dvi3jkUANjkCpJRgYPBxVuJNkaqvQDiop0AJz060IDD1EmPJPTvWTrkqv4avz/wBO8g5/3TV3VW82QRoc55b6VwnxIsGVLO8XO3mJh2HcH+ddeDpKrXjBuxz4qo6dJySua/jNvLsFJ7tivDtbXbqEvuc16fdW32LwXa+aTvlfzSD2B6fpivNNeX/Sg394VhWgqc3BO9jalJzgpNWuZDfrTDTzTDWRYlFFFMApD7U403FIBppQOaKVRzTAsQDj3rVssAgd6z4F6cVqWSHIbaQDxnFSykb9jBvAKdRzXc6DAXVPlwa5LTYvKjJGOldZ4fmZWGeCOGqUJnbaVZDK7+AfUV0FlB84CjORXOadcOynJYHOBjtXRabK+8Fyc9euMmqEbEEGFG1jnuMZq4sKccGoIGIGFGC3NW13HtQIa1vCwO4dPelWKAAjbUirntQUz9KYDRHb9hzUE0EJH3M1K0eFGBUZVscE4oAz5YIvTFNSBEVmPXBHSrbqSxyBnHeoLsmO3IxkngUgPPtbMa3BITPNaekBzpoG0Bhxx7ms++tmkvgrKTk10unW4jtwmOW5+lAzE1CBmVmX73vXPXNqPMxITxzXY6nB1Arm9YQpC7gc4wPqaAOB1iAXF67kZFZ+fKbZGBsIya1rxCRtP3j1rIdcOc5wDUjM3Xo1l0pggxt+YD05riWr0CWIyKVP3WBGK4S6jMU7oeqkiqiIrng0hpzUhqgEFafh/nVbb/fFZoHNanh0f8Ta2/3xSYHt0HQVbTpVODoKtrzUgSj3p1NXpS57daAGkmqU33mq6+ewqjN1agDw3XznVro/9ND/ADrOxWhq53alcH/bP86okVSAdEhd1VRyTiuzgRbe2jQY4HSuf0ODMvmsOB0rdDeY4/IVLGWoNxYEHitKFolUd2PPHes0Dy4gpIOetLCx83BbkHrSA3ILgkhSMZrStXZnwDgdzWPZqAwLDit2yhDthM5NMRegc/J8xGODWxFNIu37rDOORVGC0Yx425PT2/OtK3t22qzDnvTA0LW6YuNyoRjpjrWxHNEQrGFdpI6CsqxtyPmZTntxWvGgIHy9uPamBdiht3AxEMk45qRbWLLHy1HPFQQ7gAc8/StCCX5TvXIBpiK5giUfcNJ5cZBwtaKyQNlWXGPakMcBXIcgkUAU5owlqD05rEEYe/hQeua6G/QC3VQeuazbSNIZvNducYFMDTICMvvWVqDvJuWHqTjPoKt3Du8g6ge4qKYCJVVASe9AjEltUj4GS+eSazNcsodR0mS2lHysAQR1yCD/AEranDkscZB7VjTiWWUqn3Bx6U4ycGpR3QpRUk0zjfHU3/EuCNhVGAAPavJtTk87AVThO9eueNLYPYhnOCuflry27RQZFGMkVDNEYDUw09upqM0CAUUCigBTTacaQ0ANrU0KDSZppBrV7fWkYX5DaWaXBY+hDSx4Hvk1mVPbrls9qAOxgsPCB+7rmv8AH/UFh/8Akqvo/wCAsHhOH4cams9zHdaeb5jO+q20UH/LNMDb5jjHXBznOeK+WNNhMsgGDjqa6i0h2RquDz0GeBU3Gz1H4i/8K8zN/wAIx9t+3f8ATrn7Nn338/8AfPFctoABkIYn5ug9KxbG3bf35OK63SLExyROEORRuwOt0WAtFyM89DXV6fp7cE9aNB0xTCjvHyeea6q3tQqjgVQinDb8ccGrKwe2aupDtIwKeY+9MRR8nAoEWKu+Xx0pGj9cUWAoPGPSoWTHQVoOqjqaqyyRJmkBV8rLYxxVe9gyRkgKozn3pbnV7eHJDoCPeuT1TX3knbbJkdh2oAvtZ27XIKsGZRnFKc7uBxWDpOpNJfhXb7wIrpHkjCj3pAZlwNxOTxXMeIMN8qcAnJrr7iIFgy9K5fWVXeTwcUAcTq0YVS/fv71gtD5mRkgAflXU6lCGibecjNY8cQLEnp0+tIZRuYEEAkXgqenrXC+KbfydTcgYWQBxXoerxmKzfaOSM8dq4zxSnm6dZ3HVlJjY/qKEM5VqbTzTKsQCtbw2M6va/wC+KyRWv4ZH/E4tQf74pMD2qDtVtOg9aqwYwKtJ04qQJB29KcfYUg/Gl7UAMbp0qlIM7gKut0qK2h82Rs9B1oA8G1NMX0+f75/nVJULuAOprY8QoF1GcD++araZBvnyRzVDNaziEVuqgfNitO3h2YzgnFFvbj5CfStGOJSo3j/69QBRlQsg7GpbG1aSVQAdxPrWrZ2JuSFUcA5Oe1dboGh26FWdS5NMRmaRoryuu/Kn+ddfp+ihEUlSp963rKyggjBVQoFW47m28zyyRkds07AUYdMQAEIv0qylgN2Ngye4FXTdwxnBGR9as297byNjbTEQxWYwB8y9umKtCxCjjJx+tXYZIHHDAEVaSNWAKsCPrTAzEs1XIAJGQScU/wCy7VOD71p+Tz1FOEa9yKAMtrfqB360G3wFHt+davlJ7ZpCkeeTTEZd1AzxKB9KpLbhTEGHRuRW1dXdvbr87KPrVR5YpUWRNvJzjNAyCYgsAfqarXWCM9/SpnO6U9KJo+N2ARQIx7wbFYjp2rCuXKxswHPeugu0+TB6+vWufvsFMAHnmgZw/iufajhvukcV5ZdtiZ+a9M8WAuzBj8wBwK8vvjiZhUsZkzDDn61EelTT/wCsJ9aiNACCilFFAAaT8aU/hSUAAq9ZxFhx3qkK6DSLcFEJHWkxo2NEtdke58Vv28ZZwcVHYW2IjgVt6XYsZQe3vU7gafh3Q5LydQuFHcmu+s9HWECNQCVPJJo8MwJFAqKnzHvV/UrqKCQRklcdSPWqEdJpbJBAinlsflV4XR7mvOtO8TebevbP8jocAH+KuvsbaaceZO5QY6DrTEazXyjjdk1NHdBuSaqQ6bGO7n8an+woB8rMKAJjc56GopLgf3sVGbILzvekFqnQ5P1oAp3WoxxgktnFcveajd3czLHGxTttBrsJLaLGPLXg+lQPCoPTH0oEcE+m30zAmJuf7xxUb+Hrk43zIo9MZIrvHhOOBVC6TH8NAzmLXRkimVjK7MvfGK2Zrcm14Y7h60rZXDelWSN8HrkdaQGBDfNE7Ryj25NZmpiO4YrEw3jqtaWq2vmIzJwy+neuXkaWK5Eh2qB29fxoGV7y2kOVaP5Pr1rJ8ho2G5VGWxkduK6WaYToI5SoyflIrIu7dYWwxPXIYUAc9qOTaspJLdRmuQ1dN+g3S9fLkVx/Kuqv3AupEVsnGAp7cVzN9uNnfxnoyZ+mKQziD1pp609utMPWqEFbHhfnWbX/AHxWOK2vCvOtWv8Avihge0QdBVpOOtVoB0q0g45qQJB0ooAxR19qAGkd6u2EW23dz1IJqGCPe+O1aW3bayAdNp/lTA+e9bTfq0/+8ak0aE+d0pmsPs1SVx2Y1d0SeOSbKjBzyDSYzaSJgygD8K04LcsBhBzSRtCsqb+B610mnWaTqGRxj0HegRT06ERhjyM9a6TT5RHFuYkRjrinQ6QNn8yKg1YC1tuXUDoBTAivfE+yUqiEKOAc1Wk1N7tS0W/djIKjoay7GwF7MJJMmLPHoa6qwjWFAkagD2FAFOK+1GaOPfBIxUYJ6Z96v2818j5eOTb7DtWnaxglSeta1tCOtMRm299LGQDkfWtGHVpFOAcn0rQjtVdfnVW+op39mW5bJiHPWgBserMwBNTJquQcjB+tPj06AADyl9qnFjARjy1pgQf2oDyvP41Vn1VyCAQtaK2VuhwsS4+lLJbWw6woQfUUAcHr147vy5AXknNW9DmkmYSuMx/dX61raxo9tfqIViEbMfvJwRVAxnTU+zFSPL4yO5oA6OLDsrfhip7hAFx7VW0dvMt0cjFX503p6Ed6YjnLtTk9z2rIvRhTtBGep9K2b1v3pVeOfSsy8jLIw5+tAzzPxWuyUk8jnNeXanxcvj1r1DxmWVnB5P0ry3Uhidj681LGZc/aoTU0lRUAJRRRQAlJzTqSgBR1rtfDUKyCE1xQrf8ADurGznRZOY896TQ0er2Wmn92VUshGeldPpembGQlSFzzkVU8L63Z3VkgDLuHUE1vjXrWI4C59zQJnR2ELQxFwuCBkfWue1N3afnJcnNalvq8EtsxaQ7iOtYd5N5k5kGSFGAfWgRa0XSlnvEuXUb0Pyn3r0SzBKLnrXP+E4DLpkUpXBJI/DNdTbx7QopgWohxUgAoQcU4KaYEb4xxUTLk/wCFWGSkxkUAVfLPeoJsK3FXX4NUroUhFZyMnJqjdgsvHarZHf1qORcpigZhSowHUmpom/cjNTzRdcd6iICJwKAKsyo7YfoO9cvq8AildUAK9eciujuZAG6jjvWTqzJcIoJAIGeeKQHIXUzRhd+AwzjHJrOvtXdgVBwSO461d1yJo9xViBjNcddTlZj87FjxyaQwaV5LzIIzntWVq48v7QMcMhrQjP70MVPYc1U8QlfIkIxnaaBnn7UypG61H3qxAK3PCY/4ndr/AL1Ygrd8IDOuWv8AvUmB7NAOBVlKrQDgc1ZWpAlGPSjHPFA96eilnA70wLljHhS1Wbg4s58f3D/KlgTamPakvcDT7j02GgD511v/AI/ZT/tGq+mz+TcDngmp9Z/4+5T/ALRrNjJ30DO6uJS0KMD2rV0C7kVgY5GrldNvN8flSEZAwK3rCTyVUqACe/tSEdlJrE8SY8z5QMmuTfWL3VdWKbybdDyMVHfXpZNik571oeGbEbdzDCk7mNAHW6fLuiQIgUAcVr2sRYdPxrDikG8benTHpXS6X80IZufemBetrdiu4YGK1bOM8g8GorRgqKPXmrcMoVsjn6UxF6JMLVgACooZFwKmEmTjHFACqaUjJFKrAnOKlGCOOtMBioc5OKRlUDpU6jn2pHTAzTEUQpWTcTjnIrK1mItcIzciQYrQvmKyBhVC8uAUjz1VuaBl3SI/Ltwp7HvVmdsdelLaYwSB2ps7KxOCQR7UCMO/+V22AEHpXPzyS55J5NdFqO3a27aT/CR61i3SskeWCqccj2oGcB4wXO6RsHHrXk2rgGXI616x4sfh8kYPSvKNZ/1hNJjMaTvUPSpm71CaQBmikooAU02nGkNACinoeaYKetAG3o2py2cykSMB7GvTtNv1vrWOUY3/AMXNeOxnBFdBoOrTWMy/NmI/eU0mM9l06bc6K3Q8mtuWRIkYfxkAAfWuJ0fUw7oXPHHNat1dNcauvlNlWRQAKBHsnhIY0mE+oroRGARjoawvDsJt9LtoySSFGa6JRhQe+KoQgAzipAAajJzyakXpTAO9NxUmMgUwjtQBA65NVbkfKTV9k4qvcJ8mKQGaQBURHX1qyy81XZMdQeaQFK4TDknpVVkzx681oXHI6DjpVRuvYmkBjalBhCwHvXIX13tZkY9D1rvLlN6sD0xXmXiOdLa8dDwynv3oAr3eblXjdiPQEVyF/ZS+YVZM471032hbto5Yz0GCBxzU17ZGSNXiGS4/WkM5ONQJAqkYHr2rD12Xlo8jJ4/CusvbVbSFlXkjliep/wDrVwurykyyF+fSgZzD/fP1ptOfljTTVCAVveDh/wATy2/3qwRW/wCDB/xPLfjvQwR7HBxira+lVYelWkqQH8ZqzaLmUVXA5q/YpxkimBeQfLiotUOzSrk/9MzU6DAqtrZI0e5wP4DQB86avzPJ9TWWDg1p6r/x8SZ9azMZoQzRtSWKupxW7FdMVUA9q5m33BgFOK27ISMyqTmhgbWnRtc3CIBlmNdkSIIVgixx1Nc/pKLYxF2H70nA9q1w5Mm7qTgUkI0bFcOOp7V22nw+XbJnpjNctosIeUOy/Kpxj3rslyI1HoOppoCzE+O1WYj83PQc8VQjbjPcfrVyA9CefamI0ImOTkdasxt8wz1qojZA4xViPpuoAtr1qZAefzqBMnpU0ecimBMhyMmnsuVoQfLT1HIpiM+4jDHkYrltd3wtvQbQe1dxJCGByM1xHi6Jo/MBJx2+lA0WdO1A/aGjY5ygxzUt5eBQTnj24zXF6ZqLNcRSA8qNjVs3ExyRu4+8KAH3N0pbDDgjHXpmqF2wkh/dvk9MnrVa4kMrHGQ+azTO8c+0888+tAGP4ohLp93nOMV5Pr6BZ2A9cV7dewJc2M0vG1OcGvGPEcRW5bI6nIpMaOccVEalk61E1IBp60UUUABpKdTaAFHWnr1qOnrQBPGeRV2E4INUY+oq9BkkUmM27C8mg4jkIBr0r4c282pagrPkhSAD6V5bZr84FfQnwr09bPTFmYcsM/jQgPULBQoRccAVrMcgegFZVhukwe1aG7PTOOlUSKDg89DUy9sdKhHXpxjmp4xz6imBKnSlwKVRinEUDIyvFRSRZHSrBGc00g4oAyngYN0qEwNjOMGtWRDnNV5FwOtKwjJngORkdO9UbiMKQR61tyIWzWZqEeFI70gMG4JMhCnvXC/EvSzNbiaAckAMB/Ou3uVKsOprJ1VlmtGilBwRwfQ0gPBk1KfS9QCMxIU9D3FdtpevW91AVMgXP8JPSuc8aaLKrmeJdwX0FcZHfvbFuzHgikUd54ivoxE3Kkt+grzXVrszSFQeKfc6jK6ld5IPr1rMc5JPemkAykoNFMQV0Pgr/kO2/wBa56uj8ED/AIntv9aGB7BF0q0h4qtD9atL2qQJVAOAK1bZcRis2FQXUYrYiXAxTAmC8GqXiDjRLn/dq+o+X61n+JuNCuP92gD501X/AF7/AFrNFaer/wCuf61mr1oGXLBVMnzdBXR2EkcUm5RnHTNYVjH+7L+pwK27BAp3t1HAFJgbtgJbhghGc+tdHFblsiIqNuMfhWXo1u4VSec4IPpXU6PYGbzMEja2CetBJseHrZVMksv3UGcjpmtqIbgD/C3IqKzt1W22DIHTHqfWtaztQyDps+6KoCmkWGUjPvVm3X5gX6j0q4bRgw+U89xUyWpHAGAKBkUfzHgcHpVqI/LzSRQFQSeKmSPv1piJ4vujjmpkHIqJBj3qePJ4oAmj7+lS4INMRQRzU6L60xAp6g1geKbMXFqRjDYODXQsEXkmql2sU0e1vwoA8Ih3207Iww6uQ30ro4J0mgjJbgDAqPxhpv2fUTOBtDdcdDWJa3ogcDPXt60hm9cJ5i/KByMcVmGBt67xkA9e9aUNwjxK46EdfSo57iONCcgkUxEcsYWIREfIVIrxzxfGReyluDnoa9Za9U5Zjx0wa818eeX9rZwRhuaT2KR55KPmPpUBqa4YFzioTSAQUUCimAppPrSmkNIApy9abSjrQBOnar9t2qgtXrTqKTGdN4asWv8AUoYhwNw3H2r6L0SFreGOCNcBVFeLfDUxJqJ81c19D6TAsqLIvQgYOetNCZvachW2Qj0q5HGc/rSWMW2EIe3SraxYI60xEUacYNWEXpxT0jx2qQLgUxjQvFO20uRRmgBpGKYQalxmmstAFaQVXcc81edcioGhJoEVUXJrN1RQG9q2GQRjjk1jaqx2M3pSYHPXwKrkDI61zGpSBomHeugvJyQRkVzOsfcJU/hUgcTq0uc5PBrzjxLDAZ2KKEb2ru9d4yRwM5rzrWJt9w57ZxSGYMnUiomqV+pqI1QDKKU0hNAC10fgUZ12D8a5oV03gTH9uw/jQwPX4R0q2nFVYMZq3GMmpAu2KZbPpWrEOlUrNMIOOtaMS0xEgX5c1k+Ljt0C4PqK28fLxWF42JXQZaYz561UZdvrWfGuSK0tTHzt9arWsRcnaM4pDNOwi3Rrge1b2n2+SgCnrVXSI0JRMjOP1rptMgAywAyKQi/YKQsa4zzya7DSI3SFQvBY5rndLtme5yQQAAOO5ruNMtmAQAfd61SEW7ZSducEj+dblk6qNoHsD6e9RW1ngY6Zq9BFsTJXtimBYVgQAcZNSqo9RWZcmRTuRQx7AdabJPP5R3Keg6elAGu0YK4HNR+UB17VmQ3MpkBUfLjBqzcW87qHTPzdeaALibePmGPrUgeNehBPtWVFazFvnwAfQ1fgtCOppgWRNk8VIGckcUsMAFWliz9aBFcg5FQzRkcjmtNYeKk8oAdM0AcP4g01b6zYMPnXpXl2r6W1vIcBuvNe/XFoj5JFcvrmhB1cqu4GiwzyqNntrBV3FgeR7Vj3t+6Md5IH866rXdFMcpaFWCjqM9K5e7sg+VfJ+vakBzt3rM65A6E9zXLeILh7iMO+cjitzWrZreUg9OxrAvl3W757UhnNv1qOnyjBIqOmAtFA6UUgFNIetKaaaACnLTacKAJ46u2v3hVKM1etB84pAdx4RlMF9E4BweDX0J4eluI7WJg4CsAQDXgvgq1FxfW6nnLDNfS+mW6GzhAUfIoUcU0DNmwndo13YOe9aiSZXNZ1hDtAC1ppEPSqAPNJ4UU4bmPepFjA6CpVWgCJI/WpAnFSYpcUARlKaVqUimkUAREVEwqwwqNhQBTmTjIrKv0DIwx1ral4UnFZN6CFIHekxM4zVrbYGZQR7VxuqTkRvu4zwBXouqIGTHfpXn3i2IQxlgOgqQPN/Ed4I45F6nHA9TXnlzlic9a6/wAQN5j471y1zGQxyKRSMiUYqBquTL1qo45qgIzRSmmmgQV1HgH/AJDsX0NcuK6nwAP+J7H9DQwPXoe1XbddzD61Th5A4rUskHUikBpW68Dir0a+1VoVGBV2IDigQ7HHFc94640Nveukx0xXP+O0zojfWmM+f9TXLMaLNNkJAJBfrU+pJmQhQTzWzp+hT3G3am1Tg5PepGM0iE7MqOQc5rs9LtsqGC/XFP0vw+kcaqzZNdFa6eUxs5HcCmIt6NbKrBsY9q6zS4s5OBjFZVha7E5GDj/Oa3tLU+Ywx8oH60xGikeOKsD7uDUCn3qUnKkdsdaYEMsQJxyO+ant0BjwudvvT4UEmF7068kEEO2MDIoAjmaGBMzsFB6Z71HBqsO8okbsvqeK5jUbgyXaByWcDnnpV2z5I+Yg+lMDqk8qTBQcGp0jx71mWrFNqknJ6e9asDcc4oETIpGCKmVR24pq+npUyDmgY5QD+FKRzxSt6CkJ9aBjGAweKqXKAof5VbY+nWqc7bhnj3piOd1HTILzcQAJPQ159r+kGCV227Rnr1r1OcAEMK5rxRbqwLrjnqDQI8a1yxE6MjYJHII9a8/1CMxrKjDkcV6trsOzkAge1ec+JUCu8gH3hUso4KfhjUJqa45c1DQAoopBRQA/tSGnGkpAJSjNJSigCZK0rEZcVmx9a2NKTdItDA9P+HkJW/hbHTmvo7RUBt0P8JANeEfDy2zMpPBAr3Lw+5EKgnpTQHQ26hRVyOqsXPSrsQ4pgPUVIBSKKfigBuKXFLR2oAbimkU80hFAEbComFTGo2oAruMg1lXynJGa2GHas+9j3AkdaBM5bVVPbpXFeNrf/iWrJyewr0K5g3jGOc81k+INMWXSWQoCAMipYj5r1VCXJx0rn7tM5r1LXPDmQ5TA+leeapavbSNG68jvUlHM3EeM1SkWta5TGaz5VxTQykab0NSOOaYaYhBXV/D7/kNp/umuVFdX8PB/xO1/3TQwPXbcepxjvWjBfW0fBk/IVnFMWsh9qpE8DGa8TM8xqYScY00te534TCwrJuR1sWq2g+9If++asrrVh3m/8dNcUHBOMj6U4EmvM/t3Edl/XzOv+zqXdnoNhe2145W3lDMBkjoah8U24n00x8DPHNcl4Lunl8RQRnABWTIAOVx0B+tdxri/6MOK+gy/EzxNLnqKzuebiaMaU+WJ5dD4atkZ3AMjdy3aug0m2VrdFCj5eDVxMM+AO9OswLa4aJujn9a7TmLcdsM4Vck1o2tttIxjNQxHnn5TWjb4x6H1qgJIl5KqOfWtSwBWInjceKzUYD7uBg1p2uGi5/8A1UASq2fXPapYz8uDjI6VEgUZ56U5HVOeCe1AF2FvJQk8sf0qhq92ojwMEsKjmutoznnFZUjea/7xvpTAqPbo8pmbJfGAa0LGLLj5iWHt0qe0hVQFIBq/BaqJMqAB1BFICzbglVz271pRdKp28bAEkY5x1rQhGCT60xFiI/KOatRkBcmq8I4xjipjwAPSmMeDTS2KTPFNf60ARyNx3JqrNw2anZsZqnOc80CK8vX29KwtdwYZF7VtOCxA71g+JDlHAOOKAR5rr/AbHU15r4oObd/7w5r0HxA3zN/ePPJrzbxLIDBMc9sUmNHCTHLGo6kbk1HSGA60UDFFAEppDTiKbSAbThRilAoAlhGTXSaFHmROO9YFouWFdh4dt900Yx3pMD2j4c2JaJnA64Fep2a+Uyheg61zPgiy+yaPGCuHbkmustUOfmqhG5b8qDV6OqFpwgFX4+KYyZacKatOFABQaWkoAQ0GlNIaAGtUZFSGmtQBA61DLFuHNWmqJqAM17ZR0GaqX9r5tvJHjqK12qvIRmgVjx/X7Joi2F5B5rzvxJpiXcDui4lUZr3bxPY4cuq5VsnArybX7Xypiy9DzUNAjxm8iKswPBrKuBXYeIrXa7OBxXJ3I5pFGbIOaiNTydTUJqhAOK6/4bLu1wD/AGDXICu1+F651w/7hoA9Xu4ydLnVThimAfQ15dcaZr1o4MlxdTQd2gfc35GvVtSV/wCybjy8CTb8ueme1eQst8J5P7bXVS2flNuflrycXze20a22au93sd1C3s9b7i6LYXV9q10sd5dwYUsJWUhm5HWvSIxhFBPIAGfWvOI0v/PiOiLqobPzfaPu16NGG2Luxuxzj1rw82bcou6t26/M7sLZJok+Gse7xZcyMGUnfhShUY9c+tej69/x7getcp4LGdbX2jb+VdZrgzEB3r3cnnz4fm8/8jz8crVLHHPMIplGec4q/sF1DuH3x6VkagP3ygDjp9K0tNmKrgjp+teqcZoW0hdACf3gHPvV6KTjnrVHCyEnGG9anUuqjcCeOopiLquM8jPtWpYyAR8HBHvWAsoLHJxV+ylCupzwKANyUck7etU7yQxqrMcEmrsVxHIuAQR6is7V3RAg6jPWgCvLKXPcHrU1vb78MeopdMtHuJEdgQvrW8lpHjCigDOjixgjpWrawFgAAcCpoLaIH5uTVyN1QYVQBTEIkJxjaasJHgnHSnRSk4/rVmMg80DsRxJg8inck5NTbRTWXFMZEfpUbGpyBVaU9aBEUxwM9qpyc56YPSpJpMjFU5JCAc0xAvLc9eormNfbMUhYdScV0KSZDMDnFc1rbbvMHGDyPrQCPN/ES53cHAHFeS+KJSpZf7xr1XxJIRkE464rx/xK5e+bnpUspGA1NxUjDmm4pANxRTgKKAJKCKeRTSKQDKVaXFAFMC/p6ZkFei+EbXddQZAxuFefaY6rIN2eteoeELqBXj+VsgjtS6gfQ2kw4s4xitiBeQPSsrSruGSyiZAcFRWvbyoT0NMRqWy4QVcjFVoXG0YBqyjd8GmMmFOFMDcdDS7vY0APNJSbvY0hb2NACmg0hb2NN3+1ADjTDQX9qY0g9KAA1GwpTJx0NRPMo6kfnQAyQdapT8GrEt1GByU/76FUbi8jA+9H/wB9igCvqCie2IPpivLvFNngsFAOByK9JmuWkiYQJ5hHJ2NnH5V5/wCLb/y4maW3KSA9TxmkxHlOu2Qa2k46d8V5tfrskZfQ4r0vVtXHlyKYRhvevNNUm33Eh24yakpGXL1qI1LIcmojTEArufhWP+J43/XM1w4rvPhOudaf/rmaGB6tqocaPcmLBk2/LnpntXjz/bPOkOuNqqyZ+XyB8uK9l1lZP7EuvJx5u35M9M9q8n0uz1O8vpIb+41G3ucFhIp/djHavIxklCq5Nrb57vb9Tuw6vCyvv8iram/+1xf2I2pMM/N9oHy16MvQZ61wuuQeIIBEGneeCM/62HIYg4+8BXd44rwcxkpqEk099t/nt+R6GHVm07m38PZ/tGsE7NoNuXXJB4JFdlrY/djHpzXA/Cb95rWoncrKqYGOccjjOBXoupoCvIzX0eUwUMPZdzy8Y71Thr4DzBkf/Wqa2ZFwFHzfyp2pxDedoxzxVaNGAB259a9I5TVibC8cg9KspLz1wfesqGbYQGP5irsb7wDke1MReUK55UE+1WlSLGOQO5rPjyDheKuRISpGOc0AaloYY9xjzxxmszUb1Y5xFPypcDPpUwk8hQKxNdHmoWTJI5NAHf6UgaFGU5Uir+3B9q5jwNqwuYxaOpV1GRnvXXlQTQIjRehqdRx9aYBjAqRMcfWmBPGMj3q1HwOKqRkhgPWrkRzTGOzg0FsimMcZNMzz1oGDnrVaZuetTSMDzVSZu1AmVJ3wT61nXMuM8ZBFXJ8D1rJupQrFSTn3piHwOfLmx0wMVyuvXQHsOvFdHaTqUnA/hHIrgPENwzSswPB4wO1AHMeIZw67icsM15Nry7ruRhyCa9A8QXBjGCecV59qrfMSO9QykYzAU0inmkNIBg60U7FFMDE+23P/AD2ej7bc/wDPZqrUUwLP265/57NTl1C6XpM36VUooA0o9c1GP7l0y/RR/hV6Hxj4hgx5Oq3CY/u4H9K5+igDsI/ib40jULH4l1JVHQCXFSD4peOR08U6qP8Atsa4uigDth8VvHg6eK9W/wC/5oPxW8eHr4r1f/v+a4migDth8VfHY/5mvV//AAINH/C1vHf/AENWrf8Af81xNFAHan4qeOiCD4q1XBGP9eaavxS8cKMDxTquM5/15rjKKLgdofin45KhT4o1TA5/1xpsvxP8bSlS/ifUyV6fvjXG0UAdj/ws7xqR/wAjNqf/AH9qOX4keMZceZ4j1I46fvjXJUUAdxB8WPHkEHkxeKtUWLn5fNqi3xB8WNw2vXx+r1ytFAHTnx74pPXW7w/Vh/hSf8J54o/6DV1+Y/wrmaKAOysPif4008sbLxHfwFvveWwGf0r3z4D6tqXj3wlrc/i2+uNWmtbpI4WnbJRWQkgY9wK+Ua+pv2Rhnwd4kPpfRf8AotqBM6LWfC+jRiXNmCR0+Y15J4g0Sxjmcxw7QSSOTXu/ilfLMucgY/OvI/EMeXOKhgjzPULOOMnauKxiOa6jWI9pNcw/U0IoQV6D8IlJ1qX/AK5/1rz4da9G+DozrE//AFz/AK02B6t4gkW20C6mYEqihiAOcA5rhtG1q21VZWt9yeWQCHwDz6V3XiiQW/hy8mK7hGu4j1xzivEZ7nQri2e6+zz282/b5MUoyRjO7kdK8LMsMq9XVPZar1fQ9DC1HTh03Oy1TX7TTbiOGcOzOMjy8HHOOea2RXnltcaLZXFlJb20l1NKFJ8yXPlNnGCMda9CxjJNeFjMPGgopJ+r6/I9CjPnvc6n4exgardMFAJh5IHX5hXYakPlrjfhjdJd3t+0QcCOMKSwwCd3b16V2WpOq8EHFfT5PFxwqT8zyMc71nY5W8jLyc9aiSIgnmr8ypK+U7dc0LGqRO7DAUZOa9M5DDvcKOcgg96u2UDFAzsVJHQ1lw3AvtSIGTGh5rol/hwgAoGSQxyADBBH1q9Gz5ChRz3qvFkYFaVpESmT+tMQiWfnsN+RSLYxyXIgTmPv71fwxQpH19asWNqYSSwG496AIrbTEtLhJbYAAdSK6gDcoYVmRDHWtO2P7oL3FMAx26inhQR71IFyKQdaAAfezVmE/KxqDAxU0A+RsdxTAUtxURag5HFQu1ACl+STzVeY4fJ4qQHLfSq102WPoKYijeyMBla5+8clu+c4Oa175iVYVhzqHY8nOcUgHRv5en3EueSME15n4guTlvm+ld3qdyLfTJAO/GK8p125BdgD06UMaOf1iXzeM964/WW/0jYvRRXQXEuSTngdK5e+bdcyH1NQMqmilpDQACilXrRQBzFFFFUAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfVf7Hy7vB3iYf9PsP/AKLavlSvq/8AY3Xd4Q8Tf9f0P/otqAPRfGUGbHeByDtryHWYsgtivfPENp5+nXCgZIXcPwrxjXLbajAepqWJHlmux8tXGOPmNeha/CcHivP5R87fWkihg616V8GVzq9wfSP+tebAc16b8F+NTuj/ANM/60xHp3i14ovDV3JcDMKgFxjOR3rxOK8jvJHNvaaTaxKePPHJr27xcYV8O3BugvkZG/d0x3rz+1stDuR+4hs5M/3cZrw8wrwo1byi3ovTqehhoSnCyfU5izvoItThgvLLTpkdlAltx90k8GvQW6MDycGqCaPpyMrLZQAqcghehrRHXnvXgYzEQrtOCasejRhKCakbvwct5YH1QSxNHnZtDAAkZPoTXd6mBzmuc+HI+e/x6J/Wuh1lxHExPWvrMrm54aMn1v8AmeNi1aq0cwH23DkEZzzTrtj9gl5+8DVBZfMuJCBgHof61maxqwZfstuRjGGYetegc5Y8NxKrMV6sSa6MFgeMcVjeEo3bfI64iQd61ZZdrEZyD2oQi5a/vJQD+lbVvFuVcnAz0rE0noWYn72BXQW/I56g0wL0KIi4UcVNj5gaiUgj2NPB9PzoAsADirUB2sKrKB1zUqEev40AaKEY4pwGRVeKQZ9amBz0pgKxAqWDjrVdj/8ArqWA+nagBzrhjUDqMGrTfMPeoSM8UAQN8ifWs+fBPNaE+CcDoKpTAYNMRkXCk5z0rJuAIojg4NbN4x55wB61zGtXaqDtbJoGcz4pu8QlFbBrzPU5CwbnpXWeI7hm3HPH1rh9RkKIc9aljMW8lwcDpWDccyt9a07lySTWU5+Y1IxhpMU6kxQADr7UUoFFAHLV6B8Hfhpd/EvWb2zgv4tOtrSFZJLqWPeu5nComMjliTjn+E15/XrHgH4oWPgX4d3Gm6TpMd74gvdSjurmS/iJtxFF80QUpIrllcBhnAGT14qhGb4L+Gf9tTeLV17WY9Cj8NYF7I9s8+DvZD8qnPBXsD1rL+JPgaTwVc6Wyalb6ppuq2i3tleQIyCSM+qNyp6ce49wPTZvjPoFlr3jrWdAsL+C88Q2VsIo7i2heKK6TIkLKXIKHg5wSSTkCvHfGPizWvGOrDUfEV6bu5WMQp8ioscYzhFVQAAMnoO9AGFRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX1l+xmM+EvE4/6fYf/RbV8m19afsX/wDIqeJ/+v2H/wBFtQB7pMFJKN0bivI/Fmmm3mmjx0Jx9K9dvk53DqOa5LxvZiaxF4g5UYb6UmI+fNfi4cEdK8xmXEjfWvW/FKBfMOMZFeTTj9631qSkRAV6d8FkJ1O6/wCuY/nXmqRkmvb/ANnjQDqEuo3BV1SIBC5YAZJ6UwZ0vju0e58K3VvGQHlwgz05rzLTvCcS2YW7crchiRJC56dute6eNdHlXT3t7eJzKjK+CwO4e1cAum32ebWf/v2a+ezariIVOWlezS2PSwcacoXk9TlINK1Wznj+z6iJrcMNySjnGea3pnaOGR413MqkqPU+lXxpl9n/AI87j/v2aeNMveQbO4weP9Wa8Soq1Rpyj+Fjvi4RVlL8Td+ENy95a6jLKFBDIvyjA/i9zW/4llUfK2cGovh5o02lWNyZoWgErKURycgDPPPTrS+IQPNbceOuK+xy+PLh4q1vL5niYmV6jdzgNb1JLKJ1iyHcYAPYf/XrI8OxHUtR2Z+UHLH2ql4lZ575uc4Pauo8FaeLWJZmyGc11GB15Vba3EMY2oPTvWcCGmPPBP8A+qp72YumF5qKBCDkEdeh7VQjoLFF2pjotatrlt2ODWVpoYkEZ6VsW4I4x35pgW0yByakQ8c4xUSrgcUbwG2jrQBcUjApwIzUCltvvTkPNAFmOQKcGrKyYI7is5mwM9aak7rx1FMDWLdxyKmhbrWXHeIuA3eni/jQ5P40Aaweop5lRTzzVL7cki7oiCKo3ErOSSaALVxeIgzWPd6mecYH1NNuskZrEvWAyCwH407iH3eop0Zjz3FXtd8F3TataWMc6FLgMTNtOEA5bIz9Pzrgda1O1gVt82W/uqcmr/iH4xq2rzHTYJhpU80MknmoBMoTbvC4bHIXufypMaRlax4K1iXV76x022kvVs38tpEAVST0HJ6+1cHL4U8QanNcwWGjXtxJbzeRMkcZJjk67WHbpXZa/wDEbw/4jh1Ox1R9YsLR9T/tC3mtIkaRl2BSjqWAB4yCCf0557xp8TbXXdL8WxW9veWlzq+oW9xBtwFWKJAmHIbO47QcAEZ71IzO1b4X65ZW3h69ure4ew1RoVla3i3Pb+ZIEVcEgMx3DAyAcjkVz0Xw98Q6pqeqw6FpV7dW9jdvaGSVVibcrEbSC2N+ByoJxXVxeM/Dkth4Du7s6pHqnhqWESQJCjRzIs6uWDlgc7QcAjr3A5OxoPxK8NJNrx1pLy70291e51FdNudNguEZZGypVi4McmOCcsB270gPM9G8AeKtatZ7jS9Eu7iGF2jZgAMuv3lUEgsRjkLmuYdSjMrqVYHBB4Ir3DQvijoSaJpdtcRXGlXOk3E8trJFptvfHy5JC4CtKQ0bjONw64ya8d1y7S/1rULyIyGO4uJJVMgUMQzEjcF4zz24pjKFFKBzRSA5WiiiqEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX1r+xd/yKnif/r9h/wDQGoooA98ukyp+lZFxGslvJFIMo3GDRRQI8H+IOm/ZbqePjA5X6GvELlcTOP8AaNFFQUthY423IT0PSvfP2dYrstqbSsx0xWG9FYDL8YOPyoooW4PRHtOvoTeDdjGwY/Ws4JjHNFFWIlVe+alVTiiikIdjiuR8Sry5x0FFFAzzEWS3FzvcDlyT7YrrLNkWGMKuFAwo9KKKSAteWGJI5xwM09EYPyBRRQBvWBIwqn0rXgJIyQBRRTESyThUwOSelQQt8xYnJNFFMCyGIByafGcnmiigCT1BpsiYXPXvRRQBWkJC5/WqU7kdTRRTAxHupY7iTy5GU57GiTWrtBjfu+tFFAyjda9dFDyK5XVtSuZycyEewoopXA5a/Y8knnvWBeOSDRRUtj6GNOhJNU3jooqblNWIjFTDGaKKYrCeXTfLoooELHEdwooopNgf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fractures of the medial malleolus (white arrow) and lateral malleolus (blue arrow) are visible on both views. Although spacing in the mortise view appears normal, this is an unstable injury and requires orthopedic referral.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32033=[""].join("\n");
var outline_f31_18_32033=null;
var title_f31_18_32034="Erythematous nodule";
var content_f31_18_32034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    A tender, erythematous nodule on the patient's middle finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &copy;2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32034=[""].join("\n");
var outline_f31_18_32034=null;
var title_f31_18_32035="Salter IV radius fracture";
var content_f31_18_32035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Salter IV radius fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 474px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) A markedly displaced Salter-Harris type IV fracture of the distal radius in an 11-year-old boy who fell from a horse. Panel B) X-ray taken three weeks after closed reduction demonstrates displacement of the comminuted fragments. Panel C) Eighteen months after injury, there was 15 mm of radial shortening, and the patient had a pronounced radial deviation deformity of the wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32035=[""].join("\n");
var outline_f31_18_32035=null;
var title_f31_18_32036="Urinary tract infections in adolescents and adults";
var content_f31_18_32036=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/18/32036/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32036/contributors\" id=\"au4016\">",
"       Thomas M Hooton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/18/32036/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32036/contributors\" id=\"se1937\">",
"       Stephen B Calderwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/18/32036/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32036/contributors\" id=\"de8449\">",
"       Allyson Bloom, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/18/32036?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      URINARY TRACT INFECTION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The urinary tract includes the kidneys (which filter the blood to produce urine), the ureters (the tubes that carry urine from the kidneys to the bladder), the bladder (which stores urine), and the urethra (the tube that carries urine from the bladder to the outside) (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ). Urinary tract infections happen when bacteria get into the urethra and travel up into the bladder. If the infection stays just in the bladder, it is a called a bladder infection, or &ldquo;cystitis.&rdquo; If the infection travels up past the bladder and into the kidneys, it is called a kidney infection or &ldquo;pyelonephritis.&rdquo; &nbsp;",
"    </p>",
"    <p>",
"     Bladder infections are one of the most common infections, causing symptoms of burning with urination and needing to urinate frequently. Kidney infections are less common than bladder infections, and they can cause similar symptoms, but they can also cause fever, back pain, and nausea or vomiting.",
"    </p>",
"    <p>",
"     Both bladder and kidney infections are more common in women than men. Most women have an uncomplicated bladder infection that is easily treated with a short course of antibiotics. In men, bladder infections may also affect the prostate gland, and a longer course of treatment may be needed. Kidney infections can also usually be treated at home with antibiotics, but treatment typically lasts longer. In some cases, kidney infections must be treated in the hospital. &nbsp; &nbsp;",
"    </p>",
"    <p>",
"     This discussion will focus on bladder and kidney infections in a healthy adult. Urinary tract infections in children are discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=see_link\">",
"      \"Patient information: Urinary tract infections in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      URINARY TRACT INFECTION CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Bacteria do not normally live in the urinary tract, but they do live close to the urethra in women and men who are not circumcised. Urinary tract infections occur when these bacteria get into the urethra and travel up into the urinary tract.",
"    </p>",
"    <p>",
"     Factors that increase the risk of developing a urinary tract infection include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Having sex frequently or having a new sex partner",
"      </li>",
"      <li>",
"       Having diabetes",
"      </li>",
"      <li>",
"       Having a bladder or kidney infection in the past 12 months",
"      </li>",
"      <li>",
"       Using a spermicide for birth control",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In men, not being circumcised or having anal sex increases the risk of bladder infections.",
"    </p>",
"    <p>",
"     In men and women, having a condition (such as kidney stones or ureteral reflux) that blocks or changes the flow of urine in the kidneys increases the risk of a kidney infection.",
"    </p>",
"    <p>",
"     There is increasing evidence that there is a genetic predisposition to urinary tract infections.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BLADDER INFECTION SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The typical symptoms of a bladder infection include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pain or burning when urinating",
"      </li>",
"      <li>",
"       Frequent need to urinate",
"      </li>",
"      <li>",
"       Urgent need to urinate",
"      </li>",
"      <li>",
"       Blood in the urine",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26421652\">",
"     <span class=\"h2\">",
"      Is it a bladder infection or something else?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Burning with urination can also occur in women with vaginal infections (such as a yeast infection) or in people with urethritis (inflammation of the urethra). For this reason, it is important to call your healthcare provider before assuming you have a bladder infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26421610\">",
"     <span class=\"h1\">",
"      KIDNEY INFECTION SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Kidney infections can sometimes cause the same symptoms as those of a bladder infection (listed above), but they can also cause:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fever (temperature higher than 100.4&ordm; F or 38&ordm; C)",
"      </li>",
"      <li>",
"       Pain in the flank (side of lower back, where the kidney is located)",
"      </li>",
"      <li>",
"       Nausea or vomiting",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you have one or more of the symptoms of a kidney infection, you should see a healthcare provider as soon as possible. Although most kidney infections do not cause permanent damage, delaying treatment can lead to serious complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      URINARY TRACT INFECTION DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Urinary tract infections are usually diagnosed based upon the person&rsquo;s symptoms, and the results of a urine test that checks for the presence of white blood cells in the urine. White blood cells are responsible for fighting infection, so their presence in the urine suggests infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Urine culture",
"     </span>",
"     &nbsp;&mdash;&nbsp;A urine culture is a test that uses a sample of urine to try and grow bacteria in a laboratory. It usually requires about 48 hours to get results.",
"    </p>",
"    <p>",
"     A urine culture is appropriate for anyone suspected of having a kidney infection, but it is not always required to diagnose a bladder infection.",
"    </p>",
"    <p>",
"     In people suspected to have a simple bladder infection, urine culture is often recommended if they:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have never had a bladder infection before",
"      </li>",
"      <li>",
"       Have symptoms that are not typical for bladder infection",
"      </li>",
"      <li>",
"       Have had \"resistant\" bladder infections before (meaning the infections did not get better with standard antibiotics)",
"      </li>",
"      <li>",
"       Have frequent bladder infections",
"      </li>",
"      <li>",
"       Do not begin to feel better within 24 to 48 hours after starting antibiotics",
"      </li>",
"      <li>",
"       Are pregnant",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      BLADDER INFECTION TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Bladder infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;In young, healthy adolescents and adults with a bladder infection, the usual treatment includes a single dose to seven-day course of antibiotics. The typical drugs chosen are: trimethoprim-sulfamethoxazole (Bactrim&reg;), nitrofurantoin (Macrobid&reg;), fosfomycin (Monurol&reg;), ciprofloxacin (Cipro&reg;) or levofloxacin (Levaquin&reg;).",
"    </p>",
"    <p>",
"     In men, the infection may involve the prostate gland and treatment is usually given for at least seven days.",
"    </p>",
"    <p>",
"     Your symptoms should begin to resolve within one day after starting treatment. It is important to take the full course of antibiotics to completely eliminate the infection. If your symptoms persist for more than two or three days after starting treatment, call your healthcare provider.",
"    </p>",
"    <p>",
"     If needed, you can take a prescription medication that numbs the bladder and urethra (phenazopyridine [Pyridium&reg;]) to reduce the burning pain of some UTIs. A similar medication is available over the counter without a prescription (eg, Uristat). Both medications change the color of the urine (usually blue or orange) and can interfere with laboratory testing. You should not take these medications for more than 48 hours due to the risk of side effects. These medications do not treat the infection and must be taken along with an antibiotic.",
"    </p>",
"    <p>",
"     Some providers recommend drinking more fluids while treating bladder infections to help flush bacteria from the bladder. No studies have been performed to address this issue.",
"    </p>",
"    <p>",
"     There are also no good studies on the effectiveness of cranberry juice for treating a bladder infection; we do not recommend using cranberry juice to treat bladder infections.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Follow-up care",
"     </span>",
"     &nbsp;&mdash;&nbsp;Follow-up testing is not needed in healthy, young men or women with a bladder infection if symptoms resolve. Pregnant women are usually asked to have a repeat urine culture one to two weeks after treatment has ended to make sure the bacteria are no longer in the urine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26421703\">",
"     <span class=\"h1\">",
"      KIDNEY INFECTION TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The optimal treatment for a kidney infection depends upon the severity of the infection and the person&rsquo;s general health. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"      \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26421710\">",
"     <span class=\"h2\">",
"      Home treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your fever and pain are mild and you are able to eat and drink, you will probably be given a one to two week course of antibiotics to take by mouth at home. The first dose of antibiotics may be given as an injection in the office, clinic, or emergency department. Let your healthcare provider know if you do not begin to feel better within one to two days after starting treatment.",
"    </p>",
"    <p>",
"     For fever and pain, you can take a nonprescription medication like acetaminophen (eg, Tylenol&reg; and others) or ibuprofen (Motrin&reg;, Advil&reg;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26421717\">",
"     <span class=\"h2\">",
"      Hospital treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have a high fever, severe pain, or cannot keep down",
"     <span class=\"nowrap\">",
"      food/fluids,",
"     </span>",
"     you will need to be hospitalized and given intravenous (IV) antibiotics and fluids. As you begin to improve, you will be allowed to go home and continue taking oral antibiotics there.",
"    </p>",
"    <p>",
"     Most pregnant women with a kidney infection are hospitalized and treated with intravenous (IV) antibiotics and fluids. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/40/43657?source=see_link\">",
"      \"Urinary tract infections and asymptomatic bacteriuria in pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      RECURRENT BLADDER INFECTIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Bladder infections versus other causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some adults, especially women, develop bladder infections frequently. In this case, it is important to confirm that your symptoms (eg, pain or burning, frequency, and urgency) are caused by a bladder infection. Symptoms are usually similar from one infection to another. The best way to confirm an infection is to have a urine culture (see",
"     <a class=\"local\" href=\"#H6\">",
"      'Urine culture'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     If your urine culture is negative for infection, other causes of pain, burning, and frequency should be investigated. However, some urinary tract infections are caused by small quantities of bacteriuria that may not be detected on a typical urine culture. Therefore, in some cases your provider may choose to continue you on antibiotics even if the culture is reported to be negative. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=see_link\">",
"      \"Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Need for further testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you continue to develop bladder infections, you may require further testing. This is especially true if there is a chance you could have an abnormality in the kidneys, ureter, bladder, or urethra (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ), or if you could have a kidney stone. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Tests for these conditions may include a computed tomography (CT) scan, ultrasound, or cystoscopy (looking inside the bladder with a thin, lighted telescope-like instrument).",
"    </p>",
"    <p>",
"     If you continue to notice blood in your urine after your bladder infection has cleared, you should have further testing. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Preventing recurrent UTIs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with recurrent urinary tract infections may be advised to take steps to prevent bladder infections, including one or more of the following:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Changes in birth control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who develop frequent bladder infections and use spermicides, particularly those who also use a diaphragm, may be encouraged to use an alternate method of birth control. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Cranberry products",
"     </span>",
"     &nbsp;&mdash;&nbsp;Taking cranberry juice or cranberry tablets has been promoted as one way to help prevent frequent bladder infections. However, this has not been proven in clinical studies.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Drinking more fluid and urinating after intercourse",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although studies have not proven that drinking more fluids or urinating soon after intercourse can prevent infection, some healthcare providers recommend these measures since they are not harmful. Drinking more fluid may help to wash out bacteria that enter the bladder.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Postmenopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;Postmenopausal women who develop recurrent bladder infections may benefit from using vaginal estrogen. Vaginal estrogen is available in a flexible ring that is worn in the vagina for three months (eg, Estring&reg;), a small tablet (Vagifem&reg;), or a cream (eg, Premarin&reg; or Estrace&reg;). Vaginal estrogen is discussed in more detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"      \"Patient information: Vaginal dryness (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;A preventive antibiotic treatment may be recommended if you repeatedly develop bladder infections and have not responded to other preventive measures. Antibiotics are highly effective in preventing recurrent bladder infections and can be taken in several different ways.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Preventive antibiotic &ndash; You can take a low dose of an antibiotic once per day or three times per week for several months to several years.",
"      </li>",
"      <li>",
"       Antibiotics following intercourse &ndash; In women who develop urinary tract infections after sex, taking a single low dose antibiotic after intercourse can help to prevent bladder infections.",
"      </li>",
"      <li>",
"       Self-treatment &ndash; A plan to begin antibiotics at the first sign of a bladder infection may be recommended in some situations. Before starting this regimen, it is important that you have had testing (urine cultures) to confirm that your symptoms are caused by a bladder infection; some people have symptoms of a bladder infection but do not actually have an infection. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=see_link\">",
"        \"Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287497494\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13062190\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/47/20210?source=see_link\">",
"      Patient information: Urinary tract infections in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/42/42657?source=see_link\">",
"      Patient information: Group B streptococcal disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/53/27475?source=see_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/8/6274?source=see_link\">",
"      Patient information: Vesicoureteral reflux in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/44/4803?source=see_link\">",
"      Patient information: Urethritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/19/39217?source=see_link\">",
"      Patient information: Vancomycin-resistant enterococci (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13062216\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/25/28048?source=see_link\">",
"      Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=see_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/48/31490?source=see_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7537?source=see_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15479?source=see_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=see_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12868?source=see_link\">",
"      Asymptomatic bacteriuria in patients with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16102?source=see_link\">",
"      Bacterial adherence and other virulence factors for urinary tract infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39777?source=see_link\">",
"      Clinical microbiology review: Genitourinary infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/62/41961?source=see_link\">",
"      Management of vesicoureteral reflux",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5514?source=see_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=see_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"      Urinary tract infection in autosomal dominant polycystic kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20579?source=see_link\">",
"      Urinary tract infection in renal transplant recipients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/40/43657?source=see_link\">",
"      Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=see_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infectious Diseases Society of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.idsociety.org\">",
"      www.idsociety.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney and Urologic Disease Information Clearinghouse",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/utiadult/\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/utiadult/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/18/32036/abstract/1-9\">",
"      1-9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/18/32036?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/1\">",
"      Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann Intern Med 2001; 135:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/2\">",
"      Hooton TM, Besser R, Foxman B, et al. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/3\">",
"      Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/4\">",
"      Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/5\">",
"      Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003; 17:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/6\">",
"      Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Clin Infect Dis 2004; 38:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/7\">",
"      Stamm WE. Estrogens and urinary-tract infection. J Infect Dis 2007; 195:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/8\">",
"      Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012; 366:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32036/abstract/9\">",
"      Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_18_32036=[""].join("\n");
var outline_f31_18_32036=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           URINARY TRACT INFECTION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           URINARY TRACT INFECTION CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BLADDER INFECTION SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26421610\">",
"           KIDNEY INFECTION SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           URINARY TRACT INFECTION DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           BLADDER INFECTION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26421703\">",
"           KIDNEY INFECTION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           RECURRENT BLADDER INFECTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\" title=\"figure 1\">",
"           Urinary tract anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_18_32037="Echocardiography of hypoplastic left heart syndrome";
var content_f31_18_32037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiography of hypoplastic left heart syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal short-axis views in a patient with hypoplastic left heart syndrome. In (A) the right ventricle (RV) is enlarged with a smaller, hypertrophied left ventricle (LV). Scanning more superiorly from a parasternal short-axis view (B), the larger main pulmonary artery (MPA) and patent ductus arteriosus (arrow) are seen connecting to the descending aorta. No brachiocephalic vessels are seen arising from the ductal arch, a key finding in differentiating the ductal arch from the true aortic arch.",
"    <div class=\"footnotes\">",
"     Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tweddell J, Hoffman G, Ghanayem N, et al. Hypoplastic left heart syndrome. In: Moss and Adams' Heart Disease in Infants, Children and Adolescents: Including the Fetus and Young Adult, 7th, Allen H, Driscoll D, Shaddy R, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32037=[""].join("\n");
var outline_f31_18_32037=null;
var title_f31_18_32038="Endobronchial brachytherapy";
var content_f31_18_32038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endobronchial brachytherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32038/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32038/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32038/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32038/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32038/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32038/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/18/32038/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy refers to the placement of a radioactive source within or in close proximity to a malignancy in order to provide local radiation therapy. This approach delivers the highest doses of radiation in close proximity to the tumor and thus offers a theoretical advantage over external beam radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The technique is most commonly used for palliation, although it has also been employed as definitive therapy on rare occasions.",
"   </p>",
"   <p>",
"    The use of endobronchial brachytherapy for the treatment of bronchogenic carcinoma will be reviewed here. Other interventional treatment modalities, such as airway stents, bronchoscopic laser resection, endobronchial electrocautery, and cryotherapy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=see_link\">",
"     \"Endobronchial electrocautery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Principles and technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general approach to the management of NSCLC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial use of endobronchial brachytherapy for bronchogenic carcinoma was reported in the early 1920s by Yankauer, who implanted radium capsules into an endobronchial tumor using a rigid bronchoscope, and removed them several days later through the mouth via an attached string [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/3\">",
"     3",
"    </a>",
"    ]. Over the next decade, Kernan, Cracovaner, and Pancoast also described the use of endobronchial radium to treat malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Most of these cases required general anesthesia and either rigid bronchoscopy or thoracotomy for direct introduction into the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The next major advance occurred in 1964, when Henschke developed the remote afterloading device, thus reducing radiation exposure to the healthcare staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/7\">",
"     7",
"    </a>",
"    ]. Almost 20 years after this, the current practice of enclosing the brachytherapy source within a polyethylene catheter and implanting it via a flexible fiberoptic bronchoscope was described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In addition, Iridium-192 became the isotope of choice for brachytherapy around this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the mid 1980s, publications distinguishing \"low dose rate\" (LDR) from \"high dose rate\" (HDR) brachytherapy appeared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Low dose rate brachytherapy implies delivery of less than 2 Gray",
"    <span class=\"nowrap\">",
"     (Gy)/hour",
"    </span>",
"    and a total dose of 1500 to 5000 Gy, given over up to three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. HDR involves greater than 10 to 12",
"    <span class=\"nowrap\">",
"     Gy/hour,",
"    </span>",
"    with the total dose ranging from 500 to 4000 Gy, and the dose per session (fraction) varying from approximately 300 to 1000 Gy.",
"   </p>",
"   <p>",
"    The American Brachytherapy Society issued guidelines for the treatment of lung cancer in 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endobronchial brachytherapy requires implantation or insertion of a radioactive source into a patient's airway. In the past, rigid bronchoscopy was used for permanent interstitial implantation of a low energy radioactive source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/16\">",
"     16",
"    </a>",
"    ]. This method has been replaced by the use of a flexible fiberoptic bronchoscope to place an afterloading polyethylene catheter within an airway adjacent to the tumor under direct visualization. Catheter position is verified radiographically (fluoroscopically and with a plain chest radiograph), after which the catheter is loaded with a radioactive source, either manually or with a remote afterloading device. Centering devices, such as balloons, cages, or sheaths, can be employed to maintain the radioactive source within the center of the bronchial lumen and avoid dose inhomogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose rate of brachytherapy depends upon the energy and rate of decay of the radionuclide used. LDR brachytherapy requires manual manipulation of the radionuclide, 30 to 70 hours of treatment, and cumbersome radiation protection measures. HDR brachytherapy usually using iridium-192 is more commonly employed because it permits a dramatic reduction of treatment time, thus converting brachytherapy from an inpatient to an outpatient procedure. The shorter time that the catheter needs to dwell endobronchially decreases the likelihood that it will become displaced, improves patient convenience, and reduces treatment cost. Heavily shielded treatment rooms and the use of afterloading techniques (ie, inserting the radionuclide into the bronchoscopically-placed catheter by means of a remotely controlled device) have simplified radiation protection practices.",
"   </p>",
"   <p>",
"    HDR brachytherapy treatment is usually delivered in a series of dose fractions in order to optimize its effectiveness and minimize side effects. A wide variety of treatment schedules have been utilized; generally patients are treated no more than every one to two weeks because of the discomfort and logistical difficulties associated with more frequent bronchoscopies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual goal of brachytherapy is palliation of symptoms caused by large airway obstruction. However, the technique has also been employed postoperatively in patients found to have tumor at resection margins in an attempt to improve cure rates, or in patients with early stage lung cancer who can only tolerate sublobar resections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the use of endobronchial brachytherapy to treat nonmalignant lesions has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/19\">",
"     19",
"    </a>",
"    ], the technique has been used almost exclusively in patients with endobronchial tumors. Although the specific indications for this treatment modality vary among institutions, general criteria for treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biopsy-proven nonsmall cell carcinoma of the lung or an extrathoracic malignancy metastatic to lung",
"     </li>",
"     <li>",
"      Inability to tolerate or failure to respond to potentially curative therapies or debulking of the tumor with Nd:YAG laser or cryotherapy",
"     </li>",
"     <li>",
"      Inability to tolerate external bean radiation because of poor lung function",
"     </li>",
"     <li>",
"      Symptoms due to malignant endobronchial lesions, such as dyspnea, post-obstructive pneumonitis, hemoptysis, or intractable cough",
"     </li>",
"     <li>",
"      Lesions that are accessible to placement of a brachytherapy catheter",
"     </li>",
"     <li>",
"      Sufficient life expectancy (usually &gt;3 months) to derive palliative benefit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with unresectable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent lung carcinomas or malignancies metastatic to the airways are potential candidates for endobronchial brachytherapy. The lesion to be treated should be visible by bronchoscopy and generally located in the trachea, main stem, or lower lobe bronchi. Tumor can be either extrinsic or intrinsic to the airway and may involve submucosal infiltration, as long as a catheter for delivery of the radiation source can be passed distally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications to endobronchial brachytherapy include the presence of fistulas between bronchi and other structures. Patients with endotracheal lesions causing high grade obstruction should be treated with Nd:YAG laser and possible placement of a stent before brachytherapy, because immediate use of brachytherapy may result in postradiation tissue edema and complete airway obstruction. Brachytherapy is not practical in patients who cannot safely undergo bronchoscopy, and is not indicated in patients who are moribund.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of brachytherapy can occur early or late. Early complications are infrequent and usually due to bronchoscopy or catheter insertion. The most common early complications are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef50348 \" href=\"mobipreview.htm?17/19/17724\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late complications include radiation bronchitis and stenosis. They may occur days or weeks after therapy and can manifest with a cough or wheezing. Risk factors for these complications include a large cell carcinoma, use of brachytherapy for curative intent, prior laser resection, and concurrent external beam radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Massive hemoptysis and fistula formation are particularly serious late complications of endobronchial brachytherapy. Case series indicate that such adverse outcomes occur in up to 42 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/11,12,20,23-30\">",
"     11,12,20,23-30",
"    </a>",
"    ]. When treating lesions in close proximity to large vessels, it has been suggested that potential risk factors for these complications be excluded, including malignant involvement of the major arteries, significant destruction of the bronchial wall, and mediastinal invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/28,30,31\">",
"     28,30,31",
"    </a>",
"    ]. Computed tomography, magnetic resonance imaging, or digital subtraction angiography may be helpful in assessing these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major use of endobronchial brachytherapy is for the palliation of symptoms related to central airway obstruction. Data pertaining to its use for potential cure are limited.",
"   </p>",
"   <p>",
"    Responses in tumor size are most commonly evaluated by chest radiography and bronchoscopy. Some investigators use an obstruction score, but this has not been widely utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/32\">",
"     32",
"    </a>",
"    ]. According to some series, approximately 70 percent of patients have greater than 50 percent improvement in patency that persists for at least six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/11,33\">",
"     11,33",
"    </a>",
"    ]. Different series have enrolled patients with different characteristics, making the results difficult to generalize due to probable selection bias. In addition, a significant number of patients in some reports refused subsequent bronchoscopy, potentially resulting in an overestimation of effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjective improvement following brachytherapy has been reported in 20 to 100 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/13,29,34,35\">",
"     13,29,34,35",
"    </a>",
"    ]. The wide range likely reflects the variety of symptoms that existed prior to the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 50 patients treated with high dose rate (HDR) endobronchial brachytherapy, hemoptysis was relieved in 24 of 28 patients (86 percent), breathlessness in 21 of 33 (64 percent), and cough in 9 of 18 patients (50 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/36\">",
"       36",
"      </a>",
"      ]. These responses were maintained for four months.",
"     </li>",
"     <li>",
"      An observational study of 175 patients with lung cancer who received HDR brachytherapy for metastatic or locally recurrent lung cancer demonstrated symptomatic improvement in 115 patients (66 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/29\">",
"       29",
"      </a>",
"      ]. Repeat bronchoscopy found that 78 percent of patients responded to therapy, when a response to therapy was defined as at least 50 percent reopening of the normal lumen. Treatment-related complications were detected in only 19 patients (11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemoptysis tends to improve most readily, with a greater than 90 percent response rate in many series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/22,36-39\">",
"     22,36-39",
"    </a>",
"    ]. Cough and dyspnea improve less reliably, probably because they are frequently due to underlying conditions such as chronic obstructive pulmonary disease or radiation fibrosis.",
"   </p>",
"   <p>",
"    There is limited evidence suggesting that endobronchial brachytherapy plus endobronchial laser therapy may be superior to endobronchial laser therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/11,32,40\">",
"     11,32,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Curative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy might be curative in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/18,33,41,42\">",
"     18,33,41,42",
"    </a>",
"    ]. This is illustrated by the following observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 226 patients with non-small cell bronchial carcinoma (97 percent had squamous cell carcinoma) who were not candidates for surgery or external beam radiation therapy, HDR brachytherapy was associated with a complete endoscopic response rate of 94 percent at three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/43\">",
"       43",
"      </a>",
"      ]. The two- and five-year overall survival rates were 57 and 29 percent, respectively, while the two- and five-year cancer-specific survival rates were 81 and 56 percent, respectively.",
"     </li>",
"     <li>",
"      In a study of 106 patients with endobronchial lung cancer who were not candidates for surgery or external beam radiation therapy, HDR brachytherapy (six sessions of 5 or 7 Gy over five weeks) was associated with an overall five-year survival of 24 percent and a cause-specific five-year survival of 49 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/44\">",
"       44",
"      </a>",
"      ]. The difference in the five-year survival rates reflects the high rate of deaths not related to lung cancer in this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Brachytherapy versus external beam radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality studies directly comparing endobronchial brachytherapy with external beam radiation. Conventional external beam radiation therapy palliates symptoms of hemoptysis, dyspnea, or chest pain in 50 to 80 percent of patients for approximately 3 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/45\">",
"     45",
"    </a>",
"    ]. A systematic review that included several small randomized trials found external beam radiotherapy to be more effective for symptom palliation than endobronchial brachytherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/46\">",
"     46",
"    </a>",
"    ]. This suggests that for the majority of patients brachytherapy should not be considered until patients have first undergone external beam radiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39498?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of stage III non-small cell lung cancer\", section on 'Radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Brachytherapy plus external beam radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy has been combined with external beam radiation, which might theoretically translate into improved efficacy and safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/46-52\">",
"     46-52",
"    </a>",
"    ]. However, in a systematic review of a small number of trials, brachytherapy combined with external beam radiotherapy provided no greater symptom relief than external beam radiotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32038/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endobronchial brachytherapy refers to the placement of a radioactive source within or in close proximity to a malignancy in order to provide local radiation therapy. This approach delivers the highest doses of radiation in close proximity to the tumor. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific indications for endobronchial brachytherapy have not been established and the technique has been used in a wide variety of patients. Both early and late complications exist. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endobronchial brachytherapy is effective in palliating symptoms caused by malignant endobronchial tumors, including dyspnea, hemoptysis, and cough, although not more effective than external beam radiotherapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brachytherapy might be curative in selected patients, who are not candidates for surgical resection or curative external beam radiotherapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/1\">",
"      Hilaris BS, Mastoras DA. Contemporary brachytherapy approaches in non-small-cell lung cancer. J Surg Oncol 1998; 69:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/2\">",
"      Raben A, Mychalczak B. Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest. Chest 1997; 112:276S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/3\">",
"      Yankauer, S. Two cases of lung tumor treated bronchoscopically. NY Med J 1922; 21:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/4\">",
"      Kernan, JD, Cracovaner, AJ. Carcinoma of the lung. Arch Surg 1929; 18:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/5\">",
"      Kernan, JD. Carcinoma of the lung and bronchus. Treatment with radon implantation and diathermy. Arch Otolaryngol 1933; 17:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/6\">",
"      Gaspar LE. Brachytherapy in lung cancer. J Surg Oncol 1998; 67:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/7\">",
"      HENSCHKE UK, HILARIS BS, MAHAN GD. REMOTE AFTERLOADING WITH INTRACAVITARY APPLICATORS. Radiology 1964; 83:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/8\">",
"      Moylan D, Strubler K, Unal A, et al. Work in progress. Transbronchial brachytherapy of recurrent bronchogenic carcinoma: a new approach using the flexible fiberoptic bronchoscope. Radiology 1983; 147:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/9\">",
"      Mendiondo OA, Dillon M, Beach LJ. Endobronchial brachytherapy in the treatment of recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1983; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/10\">",
"      Schray MF, McDougall JC, Martinez A, et al. Management of malignant airway obstruction: clinical and dosimetric considerations using an iridium-192 afterloading technique in conjunction with the neodymium-YAG laser. Int J Radiat Oncol Biol Phys 1985; 11:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/11\">",
"      Schray MF, McDougall JC, Martinez A, et al. Management of malignant airway compromise with laser and low dose rate brachytherapy. The Mayo Clinic experience. Chest 1988; 93:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/12\">",
"      Seagren SL, Harrell JH, Horn RA. High dose rate intraluminal irradiation in recurrent endobronchial carcinoma. Chest 1985; 88:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/13\">",
"      Villanueva AG, Lo TC, Beamis JF Jr. Endobronchial brachytherapy. Clin Chest Med 1995; 16:445.",
"     </a>",
"    </li>",
"    <li>",
"     Shaw, EG, McDougall, JC. Bronchoscopic brachytherapy. In: Bronchoscopy, Prakash, UBS (Eds), Raven Press, New York 1994. p.293-300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/15\">",
"      Nag S, Kelly JF, Horton JL, et al. Brachytherapy for carcinoma of the lung. Oncology (Williston Park) 2001; 15:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/16\">",
"      Nori D, Hilaris BS, Martini N. Intraluminal irradiation in bronchogenic carcinoma. Surg Clin North Am 1987; 67:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/17\">",
"      d'Amato TA, Galloway M, Szydlowski G, et al. Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer. Chest 1998; 114:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/18\">",
"      Marsiglia H, Baldeyrou P, Lartigau E, et al. High-dose-rate brachytherapy as sole modality for early-stage endobronchial carcinoma. Int J Radiat Oncol Biol Phys 2000; 47:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/19\">",
"      Kramer MR, Katz A, Yarmolovsky A, et al. Successful use of high dose rate brachytherapy for non-malignant bronchial obstruction. Thorax 2001; 56:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/20\">",
"      Allen MD, Baldwin JC, Fish VJ, et al. Combined laser therapy and endobronchial radiotherapy for unresectable lung carcinoma with bronchial obstruction. Am J Surg 1985; 150:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/21\">",
"      Ofiara L, Roman T, Schwartzman K, Levy RD. Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma. Chest 1997; 112:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/22\">",
"      Speiser BL, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 1993; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/23\">",
"      Bedwinek J, Petty A, Bruton C, et al. The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1992; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/24\">",
"      Lo TC, Beamis JF Jr, Weinstein RS, et al. Intraluminal low-dose rate brachytherapy for malignant endobronchial obstruction. Radiother Oncol 1992; 23:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/25\">",
"      Mehta MP, Shahabi S, Jarjour NN, Kinsella TJ. Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys 1989; 17:847.",
"     </a>",
"    </li>",
"    <li>",
"     Speiser, B, Spratling, L. High dose rate remove afterloading brachytherapy in the control of endobronchial carcinoma. In: Brachytherapy HDR and LDR, Martinez, AA, Orton, CG, Mould, RF (Eds), Nucletron Corp, Columbia, MD 1990. p.10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/27\">",
"      Sutedja G, Baris G, Schaake-Koning C, van Zandwijk N. High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/28\">",
"      Khanavkar B, Stern P, Alberti W, Nakhosteen JA. Complications associated with brachytherapy alone or with laser in lung cancer. Chest 1991; 99:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/29\">",
"      Kelly JF, Delclos ME, Morice RC, et al. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys 2000; 48:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/30\">",
"      Hara R, Itami J, Aruga T, et al. Risk factors for massive hemoptysis after endobronchial brachytherapy in patients with tracheobronchial malignancies. Cancer 2001; 92:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/31\">",
"      Hennequin C, Tredaniel J, Chevret S, et al. Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysis. Int J Radiat Oncol Biol Phys 1998; 42:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/32\">",
"      Speiser B, Spratling L. Intermediate dose rate remote afterloading brachytherapy for intraluminal control of bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1990; 18:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/33\">",
"      Nori D, Allison R, Kaplan B, et al. High dose-rate intraluminal irradiation in bronchogenic carcinoma. Technique and results. Chest 1993; 104:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/34\">",
"      Taulelle M, Chauvet B, Vincent P, et al. High dose rate endobronchial brachytherapy: results and complications in 189 patients. Eur Respir J 1998; 11:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/35\">",
"      Guarnaschelli JN, Jose BO. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience. J Palliat Med 2010; 13:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/36\">",
"      Burt PA, O'Driscoll BR, Notley HM, et al. Intraluminal irradiation for the palliation of lung cancer with the high dose rate micro-Selectron. Thorax 1990; 45:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/37\">",
"      Chang LF, Horvath J, Peyton W, Ling SS. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer. Int J Radiat Oncol Biol Phys 1994; 28:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/38\">",
"      Gollins SW, Burt PA, Barber PV, Stout R. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol 1994; 33:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/39\">",
"      Pisch J, Villamena PC, Harvey JC, et al. High dose-rate endobronchial irradiation in malignant airway obstruction. Chest 1993; 104:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/40\">",
"      Shea JM, Allen RP, Tharratt RS, et al. Survival of patients undergoing Nd:YAG laser therapy compared with Nd:YAG laser therapy and brachytherapy for malignant airway disease. Chest 1993; 103:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/41\">",
"      Sutedja G, Baris G, van Zandwijk N, Postmus PE. High-dose rate brachytherapy has a curative potential in patients with intraluminal squamous cell lung cancer. Respiration 1994; 61:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/42\">",
"      P&eacute;rol M, Caliandro R, Pommier P, et al. Curative irradiation of limited endobronchial carcinomas with high-dose rate brachytherapy. Results of a pilot study. Chest 1997; 111:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/43\">",
"      Aumont-le Guilcher M, Prevost B, Sunyach MP, et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Radiat Oncol Biol Phys 2011; 79:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/44\">",
"      Hennequin C, Bleichner O, Tr&eacute;daniel J, et al. Long-term results of endobronchial brachytherapy: A curative treatment? Int J Radiat Oncol Biol Phys 2007; 67:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/45\">",
"      Murren JR, Buzaid AC. Chemotherapy and radiation for the treatment of non-small-cell lung cancer. A critical review. Clin Chest Med 1993; 14:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/46\">",
"      Reveiz L, Rueda J-R, Cardona AF. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2012; :CD004284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/47\">",
"      Saito M, Yokoyama A, Kurita Y, et al. Treatment of roentogenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1996; 34:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/48\">",
"      Yokomise H, Nishimura Y, Fukuse T, et al. Long-term remission after brachytherapy with external irradiation for locally advanced lung cancer. Respiration 1998; 65:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/49\">",
"      Hernandez P, Gursahaney A, Roman T, et al. High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation. Thorax 1996; 51:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/50\">",
"      Saito M, Yokoyama A, Kurita Y, et al. Treatment of roentgenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low-dose-rate brachytherapy: second report. Int J Radiat Oncol Biol Phys 2000; 47:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/51\">",
"      Huber RM, Fischer R, Hautmann H, et al. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 1997; 38:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32038/abstract/52\">",
"      Ozkok S, Karakoyun-Celik O, Goksel T, et al. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients. Lung Cancer 2008; 62:326.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4408 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32038=[""].join("\n");
var outline_f31_18_32038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Palliation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Curative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Brachytherapy versus external beam radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Brachytherapy plus external beam radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4408|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/19/17724\" title=\"table 1\">",
"      Complications of bronchoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=related_link\">",
"      Bronchoscopic cryosurgery: Principles and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=related_link\">",
"      Endobronchial electrocautery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_18_32039="Plasma derivatives and recombinant DNA-produced coagulation factors";
var content_f31_18_32039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Plasma derivatives and recombinant DNA-produced coagulation factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32039/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32039/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32039/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32039/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/18/32039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma derivatives are products manufactured from human plasma by plasma fractionation techniques. Although dozens of proteins can be so purified, some are considered orphan drugs, and many are not widely used or available.",
"   </p>",
"   <p>",
"    An introduction to these plasma derivatives, including those manufactured using recombinant DNA techniques, will be presented here (eg, immune globulins, coagulation proteins, and protease inhibitors). Viral inactivation of blood products is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the preparation and use of plasma \"components\" (ie, those prepared by differential centrifugation techniques, including fresh frozen plasma and cryoprecipitate) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11895?source=see_link\">",
"     \"Preparation of blood components\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link\">",
"     \"Clinical use of plasma components\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrin sealant (fibrin \"glue\"), a two-component system in which a solution of concentrated fibrinogen and factor XIII is combined with a solution of thrombin and calcium in order to form a coagulum, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY AND METHODOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During World War I surgeons developed a better understanding of shock when organ failure resulted from large volume blood loss, and by the late 1930s methods for freeze-drying plasma had been developed. The use of such plasma required mixing, under battlefield conditions, with sterile water, a time-consuming process. In addition, pooled, freeze-dried plasma frequently transmitted serum hepatitis.",
"   </p>",
"   <p>",
"    The development of plasma fractionation took place under the pressure of devising products for the treatment of war casualties in the early 1940s. Harvard biochemist Edwin J. Cohn and a team of scientists developed what became known as the Cohn plasma fractionation process, also known as cold ethanol fractionation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional methods for purifying certain of these proteins involve ion exchange, immune affinity chromatography, and other separation techniques, but modifications of the original cold ethanol process remain the mainstay for the production of plasma derivatives. Currently, derivatives manufacturers perform various additional steps to inactivate viruses and other infectious agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALBUMIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human serum albumin became the mainstay of the treatment of shock on the battlefield and in the emergency department for decades and is still in widespread use, although colloid therapy for routine resuscitation offers no therapeutic advantage over crystalloid fluid resuscitation. For reasons of efficacy and expense, non-plasma-derived crystalloids (eg, saline) and colloids (eg, hydroxyethyl starch,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    ) have generally supplanted albumin for the primary treatment of hypovolemic shock. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Available preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human serum albumin is available in both 5 and 25 percent solutions, the former being isosmotic with plasma. Both have been pasteurized and do not transmit any known infectious diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/3\">",
"     3",
"    </a>",
"    ]. The 25 percent albumin solution should never be used for shock alone without other fluid volume replacement, since the hyperosmotic 25 percent solution will draw fluids from the extravascular space into the vascular space.",
"   </p>",
"   <p>",
"    The 25 percent solution is sometimes diluted by pharmacies or nursing staff to a volume of 250 mL of 5 percent solution from its original 50 mL volume. This must be done ONLY WITH NORMAL SALINE. A number of cases of hemolysis in patients undergoing therapeutic plasmapheresis due to dilution of 25 percent albumin with sterile water have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Plasma protein fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;This less frequently used product \"plasma protein fraction\" contains primarily albumin (about 90 percent) and historically is less expensive than albumin. It is available in 5 percent solutions and contains some globulins as well as albumin. Prekallikrein activation, with attendant development of anaphylactic shock, caused some problems many years ago, but the manufacturing process now removes these proteins. The indications for use of plasma protein fraction are similar to those for albumin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major indications for use of albumin include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma volume expansion and maintenance of cardiac output in shock was a prior indication for use of albumin. However, less expensive crystalloid therapy provides similar outcomes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Choice of replacement fluid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Albumin and thawed frozen plasma are the principal replacement fluids for therapeutic plasma exchange",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plasmapheresis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link&amp;anchor=H6#H6\">",
"       \"Prescription and technique of therapeutic plasma exchange\", section on 'Replacement fluids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Albumin may be of value in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an adjunct to large volume paracentesis in the treatment of diuretic-resistant ascites in cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35465?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of diuretic-resistant ascites in patients with cirrhosis\", section on 'Colloid replacement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data on the efficacy of intravenous albumin for the prevention of ovarian hyperstimulation syndrome are conflicting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22647?source=see_link\">",
"       \"Prevention of ovarian hyperstimulation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of the hepatorenal syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=see_link&amp;anchor=H11#H11\">",
"       \"Hepatorenal syndrome\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4121?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment and prophylaxis of spontaneous bacterial peritonitis\", section on 'Intravenous albumin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of albumin solutions for nutritional supplementation is NOT an appropriate indication for this product. Its value in pancreatitis, severe burns, the edema of nephrotic syndrome, acute respiratory distress syndrome, and traumatic brain injury is either unproven or harmful (see appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMMUNE GLOBULINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original Cohn fractionation process precipitates immune globulins (and some coagulation factors) in fractions II and III, from which relatively pure concentrations of (primarily) IgG can be produced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intramuscular immune serum globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune serum globulin (ISG) is a 16 percent solution of immune globulins prepared for intramuscular injection, which contains, due to the large pool size of the plasma being fractionated, protective titers of antibodies to numerous infective agents, including hepatitis A and B viruses. ISG production includes pathogen reduction steps to reduce virus transmission; the final products must test negative for HCV RNA by nucleic acid testing.",
"   </p>",
"   <p>",
"    ISG or hepatitis A vaccination provide good protection against hepatitis A infection postexposure or as prophylaxis. Intravenous immune globulin preparations contain anti-HAV antibodies, but intramuscular preparations are used to prevent HAV infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=see_link&amp;anchor=H20#H20\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\", section on 'Postexposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IGIV, IVIG) is prepared as a 5 or 6 percent solution and has revolutionized the treatment of primary and acquired hypogammaglobulinemia in children and adults. It is also widely used for the treatment of refractory ITP, autoimmune disorders, Kawasaki syndrome, and a variety of other conditions, including post-transfusion purpura, neonatal alloimmune thrombocytopenia, and acquired hemophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17175?source=see_link\">",
"     \"Intravenous immune globulin in hematologic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperimmune globulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperimmune globulins, prepared primarily for intramuscular use, but in some instances for use intravenously, are made by selecting plasma with high titers of the desired antibody or by specifically immunizing donors to produce such antibodies.",
"   </p>",
"   <p>",
"    Hyperimmune globulins are available for temporary, passive immunization against hepatitis B (HBIG), cytomegalovirus (CMVIG), varicella zoster (VZIG), respiratory syncytial virus (RSVIG), rabies, pertussis, vaccinia, and botulinum toxin. It is theoretically possible to produce a hyperimmune globulin to any organism that can safely be used to immunize humans. This may be especially helpful in the case of pandemic disease, such as H1N1 influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Production of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=see_link\">",
"     varicella zoster immune globulin",
"    </a>",
"    (VZIG) ceased in 2004. An investigational preparation (VariZIG) is commercially available in Canada and available in the United States under an investigational new drug application expanded access protocol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link&amp;anchor=H11#H11\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\", section on 'VariZIG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-Rho(D) preparations are used for the prevention of Rh(D) sensitization in Rh(D)-negative pregnant women, and have also found use in the treatment of immune thrombocytopenia (ITP) in Rh(D)-positive individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Intravenous immunoglobulin and anti-D'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COAGULATION FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fibrinogen concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A human plasma-derived",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/20/14659?source=see_link\">",
"     fibrinogen concentrate",
"    </a>",
"    (RiaSTAP) is available. It is indicated for the treatment of bleeding in patients with congenital afibrinogenemia or hypofibrinogenemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=see_link&amp;anchor=H11520867#H11520867\">",
"     \"Disorders of fibrinogen\", section on 'Fibrinogen concentrate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Thrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A human thrombin product derived from human plasma was licensed in 2007 (Evithrom). It is indicated in order to stop oozing as well as minor capillary and small vein bleeding when standard surgical techniques are ineffective or impractical. This product is applied to surfaces of bleeding tissue and may be used along with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/4/18499?source=see_link\">",
"     absorbable gelatin sponge",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25094?source=see_link&amp;anchor=H5#H5\">",
"     \"Fibrin sealant\", section on 'Thrombin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recombinant thrombin (Recothrom), licensed in 2008, is a recombinant form of thrombin used for the same indications.",
"   </p>",
"   <p>",
"    Since these products contain no animal protein, they serve as alternatives to bovine thrombin products with their potential risk for immune-mediated coagulopathy associated with factor V, and less frequently factor IIa, antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=see_link&amp;anchor=H22#H22\">",
"     \"Acquired inhibitors of coagulation\", section on 'Factor V inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prothrombin complex concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of cryoprecipitate in 1964 thoroughly revolutionized the treatment of hemophilia A (ie, congenital factor VIII deficiency) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/6\">",
"     6",
"    </a>",
"    ]. A decade later, using the cryoprecipitated fraction of large plasma pools as starting material, several processes for isolating and purifying factor VIII were developed, along with concentrates of the prothrombin complex of proteins (ie, factors II, VII, IX, and X). The subsequent ability to purify factor IX from the prothrombin complex led to an improved source of factor IX for the treatment of hemophilia B (ie, congenital factor IX deficiency).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       solvent/detergent-treated",
"      </span>",
"      unactivated prothrombin complex concentrate, containing factors II, VII, IX, and X as well as proteins C and S, has been used in patients requiring immediate reversal of oral anticoagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. This preparation (Octaplex), which is available in Canada and Europe, but is",
"      <strong>",
"       not",
"      </strong>",
"      available in the United States, contains",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , and is contraindicated for use in patients with a prior diagnosis of heparin-induced thrombocytopenia.",
"     </li>",
"     <li>",
"      The prothrombin complex concentrates available in the United States have been called \"3-factor PCCs\", because they have low or very low concentrations of factor VII. Accordingly, the use of these concentrates for warfarin-associated bleeding may be suboptimal, although this has not been tested in a controlled setting.",
"     </li>",
"     <li>",
"      PCCs contain variable amounts of IgA. Caution must be exercised with their use in patients with IgA deficiency, anti-IgA antibodies, and previously documented reactions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30998?source=see_link&amp;anchor=H24166172#H24166172\">",
"       \"Selective IgA deficiency: Management and prognosis\", section on 'Safe administration of blood products'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Purified human plasma-derived factor IX concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;This highly purified factor IX concentrate, isolated during Cohn-Oncley fractionation, has less coagulation activation than PCCs; its use is associated with a reduced incidence of thrombotic events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of hemophilia\", section on 'Factor IX products'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Activated PCCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since varying degrees of activation of factor X, the critical protein in the common pathway of the coagulation cascade, occur during isolation of the prothrombin complex, such concentrates can be used to bypass the intrinsic pathway of the coagulation process and be used to treat patients with inhibitors of factor VIII, as can recombinant DNA factor VIIa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, prior to purification of factor IX, many patients suffered significant morbidity or mortality from excessive clotting (eg, disseminated intravascular coagulation, deep vein thrombosis, pulmonary embolus, myocardial infarction) generated by the presence of activated factors in prothrombin complex concentrates. The risk of thrombosis using this product appears to be especially high in patients receiving high or multiple doses as well as those with liver disease who are unable to adequately clear these activated products from the circulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H17#H17\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Activated prothrombin complex concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several products (Autoplex T, Feiba VH [",
"    <strong>",
"     F",
"    </strong>",
"    actor",
"    <strong>",
"     E",
"    </strong>",
"    ight",
"    <strong>",
"     I",
"    </strong>",
"    nhibitor",
"    <strong>",
"     B",
"    </strong>",
"    ypassing",
"    <strong>",
"     A",
"    </strong>",
"    ctivity]) are available in which components of the prothrombin complex have been purposefully activated during the fractionation process. These products are intended for use in bleeding patients with circulating inhibitors, although controlled trials have shown variable improvement over standard prothrombin complex concentrates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H17#H17\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Activated prothrombin complex concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Factor VIII concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Von Willebrand factor and human",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    are prepared from cryoprecipitate during Cohn-Oncley fractionation. An affinity chromatography purification stage that incorporates immobilized monoclonal anti-factor VIII antibodies may be used to capture factor VIII, allowing other proteins and viruses to pass through. Treatment with",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    or pasteurization protects against HBV, HCV, and HIV transmission.",
"   </p>",
"   <p>",
"    Ion exchange chromatography procedures rather than monoclonal anti-factor VIII affinity columns are used in the preparation of factor VIII-containing von Willebrand factor concentrates. These products are protected from viral transmission by pathogen reduction techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of von Willebrand disease\", section on 'Replacement therapy with VWF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Porcine factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porcine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    (Hyate:C, Speywood) are manufactured from porcine plasma and had been used in patients with a high titer of antibodies to human factor VIII, which either do not cross-react, or which minimally cross-react, with the porcine factor VIII molecule. However, plasma-derived porcine factor VIII has not been available since 2004.",
"   </p>",
"   <p>",
"    A recombinant porcine factor VIII is currently in phase",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    trials and has not yet been licensed by the United States FDA or the EMA in Europe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H15#H15\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Porcine factor VIII concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Protein C concentrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007 the United States FDA licensed a human plasma-derived",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/50/6949?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    (Ceprotin, Baxter) for the treatment of patients with severe congenital protein C deficiency, and for the prevention and treatment of venous thrombosis and purpura fulminans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link&amp;anchor=H10#H10\">",
"     \"Protein C deficiency\", section on 'Neonatal purpura fulminans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link&amp;anchor=H13#H13\">",
"     \"Protein C deficiency\", section on 'Warfarin-induced skin necrosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Protein C concentrate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Protein C concentrate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RECOMBINANT COAGULATION FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Factors VIII and IX",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major step towards reducing the risk of hemophilia treatment occurred with the cloning of the gene for, and subsequent expression of the protein, antihemophilic factor, factor VIII. A recombinant factor IX has also been produced for the treatment of hemophilia B. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hemophilia\", section on 'Recombinant human factor VIII'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of hemophilia\", section on 'Recombinant factor IX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies led to some concerns that these highly purified, highly specific proteins would lead to an increase in the development of antibodies to coagulation factors, which occur in up to 36 percent of patients with severe hemophilia A. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=see_link&amp;anchor=H2#H2\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Inhibitors in hemophilia A'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant DNA-produced activated factor VII (VIIa) is commercially available (Novo-Seven&reg;). Clinical use of this product, including \"off-label\" uses, is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Activated protein C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activated protein C has both anticoagulant, as well as anti-inflammatory activity. An activated, recombinant form of protein C had been commercially available (Xigris, drotrecogin alfa) for reduction of mortality from severe sepsis associated with organ dysfunction in adults at high risk of death (eg, APACHE II score &ge;25). This product was voluntarily removed from the market in September 2011 when it failed to show a survival benefit for such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROTEASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human plasma contains a variety of protease inhibitors designed to inhibit, or modulate, the activation of coagulation, fibrinolysis, complement activation, and other functions. Three protease inhibitors isolated from human plasma are commercially available and have important clinical applications. These include antithrombin (AT), C1-esterase inhibitor, and alpha-1 antitrypsin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antithrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombin (AT, Thrombate III, formerly called antithrombin III) is a major inhibitor of thrombin and of activated Factor X (Xa), and also has an effect on activated Factors IX and XI. It has a strong affinity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , which enhances its anticoagulant effects.",
"   </p>",
"   <p>",
"    AT concentrates derived from human plasma are indicated for treatment of patients with hereditary AT deficiency in connection with surgery or obstetrical procedures or when they suffer from thromboembolism. This product is no longer recommended for patients with DIC who are not receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23752?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of inherited thrombophilia\", section on 'Antithrombin deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A recombinant AT, produced in the milk of transgenic goats carrying a copy of the cDNA for human AT, has been used in Europe since 2006. It has been approved by the United States FDA (rhAT, ATryn, Lundbeck) for use in patients with inherited AT deficiency to prevent thrombosis during or after surgery or childbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32039/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     C1-esterase inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1-esterase inhibitor limits the activity of C1-esterase on complement activation; a deficiency of this factor is associated with hereditary angioneurotic edema. The transfusion of C1-esterase inhibitor concentrate prepared from human plasma (or fresh frozen plasma) is indicated for routine prophylaxis against angioedema in adolescent or adult patients with this disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'C1-inhibitor (plasma-derived)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Alpha-1 antitrypsin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-1 antitrypsin prepared from human plasma (Prolastin) has been used to treat the autosomal defect characterized by an increased risk for emphysema, and less frequently for liver disease and panniculitis. It is indicated for chronic replacement therapy for individuals with congenital alpha-1-antitrypsin deficiency with clinically demonstrable panacinar emphysema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16361?source=see_link\">",
"     \"Treatment of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13611864\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma derivatives are products manufactured from human plasma by plasma fractionation techniques. Although dozens of proteins can be so purified, some are considered orphan drugs. Many are not widely used and some are available only in certain countries. The most important ones are listed below and are discussed in the text and elsewhere in UpToDate:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Albumin and plasma protein fraction",
"     </li>",
"     <li>",
"      Immune globulins and hyperimmune globulins",
"     </li>",
"     <li>",
"      Coagulation factors (eg, fibrinogen, prothrombin complex, factors VIII, IX, XI, von Willebrand factor)",
"     </li>",
"     <li>",
"      Protease inhibitors (eg, antithrombin, C1-esterase inhibitor, alpha-1 antitrypsin)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the possibility of viral infection from the use of human plasma, a number of the above-listed proteins are now commercially available through the use of recombinant techniques, and are listed below. Others are in active development.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Factors VIIa, VIII, IX",
"     </li>",
"     <li>",
"      Thrombin",
"     </li>",
"     <li>",
"      Activated protein C",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Starr D. Again and again in World War II, blood made the difference. The Smithsonian Magazine, Washington, DC, March 1995. p.124.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/2\">",
"      Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/3\">",
"      Bl&uuml;mel J, Schmidt I, Willkommen H, L&ouml;wer J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/4\">",
"      Arroyo V, Guevara M, Gin&egrave;s P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/5\">",
"      Kreil TR, Mc Vey JK, Lei LS, et al. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Transfusion 2012; 52:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/6\">",
"      POOL JG, GERSHGOLD EJ, PAPPENHAGEN AR. HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE. Nature 1964; 203:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/7\">",
"      Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/8\">",
"      Riess HB, Meier-Hellmann A, Motsch J, et al. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/9\">",
"      Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009; 113:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/10\">",
"      Barnett B, Kruse-Jarres R, Leissinger CA. Current management of acquired factor VIII inhibitors. Curr Opin Hematol 2008; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/11\">",
"      Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/12\">",
"      Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/13\">",
"      Tiede A, Tait RC, Shaffer DW, et al. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost 2008; 99:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32039/abstract/14\">",
"      Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43:390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7925 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32039=[""].join("\n");
var outline_f31_18_32039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13611864\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY AND METHODOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALBUMIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Available preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Plasma protein fraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMMUNE GLOBULINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intramuscular immune serum globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperimmune globulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COAGULATION FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fibrinogen concentrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Thrombin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prothrombin complex concentrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Purified human plasma-derived factor IX concentrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Activated PCCs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Factor VIII concentrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Porcine factor VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Protein C concentrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RECOMBINANT COAGULATION FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Factors VIII and IX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Activated protein C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROTEASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antithrombin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      C1-esterase inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Alpha-1 antitrypsin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13611864\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17175?source=related_link\">",
"      Intravenous immune globulin in hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22647?source=related_link\">",
"      Prevention of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30998?source=related_link\">",
"      Selective IgA deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4121?source=related_link\">",
"      Treatment and prophylaxis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/62/16361?source=related_link\">",
"      Treatment of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_18_32040="Enalapril: Pediatric drug information";
var content_f31_18_32040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enalapril: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"    see \"Enalapril: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/31/30197?source=see_link\">",
"    see \"Enalapril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vasotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F164752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Enalapril&reg;;",
"     </li>",
"     <li>",
"      CO Enalapril;",
"     </li>",
"     <li>",
"      Mylan-Enalapril;",
"     </li>",
"     <li>",
"      Novo-Enalapril;",
"     </li>",
"     <li>",
"      PMS-Enalapril;",
"     </li>",
"     <li>",
"      PRO-Enalapril;",
"     </li>",
"     <li>",
"      RAN&trade;-Enalapril;",
"     </li>",
"     <li>",
"      ratio-Enalapril;",
"     </li>",
"     <li>",
"      Riva-Enalapril;",
"     </li>",
"     <li>",
"      Sandoz-Enalapril;",
"     </li>",
"     <li>",
"      Sig-Enalapril;",
"     </li>",
"     <li>",
"      Taro-Enalapril;",
"     </li>",
"     <li>",
"      Teva-Enalapril;",
"     </li>",
"     <li>",
"      Vasotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13732756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13732924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or in those receiving diuretics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 0.04-0.1 mg/kg/day every 24 hours; initiate at the lower end of the range and titrate to effect as required every few days; hypotension and oliguria have been associated with initial doses of 0.1 mg/kg (Dutta, 2003; Schilder, 1995); maximum reported dose: 0.27 mg/kg/day (Leversha, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Use in neonates with GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     is not recommended; no dosing data available",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13732764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"      see \"Enalapril: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or in those receiving diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heart Failure:",
"     </b>",
"     Limited data available: Oral: Initial: 0.1 mg/kg/day in 1-2 divided doses; increase as required over 2 weeks to maximum of 0.5 mg/kg/day; mean dose required for CHF improvement in 39 children (mean age: 4 years) was 0.36 mg/kg/day; select individuals have been treated with doses up to 0.94 mg/kg/day (Leversha, 1994; Momma, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 0.08 mg/kg once daily (maximum dose: 5 mg); adjust dose according to blood pressure readings; doses &gt;0.58 mg/kg (or &gt;40 mg) have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Proteinuria, nephrotic syndrome:",
"     </b>",
"     Limited data available; further studies are needed: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Fixed dosing: Children &ge;7 years and Adolescents: 2.5-5 mg/day was reported in a retrospective study in normotensive pediatric patients as either monotherapy (n=17; mean age: 13.7 years; range: 8-17 years) or with prednisone (n=11; mean age: 12.6 years; range: 7-16 years); significant decrease in proteinuria (with or without nephrotic syndrome) occurred; no significant change in blood pressure was observed (Sasinka, 1999); a case series of three adolescents with sickle anemia  nephropathy reported an initial dose of 5 mg/day; one patient required an increase to 7.5 mg/day (Fitzhugh, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight-based directed dosing: Children and Adolescents: Initial: 0.2 mg/kg/day; titrate to response at 4- to 12-week intervals; range: 0.2-0.6 mg/kg/day; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; a crossover dose comparison trial showed effects on proteinuria were dose-dependent (Bagga, 2004; Chandar, 2007; Delucchi, 2000; Lama, 2000; White, 2003); if combined with other angiotensin blockade (ARB), lower doses have been reported (0.1-0.16 mg/kg/day) (Chandar, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Asymptomatic left ventricular dysfunction:",
"     </b>",
"     Oral: Initial: 2.5 mg twice daily; increase as tolerated; usual dose: 20 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 2.5 mg once or twice daily (usual range: 5-40 mg/day in 2 divided doses); titrate slowly at 1- to 2-week intervals. Target dose: 10-20 mg twice daily (ACC/AHA 2009 Heart Failure Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 2.5-5 mg/day then increase as required, usually at 1- to 2-week intervals; usual dose range (JNC 7): 2.5-40 mg/day in 1-2 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Initiate with 2.5 mg if patient is taking a diuretic which cannot be discontinued. May add a diuretic if blood pressure cannot be controlled with enalapril alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s labeling: Use in infants, children, and adolescents &le;16 years of age with GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     is not recommended; no dosing data available in this population",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &gt;50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR 10-50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &lt;10 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Administer 2.5 mg/day; titrate upward until blood pressure is controlled",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Alternate recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR 10-50 mL/minute: Administer 50% to 100% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &lt;10 mL/minute: Administer 25% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary, although some removal of drug occurs",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 2.5 mg, 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vasotec&reg;: 2.5 mg, 5 mg, 10 mg, 20 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13732991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13732874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13732757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild to severe hypertension (FDA approved in ages 1 month to 16 years and adults), CHF (FDA approved in adults), and asymptomatic left ventricular dysfunction (FDA approved in adults); has also been used to treat proteinuria in steroid-resistant nephrotic syndrome patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F164813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Enalapril may be confused with Anafranil&reg;, Elavil&reg;, Eldepryl&reg;, ramipril",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril [Hungary, Switzerland] may be confused with Accupril which is a brand name for quinapril [U.S., Canada, multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril: Brand name for enalapril [Hungary, Switzerland], but also brand name for captopril [Great Britain]; lisinopril [Malaysia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F164810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypotension, orthostasis, orthostatic hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abnormal taste, anorexia, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased, worsening of renal function (in patients with bilateral renal artery stenosis or hypovolemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alopecia, anaphylactoid reaction, angina pectoris, angioedema, ataxia, atrial fibrillation, atrial tachycardia, bone marrow suppression, bradycardia, cardiac arrest, cerebral vascular accident, cholestatic jaundice, depression, eosinophilia, eosinophilic pneumonitis, erythema multiforme, erythrocyte sedimentation rate increased, exfoliative dermatitis, giant cell arteritis, gynecomastia, hallucinations, hemolysis with G6PD, Henoch-Sch&ouml;nlein purpura, hepatitis, ileus, interstitial nephritis, lichen-form reaction, melena, MI, neutropenia, ototoxicity, pancreatitis, pemphigus, pemphigus foliaceus, peripheral neuropathy, photosensitivity, positive ANA, psychosis, pulmonary edema, pulmonary embolism, pulmonary infiltrates, Raynaud&rsquo;s phenomenon, sicca syndrome, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombocytopenia, toxic epidermal necrolysis, toxic pustuloderma, vasculitis, visual hallucinations (Doane, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13732758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enalapril, enalaprilat, any component, or other ACE inhibitors; patients with idiopathic or hereditary angioedema or a history of angioedema with ACE inhibitors; in patients with diabetes, concurrent use with aliskiren",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13732771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Use with caution in patients with renal impairment; dosage reduction may be necessary; avoid rapid dosage escalation which may lead to further renal impairment. Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Use with caution when initiating therapy and in volume-depleted patients; may cause symptomatic hypotension with or without syncope, usually with the first several doses; correct volume depletion prior to initiation; initiate lower doses in patients with sodium or volume depletion; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension alone is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation. Use caution in patients with ischemic heart disease or cerebrovascular disease during therapy initiation; observe closely due to the potential consequences posed by falling blood pressure (eg, MI, stroke); fluid replacement, may be required to restore blood pressure; therapy may then be resumed; discontinue therapy in patients whose hypotension recurs. Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hyperkalemia; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution, if at all, with these agents, and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution before, during, or immediately after major surgery; cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release; use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. In pediatric patients, an isolated dry hacking cough  lasting &gt;3 weeks was reported in seven of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier, 2000); a review of pediatric randomized-controlled ACE inhibitor trials reported a lower incidence of  3.2% (Baker-Smith, 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13732759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Angioedema can occur at any time during treatment (especially following first dose). The relative risk of angioedema with ACE inhibitors is higher within the first 30 days of use (compared to &gt;1 year of use), for Black Americans (compared to Whites), for lisinopril or enalapril (compared to captopril), and for patients previously hospitalized within 30 days (Brown, 1996). Angioedema may occur in the head, neck, extremities, or intestines; patients with angioedema of the intestines may present with abdominal pain (with or without nausea or vomiting); angioedema of the larynx, glottis, or tongue may cause airway obstruction, especially in patients with a history of airway surgery. Prolonged monitoring may be required, even in patients with swelling of only the tongue (ie, without respiratory distress) because treatment with corticosteroids and antihistamines may not be sufficient; very rare fatalities have occurred with angioedema of the larynx or tongue; appropriate treatment (eg, establishing patent airway and/or SubQ epinephrine) should be readily available for patients with angioedema of larynx, glottis, or tongue, in whom airway obstruction is likely to occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Life-threatening anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Enalapril has been associated with rare but potentially fatal cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia; higher risk for development of neutropenia is associated with renal impairment; risk is further increased in patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus). Onset of neutropenia is usually within 3 months of captopril initiation; closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients; neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     ACE inhibitor use has been associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs and initiate appropriate medical treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13732761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect absorption. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Enalaprilat, the active metabolite of enalapril, crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. The use of these drugs in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13732765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, renal function, WBC, serum potassium, serum glucose; monitor for angioedema and anaphylactoid reactions",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13732762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13732875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Antihypertensive effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:  Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13732763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 55% to 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 50% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Enalapril is a prodrug (inactive) and undergoes biotransformation to enalaprilat (active) in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Enalapril:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;\">",
"     CHF: Neonates (n=3, PNA: 10-19 days): 10.3 hours (range: 4.2-13.4 hours) (Nakamura, 1994)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;\">",
"     CHF: Infants and Children &le;6.5 years of age (n=11): 2.7 hours (range: 1.3-6.3 hours) (Nakamura, 1994)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;\">",
"     Healthy Adults: 2 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;\">",
"     CHF: Adults: 3.4-5.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Enalaprilat (active metabolite):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CHF: Neonates (n=3, PNA: 10-19 days): 11.9 hours (range: 5.9-15.6 hours)  (Nakamura, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CHF: Infants and Children &le;6.5 years of age (n=11): 11.1 hours (range: 5.1-20.8 hours)  (Nakamura, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants 6 weeks to 8 months: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 35-38 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Enalapril: Within 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Enalaprilat (active): Within 3-4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Principally in urine (60% to 80%) with some fecal excretion",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13732766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/31/30197?source=see_link\">",
"      see \"Enalapril: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol. Notify physician immediately if swelling of face, lips, tongue, or difficulty in breathing occurs; if these occur, do not take any more doses until a physician can be consulted. Notify physician if vomiting, diarrhea, excessive perspiration, dehydration, or persistent cough occurs. Do not use a salt substitute (potassium-containing) without physician advice. May cause dizziness, fainting, and lightheadedness, especially in first week of therapy; sit and stand up slowly. May cause rash. Report sore throat, fever, other signs of infection, or other side effects. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13732993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypotension was reported in a",
"     <b>",
"      preterm",
"     </b>",
"     neonate (birth weight: 835 g, gestational age: 26 weeks, postnatal age: 9 days) who was treated with enalapril 0.1 mg/kg orally; hypotension responded to I.V. plasma and dopamine; the authors suggest starting enalapril in preterm infants at 0.01 mg/kg and increasing upwards in a stepwise fashion with very close monitoring of blood pressure and urine output. However, in this case report, oral enalapril at doses of 0.01 mg/kg to 0.04 mg/kg did not adequately control blood pressure. Further studies are needed (Schilder, 1995).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F164726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets, Bicitra&reg; [discontinued] or equivalent, and Ora-Sweet&reg; SF. Place ten 20 mg tablets in a 200 mL polyethylene terephthalate bottle; add 50 mL of Bicitra&reg; [discontinued] or equivalent and shake well for at least 2 minutes. Let stand for 1 hour then shake for 1 additional minute; add 150 mL of Ora-Sweet&reg; SF and shake well. Label &ldquo;shake well&rdquo; and \"refrigerate\". Stable for 30 days when stored in a polyethylene terephthalate bottle and refrigerated (Vasotec&reg; prescribing information, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 1 mg/mL oral suspension may be made with tablets and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush six 20 mg tablets in a mortar and reduce to a fine powder. Add 15 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated (Allen, 1998).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 1 mg/mL oral suspension may be made with tablets and one of three different vehicles (deionized water, citrate buffer solution at pH 5.0, or a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;). Crush twenty 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL.  Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Preparations made in citrate buffer solution at pH 5.0 and the 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; are stable for 91 days when stored in plastic prescription bottles in the dark at room temperature or refrigerated. Preparation made in deionized water is stable for 91 days refrigerated or 56 days at room temperature when stored in plastic prescription bottles in the dark.",
"     <b>",
"      Note:",
"     </b>",
"     To prepare the isotonic citrate buffer solution (pH 5.0), see reference (Nahata, 1998).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A more dilute, 0.1 mg/mL oral suspension may be made with tablets and an isotonic buffer solution at pH 5.0. Grind one 20 mg tablet in a glass mortar and reduce to a fine powder; mix with isotonic citrate buffer (pH 5.0) and filter; add quantity of buffer solution sufficient to make 200 mL. Label &ldquo;shake well&rdquo;, &ldquo;protect from light&rdquo;, and \"refrigerate\". Stable for 90 days (Boulton, 1994).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Alprazolam, Chloroquine Phosphate, Cisapride, Enalapril Maleate, and Hydralazine Hydrochloride in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1998, 55(18):1915-20.",
"     <span class=\"pubmed-id\">",
"      9784772",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Boulton DW, Woods DJ, Fawcett JP, et al, &ldquo;The Stability of an Enalapril Maleate Oral Solution Prepared From Tablets,&rdquo;",
"     <i>",
"      Aust J Hosp Pharm",
"     </i>",
"     , 1994, 24(2):151-6.",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Hipple TF, \"Stability of Enalapril Maleate in Three Extemporaneously Prepared Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1998, 55(11):1155-7.",
"     <span class=\"pubmed-id\">",
"      9626379",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Vasotec&reg; prescribing information, Merck &amp; Co, Inc, West Point, PA, 2001.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagga A, Mudigoudar BD, Hari P, et al, \"Enalapril Dosage in Steroid-Resistant Nephrotic Syndrome,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2004, 19(1):45-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/14648339/pubmed\" id=\"14648339\" target=\"_blank\">",
"        14648339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, \"Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 87(6):668-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/20130570/pubmed\" id=\"20130570\" target=\"_blank\">",
"        20130570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown NJ, Ray WA, Snowden M, et al, \"Black Americans Have an Increased Rate of Angiotensin Converting Enzyme Inhibitor-Associated Angioedema,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(1):8-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/8689816/pubmed\" id=\"8689816\" target=\"_blank\">",
"        8689816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bult Y and van den Anker J, &ldquo;Hypertension in a Preterm Infant Treated With Enalapril,&rdquo;",
"      <i>",
"       J Pediatr Pharm Pract",
"      </i>",
"      , 1997, 2(4):229-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chandar J, Abitbol C, Montan&eacute; B, et al, \"Angiotensin Blockade as Sole Treatment for Proteinuric Kidney Disease in Children,\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2007, 22(5):1332-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/17299000/pubmed\" id=\"17299000\" target=\"_blank\">",
"        17299000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delucchi A, Cano F, Rodriguez E, et al, \"Enalapril and Prednisone in Children With Nephrotic-Range Proteinuria,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 14(12):1088-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/11045392/pubmed\" id=\"11045392\" target=\"_blank\">",
"        11045392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dutta S and Narang A, \"Enalapril-Induced Acute Renal Failure in a Newborn Infant,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2003, 18(6):570-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/12698328/pubmed\" id=\"12698328\" target=\"_blank\">",
"        12698328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fitzhugh CD, Wigfall DR, and Ware RE, \"Enalapril and Hydroxyurea Therapy for Children With Sickle Nephropathy,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 45(7):982-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/15704213/pubmed\" id=\"15704213\" target=\"_blank\">",
"        15704213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frenneaux M, Stewart RA, Newman CM, et al, \"Enalapril for Severe Heart Failure in Infancy,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1989, 64(2):219-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/2539059/pubmed\" id=\"2539059\" target=\"_blank\">",
"        2539059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogg RJ, Portman RJ, Milliner D, et al, \"Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(6):1242-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/10835064/pubmed\" id=\"10835064\" target=\"_blank\">",
"        10835064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, \"2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):1-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lama G, Luongo I, Piscitelli A, et al, \"Enalapril: Antiproteinuric Effect in Children With Nephrotic Syndrome,\"",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 2000, 53(6):432-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/10879662/pubmed\" id=\"10879662\" target=\"_blank\">",
"        10879662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leversha AM, Wilson NJ, Clarkson PM, et al, &ldquo;Efficacy and Dosage of Enalapril in Congenital and Acquired Heart Disease,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(1):35-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/8110005/pubmed\" id=\"8110005\" target=\"_blank\">",
"        8110005",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd TR, Mahoney LT, Knoedel D, et al, &ldquo;Orally Administered Enalapril for Infants With Congestive Heart Failure: A Dose-Finding Study,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(4):650-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/2538615/pubmed\" id=\"2538615\" target=\"_blank\">",
"        2538615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Momma K, \"ACE Inhibitors in Pediatric Patients With Heart Failure,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2006, 8(1):55-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/16494512/pubmed\" id=\"16494512\" target=\"_blank\">",
"        16494512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakamura H, Ishii M, Sugimura T, et al, &ldquo;The Kinetic Profiles of Enalapril and Enalaprilat and Their Possible Developmental Changes in Pediatric Patients With Congestive Heart Failure,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 56(2):160-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/8062492/pubmed\" id=\"8062492\" target=\"_blank\">",
"        8062492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sasinka MA, Podracka L, Boor A, et al, \"Enalapril Treatment of Proteinuria in Normotensive Children,\"",
"      <i>",
"       Bratisl Lek Listy",
"      </i>",
"      , 1999, 100(9):476-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/10645036/pubmed\" id=\"10645036\" target=\"_blank\">",
"        10645036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schilder JL and Van den Anker JN, \"Use of Enalapril in Neonatal Hypertension,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 1995, 84(12):1426-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/8645963/pubmed\" id=\"8645963\" target=\"_blank\">",
"        8645963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Mozzettini S, Truttmann AC, et al, &ldquo;Cough is Common in Children Prescribed Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 2000, 84(1):98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/10644922/pubmed\" id=\"10644922\" target=\"_blank\">",
"        10644922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells TG, Bunchman TE, and Kearns GL, \"Treatment of Neonatal Hypertension With Enalaprilat,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 117(4):664-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/2170612/pubmed\" id=\"2170612\" target=\"_blank\">",
"        2170612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White CT, Macpherson CF, Hurley RM, et al, \"Antiproteinuric Effects of Enalapril and Losartan: A Pilot Study,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2003, 18(10):1038-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/18/32040/abstract-text/12920631/pubmed\" id=\"12920631\" target=\"_blank\">",
"        12920631",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83360 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32040=[""].join("\n");
var outline_f31_18_32040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708730\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732756\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732924\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732764\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164720\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164704\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732991\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732874\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732757\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164813\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164810\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732758\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732771\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732759\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164713\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732761\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164716\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164731\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732765\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732762\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732875\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732763\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732766\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732993\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164726\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83360\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83360|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=related_link\">",
"      Enalapril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/31/30197?source=related_link\">",
"      Enalapril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_18_32041="Overview of heavy proteinuria and the nephrotic syndrome";
var content_f31_18_32041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of heavy proteinuria and the nephrotic syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32041/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32041/contributors\">",
"     Ellie Kelepouris, MD, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32041/contributors\">",
"     Brad H Rovin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32041/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32041/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/18/32041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases of the glomerulus can result in three different urinary and clinical patterns: focal nephritic; diffuse nephritic; and nephrotic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focal nephritic &ndash; Disorders resulting in a focal nephritic sediment are generally associated with inflammatory lesions in less than one-half of glomeruli on light microscopy. The urinalysis reveals red cells (which often have a dysmorphic appearance), occasionally red cell casts, and mild proteinuria (usually less than 1.5",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"      The findings of more advanced disease are usually absent, such as heavy proteinuria, edema, hypertension, and renal insufficiency. These patients often present with asymptomatic hematuria and proteinuria discovered on routine examination or, occasionally, with episodes of gross hematuria.",
"     </li>",
"     <li>",
"      Diffuse nephritic &ndash; The urinalysis in diffuse glomerulonephritis is similar to focal disease, but heavy proteinuria (which may be in the nephrotic range), edema, hypertension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal insufficiency may be observed. Diffuse glomerulonephritis affects most or all of the glomeruli.",
"     </li>",
"     <li>",
"      Nephrotic &ndash; The nephrotic sediment is associated with heavy proteinuria and lipiduria, but few cells or casts. The term nephrotic syndrome refers to a distinct constellation of clinical and laboratory features of renal disease. It is specifically defined by the presence of heavy proteinuria (protein excretion greater than 3.5",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours), hypoalbuminemia (less than 3.0",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      and peripheral edema. Hyperlipidemia and thrombotic disease are also frequently observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated heavy proteinuria without edema or other features of the nephrotic syndrome is suggestive of a glomerulopathy (with the same etiologies as the nephrotic syndrome), but is not necessarily associated with the multiple clinical and management problems characteristic of the nephrotic syndrome. This is an important clinical distinction because heavy proteinuria in patients without edema or hypoalbuminemia is more likely to be due to secondary focal segmental glomerulosclerosis (due, for example, to diabetes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of heavy proteinuria and the nephrotic syndrome, with emphasis on those disorders with a nephrotic presentation (ie, bland rather than active urine sediment). More specific issues relating to complications of the nephrotic syndrome are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43829?source=see_link\">",
"     \"Endocrine dysfunction in the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The individual disorders that cause the nephrotic syndrome are discussed in detail in separate topic reviews. Readers will be referred to these individual topics where appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy proteinuria with or without the nephrotic syndrome may occur in association with a wide variety of primary and systemic diseases. Minimal change disease is the predominant cause in children. In adults, approximately 30 percent have a systemic disease such as diabetes mellitus, amyloidosis, or systemic lupus erythematosus; the remaining cases are usually due to primary renal disorders such as minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/2-9\">",
"     2-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of the different forms of nephropathy underlying the nephrotic syndrome in adults was evaluated in a Spanish glomerulonephritis registry of 2000 patients biopsied between the years 1994 and 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/2\">",
"     2",
"    </a>",
"    ]. Among patients between 15 and 65 years of age, the most common causes of nephrotic syndrome were membranous nephropathy (24 percent), minimal change disease (16 percent), lupus (14 percent), focal segmental glomerulosclerosis (12 percent), membranoproliferative glomerulonephritis (7 percent), amyloidosis (6 percent), and IgA nephropathy (6 percent). A similar distribution was observed among the 725 elderly individuals (age greater than 65 years) except for an increased prevalence of amyloidosis (17 percent) and a decreased prevalence of lupus (1 percent).",
"   </p>",
"   <p>",
"    The relative frequency of the different disorders has varied over time in some series as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 233 renal biopsies performed between 1995 and 1997 at the University of Chicago in adults with nephrotic syndrome (in the absence of an obvious underlying disease such as diabetes mellitus or lupus) found the major causes to be membranous nephropathy and focal segmental glomerulosclerosis (33 and 35 percent, respectively), minimal change disease (15 percent), and amyloidosis (4 percent overall, but 10 percent in patients over age 44) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/3\">",
"       3",
"      </a>",
"      ]. Focal segmental glomerulosclerosis accounted for more than 50 percent of cases of nephrotic syndrome in black individuals.",
"      <br/>",
"      <br/>",
"      The frequency of focal segmental glomerulosclerosis was much lower (15 percent) among biopsies for nephrotic syndrome performed at the same institution between 1976 and 1979. The increased prevalence of focal segmental glomerulosclerosis in the 1995 to 1997 series was observed in both black and white individuals.",
"     </li>",
"     <li>",
"      Similar findings were noted in a report from Springfield, Massachusetts, which compared renal biopsies at a single center that were performed in two time periods: 1975-1979 and 1990-1994 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/4\">",
"       4",
"      </a>",
"      ]. Over time, the relative frequency of membranous nephropathy fell from 38 to 15 percent, while the frequency of focal segmental glomerulosclerosis increased from 14 to 25 percent overall; this increase was primarily seen in black and Hispanic patients. The relative incidence of focal segmental glomerulosclerosis also appears to have increased in Brazil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The increase in FSGS is not restricted to black populations. A retrospective analysis of the patterns of glomerular disease a in predominantly white cohort from Minnesota showed a 13-fold increase in FSGS and no change in membranous nephropathy frequency between 1994 and 2003 compared with the interval between 1974 and 1983 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/10\">",
"       10",
"      </a>",
"      ]. Nephrotic proteinuria was present in 80 percent of the patients with FSGS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nephrotic syndrome can also develop in patients with postinfectious glomerulonephritis, membranoproliferative glomerulonephritis, and IgA nephropathy. However, these individuals typically have a \"nephritic\" type of urinalysis with hematuria and cellular (including red cell) casts as a prominent feature. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction and terminology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Minimal change disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal change disease (also called nil disease or lipoid nephrosis) accounts for 90 percent of cases of the nephrotic syndrome in children under the age of 10, and more than 50 percent of cases in older children. It also may occur in adults as an idiopathic condition, in association with the use of nonsteroidal antiinflammatory drugs (NSAIDS), or as a paraneoplastic effect of malignancy, most often Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The terms minimal change and nil disease reflect the observation that light microscopy in this disorder is either normal or reveals only mild mesangial cell proliferation (",
"    <a class=\"graphic graphic_picture graphicRef71232 graphicRef58414 \" href=\"mobipreview.htm?38/16/39178\">",
"     picture 1A-B",
"    </a>",
"    ). Immunofluorescence and light microscopy typically show no evidence of immune complex deposition. The characteristic histologic finding in minimal change disease is diffuse effacement of the epithelial cell foot processes on electron microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Focal segmental glomerulosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal segmental glomerulosclerosis (FSGS) is among the most common lesion found to underlie the idiopathic nephrotic syndrome in adults, accounting for 35 percent of all cases in the United States and over 50 percent of cases among blacks. FSGS is characterized on light microscopy by the presence in some but not all glomeruli (hence the name focal) of segmental areas of mesangial collapse and sclerosis (",
"    <a class=\"graphic graphic_picture graphicRef67677 graphicRef63456 \" href=\"mobipreview.htm?42/20/43338\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/11\">",
"     11",
"    </a>",
"    ]. FSGS can present as an idiopathic syndrome (primary FSGS) or may be associated with HIV infection, reflux nephropathy, healed previous glomerular injury, or massive obesity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Diagnostic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three important diagnostic concerns in FSGS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sampling error",
"     </li>",
"     <li>",
"      Distinguishing primary and secondary FSGS",
"     </li>",
"     <li>",
"      Identifying FSGS associated with collapsing glomerulopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sampling error can easily lead to misclassification of a patient with FSGS as having minimal change disease. Clinical features that are more common in FSGS are hematuria, hypertension, and decreased renal function. There is, however, substantial overlap in these features. In addition to careful review of the renal biopsy, steroid-resistance in a patient considered to have minimal change disease should raise suspicion about FSGS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary FSGS is an epithelial cell disorder that may be related etiologically to minimal change disease; congenital forms also exist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .) In addition, as noted above, FSGS can occur as a secondary response to nephron loss (as is reflux nephropathy) or previous glomerular injury. Differentiating primary and secondary FSGS has important therapeutic implications. The former sometimes responds to immunosuppressive agents such as corticosteroids, while secondary disease is best treated with modalities aimed at lowering the intraglomerular pressure, such as angiotensin converting enzyme inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between primary and secondary FSGS can usually be made from the history (such as one of the disorders associated with secondary disease) and the rate of onset and degree of proteinuria. Patients with primary FSGS typically present with the",
"    <strong>",
"     acute onset of the nephrotic syndrome",
"    </strong>",
"    , whereas slowly increasing proteinuria and renal insufficiency over time are characteristic of the secondary disorders. The proteinuria in secondary FSGS is often nonnephrotic; even when protein excretion exceeds 3 to 4",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    both hypoalbuminemia and edema are unusual.",
"   </p>",
"   <p>",
"    Collapsing FSGS is a histologic variant that is usually but not always associated with HIV infection, bisphosphonate therapy, or systemic lupus erythematosus. Two major features distinguish it from primary FSGS: a tendency toward",
"    <strong>",
"     collapse",
"    </strong>",
"    and sclerosis of the entire glomerular tuft, rather than segmental injury; and often severe tubular injury with proliferative microcyst formation and tubular degeneration (",
"    <a class=\"graphic graphic_picture graphicRef81601 graphicRef59839 \" href=\"mobipreview.htm?38/60/39882\">",
"     picture 3A-B",
"    </a>",
"    ). These patients often have rapidly progressive renal failure and optimal therapy is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Membranous nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy is among the most common cause of primary nephrotic syndrome in adults. It is characterized by basement membrane thickening with little or no cellular proliferation or infiltration, and the presence of electron dense deposits across the glomerular basement membrane (",
"    <a class=\"graphic graphic_picture graphicRef57841 graphicRef74698 graphicRef55226 graphicRef69629 graphicRef62937 graphicRef69348 \" href=\"mobipreview.htm?0/2/33\">",
"     picture 4A-F",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Membranous nephropathy is most often a primary (idiopathic) disorder in adults and a secondary disorder in children. Many cases of idiopathic membranous nephropathy may be due to autoantibodies directed against the phospholipase A2 receptor found on podocytes. Secondary causes include hepatitis B antigenemia, autoimmune diseases, thyroiditis, carcinoma, and the use of certain drugs such as gold,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , and nonsteroidal antiinflammatory drugs. The malignancy in presumed tumor-induced membranous nephropathy has usually been diagnosed or is clinically apparent at the time the proteinuria is discovered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Phospholipase A2 receptor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H16#H16\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted above, amyloidosis accounts for 4 to 17 percent of cases of seemingly idiopathic nephrotic syndrome, with an increased frequency observed among older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There are two major types of renal amyloidosis: AL or primary amyloid, which is a light chain dyscrasia in which fragments of monoclonal light chains form the amyloid fibrils; and AA or secondary amyloidosis, in which the acute phase reactant serum amyloid A forms the amyloid fibrils. AA amyloid is associated with a chronic inflammatory disease such as rheumatoid arthritis or osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is suspected by a history of a chronic inflammatory disease or, with primary disease, detection of a monoclonal paraprotein in the serum or urine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three basic types of proteinuria; glomerular; tubular; and overflow. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the nephrotic syndrome, protein loss is due to glomerular proteinuria, characterized by increased filtration of macromolecules across the glomerular capillary wall. Electrical potential differences generated by transglomerular flow may modulate the flux of macromolecules across the glomerular capillary wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/12\">",
"     12",
"    </a>",
"    ], although other theories exist for the mechanism of glomerular proteinuria.",
"   </p>",
"   <p>",
"    The podocyte appears to be the major target of injury in diseases that cause idiopathic nephrotic syndrome in adults and children (membranous nephropathy, minimal change disease, and FSGS), as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The common ultrastructural phenotype seen in these diseases is podocyte foot process effacement, slit diaphragm disruption, and a relative or absolute depletion of podocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hereditary podocyte injury (eg, in patients with congenital nephrotic syndrome) is due to mutations of podocyte proteins that are important in the maintenance of the slit diaphragm such as nephrin and podocin, or mutations in proteins that affect the integrity of the podocyte cytoskeleton such as alpha-actinin-4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link\">",
"       \"Congenital and infantile nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adult onset idiopathic membranous nephropathy and focal segmental glomerulosclerosis may be due to autoantibodies to podocyte antigens, circulating factors like soluble urokinase-type plasminogen activator receptor that active podocyte integrins, or circulating factors like cytokines or microbial products that may induce podocyte CD80. The engagement or activation of these podocyte proteins alters the arrangement of the slit diaphragm or podocyte cytoskeleton. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H5#H5\">",
"       \"Causes and diagnosis of membranous nephropathy\", section on 'Pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H11#H11\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with nephrotic syndrome, albumin is the principal urinary protein, but other plasma proteins including clotting inhibitors, transferrin, immunoglobulins, and hormone carrying proteins such as vitamin D-binding protein may be lost as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43829?source=see_link\">",
"     \"Endocrine dysfunction in the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypoalbuminemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of hypoalbuminemia in nephrotic patients is not completely understood. Most of albumin loss is due to urinary excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, at the same level of albumin loss, patients with the nephrotic syndrome have a plasma albumin concentration that is approximately 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    lower than patients treated with continuous ambulatory peritoneal dialysis, in which there is significant albumin loss in the dialysate (",
"    <a class=\"graphic graphic_figure graphicRef59892 \" href=\"mobipreview.htm?30/48/31501\">",
"     figure 1",
"    </a>",
"    ). One proposed explanation is that, in patients with nephrotic syndrome, a substantial fraction of the filtered albumin is taken up by and catabolized in the proximal tubular cells, resulting in a much greater degree of albumin loss than estimated from the rate of albumin excretion, although this hypothesis is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic albumin synthesis does increase in response to the albumin loss. This effect is mediated by an increase in hepatic albumin gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/18\">",
"     18",
"    </a>",
"    ] stimulated in part by the low oncotic pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/19\">",
"     19",
"    </a>",
"    ]. Hypoalbuminemia may also lead to the release of an as yet unidentified circulating factor that contributes to the elevation in hepatic albumin synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/20\">",
"     20",
"    </a>",
"    ]. The low oncotic pressure has a second clinically important effect: it increases hepatic lipoprotein synthesis, which plays an important role in the development of hyperlipidemia. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Hyperlipidemia and lipiduria'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It remains unclear why, in a patient excreting 4 or 6 g of protein per day, the liver is usually unable to sufficiently increase albumin synthesis to normalize the plasma albumin concentration. There are patients with nephrotic range proteinuria who have little or no hypoalbuminemia; these patients are more likely to have one of the secondary forms of focal segmental glomerulosclerosis (such as reflux nephropathy) rather than one of the primary nephrotic disorders such as membranous nephropathy or minimal change disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/1\">",
"     1",
"    </a>",
"    ]. One contributory factor may be the release of cytokines in the latter conditions; tumor necrosis factor and interleukin-1, for example, directly suppress hepatic albumin synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H1498484543#H1498484543\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Distinguishing between primary and secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two mechanisms have been proposed to explain the occurrence of edema in the nephrotic syndrome. In some patients, marked hypoalbuminemia leads to egress of fluid into the interstitial space by producing a decrease in plasma oncotic pressure. In most patients however, there is a parallel fall in the interstitial protein concentration and little change in the transcapillary oncotic pressure gradient (",
"    <a class=\"graphic graphic_figure graphicRef74352 \" href=\"mobipreview.htm?26/17/26908\">",
"     figure 2",
"    </a>",
"    ). In the latter patients, edema appears to be the consequence of primary renal sodium retention in the collecting tubules (",
"    <a class=\"graphic graphic_figure graphicRef82649 \" href=\"mobipreview.htm?27/23/28029\">",
"     figure 3",
"    </a>",
"    ) mediated through the epithelial sodium channel and the basolateral Na-K-ATPase (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/22\">",
"     22",
"    </a>",
"    ]. The lack of major arterial underfilling has important implications for diuretic therapy since the excess fluid can usually be removed without inducing volume depletion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperlipidemia and lipiduria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common lipid abnormalities in the nephrotic syndrome are hypercholesterolemia and hypertriglyceridemia. Decreased plasma oncotic pressure appears to stimulate hepatic lipoprotein synthesis resulting in hypercholesterolemia. Diminished clearance may also play a role in the development of hypercholesterolemia. Impaired metabolism is primarily responsible for nephrotic hypertriglyceridemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lipiduria is usually present in the nephrotic syndrome. Urinary lipid may be present in the sediment, entrapped in casts (fatty casts), enclosed by the plasma membrane of degenerative epithelial cells (oval fat bodies), or free in the urine. Under polarized light, the fat droplets have the appearance of a Maltese cross (",
"    <a class=\"graphic graphic_picture graphicRef69603 graphicRef79604 \" href=\"mobipreview.htm?18/28/18883\">",
"     picture 5A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link&amp;anchor=H26#H26\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'The assessment of lipiduria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria and edema are the principal clinical manifestations of the nephrotic syndrome. Interstitial fluid tends to accumulate in dependent areas where tissue turgor is low. Thus periorbital edema upon awakening in the morning and pedal edema are common. Edema is often accompanied by serous effusions when it becomes generalized and massive (anasarca).",
"   </p>",
"   <p>",
"    Less well appreciated manifestations of the nephrotic syndrome include protein malnutrition, hypovolemia, acute kidney injury, urinary loss of hormones, hyperlipidemia and the potential for accelerated atherosclerosis, a tendency to venous or arterial thrombosis, and increased susceptibility to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Protein malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A loss in lean body mass with negative nitrogen balance often occurs in patients with marked proteinuria, although it may be masked by weight gain due to concurrently increasing edema. Protein malnutrition may be compounded by gastrointestinal symptoms of anorexia and vomiting which are secondary to edema of the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic hypovolemia can occur in nephrotic patients, often as a result of over diuresis in those with a serum albumin less than 1.5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Occasional untreated children show signs of volume depletion thought to be due to severe hypoalbuminemia causing fluid movement into the interstitium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury can develop in some patients with the nephrotic syndrome, particularly in older adults with minimal change disease and profound hypoalbuminemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/24\">",
"     24",
"    </a>",
"    ]. The mechanism is not understood; several factors including hypovolemia, interstitial edema, ischemic tubular injury, and the use of nonsteroidal antiinflammatory drugs have been suggested. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two other major settings are collapsing focal glomerulosclerosis, in which the tubular injury is thought to play an important role, and crescentic glomerulonephritis superimposed upon membranous nephropathy, in which the urine sediment becomes active. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the nephrotic syndrome have an increased incidence (10 to 40 percent of patients) of arterial and venous thrombosis (particularly deep vein and renal vein thrombosis) and pulmonary emboli. Cerebral vein thrombosis has also been rarely reported. The mechanism of the hypercoagulability is not completely understood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal vein thrombosis is found disproportionately in patients with membranous nephropathy, particularly those excreting more than 10 g of protein per day. It can present acutely or, much more commonly, in an indolent manner. The acute presentation includes flank pain, gross hematuria, and a decline in renal function. Most patients are asymptomatic, and the diagnosis of renal vein thrombosis is suspected only when pulmonary thromboembolism develops. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\", section on 'Renal vein thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the nephrotic syndrome are susceptible to infection, which was the leading cause of death in children with the nephrotic syndrome before antibiotics became available. Pneumococcal infections, are particularly common, and all patients should receive pneumococcal vaccinations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of the impairment of normal defense mechanisms is not well understood; low levels of immunoglobulin G due to urinary loss may play a role. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications of idiopathic nephrotic syndrome in children\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal tubular dysfunction has been noted in some patients with the nephrotic syndrome, often in association with advanced disease. This can result in glucosuria, aminoaciduria, phosphaturia, bicarbonaturia, and vitamin D deficiency (all features of a proximal renal tubular acidosis). A decrease in thyroxine-binding globulins can cause marked changes in various thyroid function tests, although patients are clinically euthyroid. Anemia, perhaps due to the urinary loss or impaired synthesis of erythropoietin, has also been described in a few patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43829?source=see_link\">",
"     \"Endocrine dysfunction in the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein excretion can be measured on a 24-hour urine collection, with the normal value being less than 150",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Patients excreting more than 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    are considered to have nephrotic-range proteinuria.",
"   </p>",
"   <p>",
"    There is an alternative to the cumbersome 24-hour urine collection: calculating the total protein-to-creatinine ratio",
"    <span class=\"nowrap\">",
"     (mg/mg)",
"    </span>",
"    on a random urine specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/28\">",
"     28",
"    </a>",
"    ]. This ratio correlates closely with daily protein excretion in",
"    <span class=\"nowrap\">",
"     g/1.73",
"    </span>",
"    m2 of body surface area. Thus, a ratio of 4.9 (as with respective urinary protein and creatinine concentrations of 210 and 43",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    represents daily protein excretion of approximately 4.9",
"    <span class=\"nowrap\">",
"     g/1.73",
"    </span>",
"    m2 (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). There are limitations to estimating proteinuria from a random urine specimen, particularly in patients whose daily creatinine generation varies substantially from 1000 mg. We prefer to obtain a 24-hour urine collection in most patients during the initial evaluation of proteinuria. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once it has been determined that the patient has heavy proteinuria, the etiology may be suggested from the history and physical examination. This is particularly true for patients who have a systemic disease such as diabetes mellitus, systemic lupus erythematosus, HIV infection, or have been taking drugs such as nonsteroidal antiinflammatory drugs, interferons, bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , gold, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    . In most cases, however, renal biopsy is required to establish the diagnosis. A review of the findings suggesting that a diabetic patient might have a different form of renal disease is available in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of diabetic nephropathy\", section on 'Nondiabetic renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Serologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of serologic studies often are obtained in the evaluation of patients with the nephrotic syndrome depending upon clinical setting, including antinuclear antibodies (ANA), complement",
"    <span class=\"nowrap\">",
"     (C3/C4",
"    </span>",
"    and total hemolytic complement), serum free light chains and urine protein electrophoresis and immunofixation, syphilis serology, hepatitis B and hepatitis C serologies, and the measurement of cryoglobulins. The value of all of these tests on a routine basis is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32041/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H460668346#H460668346\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Laboratory testing in patients with suspected glomerular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although serologic tests and hypocomplementemia can establish the diagnosis of systemic lupus erythematosus, renal biopsy is still indicated to determine the type of disease that is present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsy is the standard procedure for determining the cause of proteinuria. Pediatric nephrologists often use an initial empiric trial of steroids because of the high incidence of minimal change disease. Most adult nephrologists, however, feel that biopsy is indicated when the etiology of persistent nephrotic range proteinuria is in doubt in order to determine management decisions. In one study of 28 adults with nephrotic range proteinuria, for example, knowledge of the histology altered management in 24 (86 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous renal biopsy is generally contraindicated in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncorrectable bleeding diathesis",
"     </li>",
"     <li>",
"      Small kidneys which are generally indicative of chronic irreversible disease",
"     </li>",
"     <li>",
"      Severe hypertension, which cannot be controlled with antihypertensive medications",
"     </li>",
"     <li>",
"      Multiple, bilateral cysts or a renal tumor",
"     </li>",
"     <li>",
"      Hydronephrosis",
"     </li>",
"     <li>",
"      Active renal or perirenal infection",
"     </li>",
"     <li>",
"      An uncooperative patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also several relative contraindications (eg, solitary kidney). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=see_link&amp;anchor=H10#H10\">",
"     \"Indications for and complications of renal biopsy\", section on 'Relative contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will review the general management issues in patients with nephrotic syndrome (ie, proteinuria, edema, hyperlipidemia, and hypercoagulability).",
"   </p>",
"   <p>",
"    Immunosuppressive therapy in patients with one of the major causes of idiopathic nephrotic syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"     \"Treatment of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of specific therapy directed against the underlying disease, efforts to lower intraglomerular pressure, which may be manifested as a reduction in protein excretion, may slow the rate of disease progression. This is usually achieved by the administration of an angiotensin converting enzyme inhibitor or angiotensin receptor blockers. Potentially adverse effects of these agents include an acute decline in glomerular filtration rate and hyperkalemia; serum creatinine and potassium levels should be measured during the initiation and titration of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although protein restriction also may slow disease progression, the evidence is unclear and this modality is not usually used in nephrotic patients because of the heavy protein losses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=see_link\">",
"     \"Protein restriction and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral edema and ascites is due to primary renal sodium retention in most patients and should be treated with dietary sodium restriction (to approximately 2 g of sodium per day) and diuretics. Edema should be reversed slowly to prevent acute hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"     \"Patient information: Low sodium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loop diuretics are usually required. There generally is a lesser natriuresis than seen in normal patients because of hypoalbuminemia (causing decreased delivery of protein bound drug to the kidney) and albuminuria (binding the drug within the tubular lumen). For these reasons, the diuretic dose often has to be increased. Addition of diuretics that act on different nephron segments may also be useful. An important guide for the evaluation of diuretic therapy is serial measurement of body weight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=see_link\">",
"     \"General principles of the treatment of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipid abnormalities induced by the nephrotic syndrome reverse with resolution of the disease, as with corticosteroid therapy in minimal change disease. The optimal treatment of patients with persistent nephrosis is uncertain. Dietary modification is generally of little benefit. Most patients are initially treated with an HMG CoA reductase inhibitor (statin). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hypercoagulability",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a relatively high incidence of arterial and venous thromboemboli among patients with the nephrotic syndrome; however, this seems to be particularly prevalent in those with membranous nephropathy. If thrombosis occurs, it is typically treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for as long as the patient remains nephrotic. The issue of routine prophylactic anticoagulation in patients with nephrotic syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=see_link\">",
"       \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/2/35875?source=see_link\">",
"       \"Patient information: The nephrotic syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"       \"Patient information: Low sodium diet (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1040244\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nephrotic syndrome is defined by the presence of heavy proteinuria (protein excretion greater than 3.5",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours in an adult), hypoalbuminemia (less than 3.0",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      and peripheral edema. Hyperlipidemia and thrombotic disease may be present. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant cause of the nephrotic syndrome in children is minimal change disease. Approximately 30 percent of adults with the nephrotic syndrome have a systemic disease such as diabetes mellitus, amyloidosis, or systemic lupus erythematosus; the remaining cases are usually due to primary disorders including minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. Heavy proteinuria in patients without edema or hypoalbuminemia is more likely to be due to secondary focal segmental glomerulosclerosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proteinuria and edema are the principal clinical manifestations of the nephrotic syndrome. Other manifestations include protein malnutrition, hypovolemia, acute renal failure, urinary loss of hormones, hyperlipidemia and the potential for accelerated atherosclerosis, a tendency to venous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arterial thromboses and pulmonary embolism, and increased susceptibility to infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proteinuria is due to increased filtration of macromolecules across the glomerular capillary wall. Albumin is the principal urinary protein, but other plasma proteins including clotting inhibitors, transferrin, and hormone carrying proteins such as vitamin D-binding protein may be lost as well. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of heavy proteinuria may be suggested from the history and physical. In most adults, however, a renal biopsy is required to establish the diagnosis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment includes the administration of an angiotensin converting enzyme inhibitor or angiotensin receptor blockers to lower intraglomerular pressure, and dietary sodium restriction and loop diuretics to slowly reduce edema. The lipid abnormalities induced by the nephrotic syndrome usually reverse with resolution of the disease, but most patients are initially treated with an HMG CoA reductase inhibitor (statin). Arterial and venous thromboemboli are typically treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for as long as the patient remains nephrotic. Patients with primary (idiopathic) nephrotic syndrome often receive immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/1\">",
"      Praga M, Borstein B, Andres A, et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991; 17:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/2\">",
"      Rivera F, L&oacute;pez-G&oacute;mez JM, P&eacute;rez-Garc&iacute;a R, Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004; 66:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/3\">",
"      Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/4\">",
"      Braden GL, Mulhern JG, O'Shea MH, et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/5\">",
"      Simon P, Ramee MP, Boulahrouz R, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int 2004; 66:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/6\">",
"      Malafronte P, Mastroianni-Kirsztajn G, Bet&ocirc;nico GN, et al. Paulista Registry of glomerulonephritis: 5-year data report. Nephrol Dial Transplant 2006; 21:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/7\">",
"      Bahiense-Oliveira M, Saldanha LB, Mota EL, et al. Primary glomerular diseases in Brazil (1979-1999): is the frequency of focal and segmental glomerulosclerosis increasing? Clin Nephrol 2004; 61:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/8\">",
"      Gesualdo L, Di Palma AM, Morrone LF, et al. The Italian experience of the national registry of renal biopsies. Kidney Int 2004; 66:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/9\">",
"      Heaf J. The Danish Renal Biopsy Register. Kidney Int 2004; 66:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/10\">",
"      Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006; 1:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/11\">",
"      D'Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int 1994; 46:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/12\">",
"      Hausmann R, Kuppe C, Egger H, et al. Electrical forces determine glomerular permeability. J Am Soc Nephrol 2010; 21:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/13\">",
"      Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/14\">",
"      Sch&ouml;nenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011; 26:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/15\">",
"      Gbadegesin R, Lavin P, Foreman J, Winn M. Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. Pediatr Nephrol 2011; 26:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/16\">",
"      Kaysen GA, Gambertoglio J, Jimenez I, et al. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986; 29:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/17\">",
"      Kaysen GA, Kirkpatrick WG, Couser WG. Albumin homeostasis in the nephrotic rat: nutritional considerations. Am J Physiol 1984; 247:F192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/18\">",
"      Sun X, Martin V, Weiss RH, Kaysen GA. Selective transcriptional augmentation of hepatic gene expression in the rat with Heymann nephritis. Am J Physiol 1993; 264:F441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/19\">",
"      Pietrangelo A, Panduro A, Chowdhury JR, Shafritz DA. Albumin gene expression is down-regulated by albumin or macromolecule infusion in the rat. J Clin Invest 1992; 89:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/20\">",
"      Sun X, Kaysen GA. Albumin and transferrin synthesis are increased in H4 cells by serum from analbuminemic or nephrotic rats. Kidney Int 1994; 45:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/21\">",
"      Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/22\">",
"      Zacchia M, Trepiccione F, Morelli F, et al. Nephrotic syndrome: new concepts in the pathophysiology of sodium retention. J Nephrol 2008; 21:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/23\">",
"      Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 2004; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/24\">",
"      Chen T, Lv Y, Lin F, Zhu J. Acute kidney injury in adult idiopathic nephrotic syndrome. Ren Fail 2011; 33:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/25\">",
"      Vaziri ND, Kaupke CJ, Barton CH, Gonzales E. Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am J Med 1992; 92:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/26\">",
"      Vaziri ND. Endocrinological consequences of the nephrotic syndrome. Am J Nephrol 1993; 13:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/27\">",
"      M&auml;hr N, Neyer U, Prischl F, et al. Proteinuria and hemoglobin levels in patients with primary glomerular disease. Am J Kidney Dis 2005; 46:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/28\">",
"      Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32041/abstract/29\">",
"      Howard AD, Moore J Jr, Gouge SF, et al. Routine serologic tests in the differential diagnosis of the adult nephrotic syndrome. Am J Kidney Dis 1990; 15:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3084 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32041=[""].join("\n");
var outline_f31_18_32041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1040244\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Diagnostic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperlipidemia and lipiduria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Protein malnutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Serologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hypercoagulability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1040244\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3084|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/48/31501\" title=\"figure 1\">",
"      Albumin in nephrosis and CAPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/17/26908\" title=\"figure 2\">",
"      Oncotic pressures in nephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/23/28029\" title=\"figure 3\">",
"      Na handling in nephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/31/12797\" title=\"figure 4\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3084|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/20/12617\" title=\"picture 1A\">",
"      Light microscopy in minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/6/20584\" title=\"picture 1B\">",
"      Electron microscopy in minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/19/9530\" title=\"picture 2A\">",
"      Mild FGS Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/9/8346\" title=\"picture 2B\">",
"      Moderate FGS Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/19/17721\" title=\"picture 3A\">",
"      Light micrograph showing collapsing FGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/33/31256\" title=\"picture 3B\">",
"      HIV nephropathy EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/16/16649\" title=\"picture 4A\">",
"      Membranous Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/42/28321\" title=\"picture 4B\">",
"      Membranous IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/46/39656\" title=\"picture 4C\">",
"      Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/54/25445\" title=\"picture 4D\">",
"      Membranous Silver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/5/32856\" title=\"picture 4E\">",
"      Membranous EM II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/39/39543\" title=\"picture 4F\">",
"      SLE Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/6/29792\" title=\"picture 5A\">",
"      Fatty cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/0/31758\" title=\"picture 5B\">",
"      Fatty cast polarized",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=related_link\" title=\"calculator 1\">",
"      Calculator: Urinary protein excretion estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/10/18598?source=related_link\">",
"      Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25974?source=related_link\">",
"      Complications of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43829?source=related_link\">",
"      Endocrine dysfunction in the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=related_link\">",
"      General principles of the treatment of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/2/35875?source=related_link\">",
"      Patient information: The nephrotic syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=related_link\">",
"      Protein restriction and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=related_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_18_32042="Pathogenetic factors in soft tissue and bone sarcomas";
var content_f31_18_32042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenetic factors in soft tissue and bone sarcomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32042/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32042/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32042/contributors\">",
"     David G Kirsch, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32042/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32042/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/18/32042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/18/32042/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/18/32042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas are malignant tumors arising from skeletal and extraskeletal connective tissues including the peripheral nervous system. Approximately 76 percent arise in soft tissue and the remainder in bone.",
"   </p>",
"   <p>",
"    There is no clearly defined etiology in most cases of soft tissue sarcoma, but a number of associated or predisposing factors have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/1\">",
"     1",
"    </a>",
"    ]. These include a genetic predisposition, gene mutations, radiation therapy (RT), chemotherapy, chemical carcinogens, chronic irritation, and lymphedema. In addition, an association between viral infection and sarcoma has been shown for HIV and human herpesvirus 8 in Kaposi&rsquo;s sarcoma, and for Epstein-Barr virus and smooth muscle tumors in immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC PREDISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients, particularly children, have a familial predisposition to cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Li-Fraumeni syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 7 percent of children with soft tissue sarcomas may have Li-Fraumeni syndrome (LFS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/5\">",
"     5",
"    </a>",
"    ]. In a series of 151 children with soft tissue sarcomas, for example, five of the families (3.3 percent) manifested the classic LFS familial cancer syndrome, 10 (6.6 percent) had features consistent with the syndrome, and 16 (10.5 percent) had one parent with a possible hereditary cancer syndrome or with cancer before the age of 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LFS is inherited as an autosomal dominant trait, and a germline mutation in the p53 tumor suppressor gene is found in most affected families (see",
"    <a class=\"local\" href=\"#H10\">",
"     'p53 gene'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. LFS is primarily characterized by soft tissue and bone sarcomas and breast cancer; other features include brain tumor, leukemia, and adrenocortical cancer occurring before the age of 45. Sarcomas account for 25 percent of tumors in affected individuals, and they arise at a younger age than those unassociated with LFS. In one series of individuals from the IARC database, 96 percent of the sarcomas arising in individuals with LFS arose before the age of 50, compared to 38 percent before 50 years of age in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     FAP and Gardner's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high frequency of intraabdominal desmoid tumors among patients with familial adenomatous polyposis or Gardner's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .) This disorder is characterized by mutations in the APC (adenomatous polyposis coli) gene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7352?source=see_link\">",
"     \"Gardner syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Retinoblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas of soft tissue and bone, particularly osteosarcoma, develop later in life in surviving patients with retinoblastoma (RB), particularly of the familial or bilateral type, in which individuals inherit a mutant copy of RB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The gene itself appears to predispose to second cancers of bone and soft tissue, with RT shortening the latent period and increasing the risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These relationships were illustrated in a longitudinal study of 1601 patients with RB (963 with the inherited type) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. The cumulative frequency of a second cancer at 50 years after diagnosis was significantly different based upon whether the patient had the genetic form of RB (bilateral tumors or unilateral disease with a positive family history) versus nongenetic form of RB (ie, unilateral disease in the absence of a positive family history, due to a somatic mutation) (36 versus 6 percent), and whether the second tumor was associated with RT or not (38 versus 21 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/12\">",
"     12",
"    </a>",
"    ]. More than 60 percent of the cancers were sarcomas.",
"   </p>",
"   <p>",
"    A later publication provided a detailed description of 69 secondary soft tissue sarcomas among 68 children with hereditary RB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/14\">",
"     14",
"    </a>",
"    ]. Almost all of the sarcomas (n = 66) developed in children who had received orbital RT, but 18 did not arise within the irradiated field. The predominant histology was leiomyosarcoma (33 percent), followed by fibrosarcoma, malignant fibrous histiocytoma (MFH), soft tissue",
"    <span class=\"nowrap\">",
"     tumors/sarcomas",
"    </span>",
"    not otherwise specified, rhabdomyosarcoma, and liposarcoma (19, 17, 15, 12, and 4 percent of cases, respectively).",
"   </p>",
"   <p>",
"    There were some major differences between histologic types. Leiomyosarcomas were diagnosed more often outside of the RT field than within it (14 of 23), suggesting that genetic predisposition may have played a more important role than RT. Leiomyosarcoma was also the only histology for which risk was significantly higher among patients receiving chemotherapy plus RT versus RT alone. Furthermore, these were also late developing tumors; 18 were diagnosed more than 30 years after diagnosis (ie, at the same age as individuals in the general population).",
"   </p>",
"   <p>",
"    In contrast, seven of eight secondary rhabdomyosarcomas occurred within the RT field, and seven developed within 20 years of treatment, during a normal growth period.",
"   </p>",
"   <p>",
"    These data underscore the need for long-term surveillance for second cancers in RB survivors, particularly for those with the bilateral or inherited form of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of retinoblastoma\", section on 'Long-term follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurofibromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the multiple benign neurofibromas of von Recklinghausen's disease (type 1 neurofibromatosis, NF1) can undergo malignant change to malignant peripheral nerve sheath tumors (MPNSTs, including neurofibrosarcomas, malignant schwannomas). The specific molecular event(s) underlying the acquisition of invasive growth and metastatic behavior in a benign neurofibroma are unknown. The karyotypic changes seen in MPNSTs are typically complex and not molecularly distinct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among nonneurogenic sarcomas, rhabdomyosarcomas also tend to arise more often in NF1 patients than in the general population. In one series, the risk of developing a malignant peripheral nerve sheath tumor among patients with NF1 was 4.6 percent, compared to 0.001 percent among the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link&amp;anchor=H4#H4\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\", section on 'Inherited syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NF1 is associated with a mutation in the NF1 gene; it has been proposed that malignant degeneration reflects the two-hit hypothesis in which one allele is constitutionally inactivated in the germline while the other allele undergoes somatic inactivation (the second hit). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rothmund-Thomson syndrome (poikiloderma congenitale) is an autosomal recessive condition characterized by a distinctive skin finding (atrophy, telangiectasias, pigmentation), sparse hair, cataracts, small stature, skeletal anomalies, and a significantly increased risk for osteosarcoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H9#H9\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Inherited conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GENETICS AND MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics of sarcomas segregate into two major types: those with specific genetic alterations and usually simple karyotypes, including fusion genes due to reciprocal translocations (eg, PAX3-FKHR in alveolar rhabdomyosarcomas) or specific point mutations (eg, c-kit mutations in gastrointestinal stromal tumors [GIST]), and those with nonspecific genetic alterations and complex, unbalanced karyotypes, reflected by numerous genetic losses and gains (eg, osteosarcoma, MFH, liposarcomas other than the myxoid type, angiosarcoma, leiomyosarcoma).",
"   </p>",
"   <p>",
"    Fusion gene-related sarcomas account for approximately one-third of all sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/18\">",
"     18",
"    </a>",
"    ]. In many cases, the aberrant protein product of the fused gene acts as an abnormal transcriptional regulator, thus providing the molecular basis for oncogenesis. In contrast, the molecular pathogenesis of sarcomas with unbalanced karyotypic complexity has not been definitively proven, but inactivation of the p53 pathway appears to be a main differentiating feature between these tumors and those with simple genetic alterations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/19\">",
"     19",
"    </a>",
"    ]. Among the mechanisms for p53 pathway inactivation are p53 point mutations, homozygous deletion in CDKN2A, and MDM2 amplification (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Somatic gene mutations'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Somatic gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high incidence of acquired (somatic) gene alterations in soft tissue and bone sarcomas. In one study of tumor biopsies of soft tissue sarcomas, for example, the concurrent application of standard cytogenetics and DNA ploidy by flow cytometry identified an abnormal cell population by one or both methods in 84 percent of the tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/20\">",
"     20",
"    </a>",
"    ]. This discussion will focus on those mutations that are seen in soft tissue sarcomas. The degree to which mutations affect prognosis in soft tissue sarcomas, and the molecular pathogenesis of bone sarcomas, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Risk factors and pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\", section on 'Molecular genetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Somatic mutations in specific genes vary across histological subtypes of soft tissue sarcoma. One study performed DNA sequencing of 722 protein-coding genes that have been implicated in cancer in 200 samples of soft tissue sarcomas encompassing seven distinct histological subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/21\">",
"     21",
"    </a>",
"    ]. Frequently mutated genes included the p53 tumor suppressor gene (17 percent of pleomorphic liposarcomas), NF1 (10.5 percent of myxofibrosarcomas and 8 percent of pleomorphic liposarcomas), and PIK3CA (18 percent of",
"    <span class=\"nowrap\">",
"     myxoid/round",
"    </span>",
"    cell liposarcomas). The RB gene was mutated in 4 percent of pleomorphic liposarcomas. DNA amplifications of chromosome 12q were observed in 90 percent of patients with dedifferentiated liposarcomas. Genes amplified in the 12q13-15 amplicon in well differentiated and dedifferentiated liposarcomas include MDM2, HMGA2, YEATS4, CDK4, and SAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/22\">",
"     22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Mutations in the c-kit protooncogene, which are associated with GISTs, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29785294\">",
"    <span class=\"h3\">",
"     NF1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NF1 gene encodes the neurofibromin protein that functions as a Ras-GTPase to suppress the Ras pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Loss of NF1, which occurs in malignant peripheral nerve sheath tumors in NF1 patients, and in a variety of other sporadic soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/21\">",
"     21",
"    </a>",
"    ], activates Ras signaling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29785309\">",
"    <span class=\"h3\">",
"     PI3KCA gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PI3KCA gene encodes for the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which phosphorylates lipids to create second messengers that regulate cell proliferation, survival, and motility. Mutations of PIK3A in",
"    <span class=\"nowrap\">",
"     myxoid/round",
"    </span>",
"    cell liposarcomas are associated with a shorter duration of disease-specific survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     p53 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The p53 protein is a transcriptional activator that plays a key role in the integration of signals inducing cell division, arrest of DNA synthesis following DNA damage, and programmed cell death (apoptosis). DNA damage results in increased levels of p53 protein, which induces cell cycle arrest at the",
"    <span class=\"nowrap\">",
"     G1/S",
"    </span>",
"    interface, thereby permitting the cell to repair genomic damage or to initiate apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The p53 gene also functions as a tumor suppressor gene, and alterations are the most commonly detected mutations in a diverse group of malignancies. The wild-type p53 in normal tissue has a short half-life and is not detectable by immunohistochemical methods; in comparison, mutations of the gene result in a stabilized p53 protein, which accumulates in the cell and often becomes detectable by immunohistochemistry.",
"   </p>",
"   <p>",
"    As noted above, germline mutations in the p53 gene are present in most families with the Li-Fraumeni syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Germline mutations in this gene also may occur in other patients with soft tissue sarcoma, particularly those with other cancers that are not considered indicative of the Li-Fraumeni syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In one study of patients with sarcoma, for example, germline p53 mutations were relatively common (5 of 15) in those with multiple primary cancers or a positive family history of cancer but rare (3 of 185) in those without such a history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/28\">",
"     28",
"    </a>",
"    ]. Germline mutations in p53 also may predispose to sarcoma formation in NF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatic mutations in the p53 gene are the most frequently detected molecular alteration in sporadic soft tissue sarcomas. These mutations have been detected in a variety of soft tissue sarcomas including MFH, leiomyosarcoma, liposarcoma, and rhabdomyosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/32-41\">",
"     32-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    p53 gene mutations are present in approximately one-third of tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ]. In one series of 127 bone and soft tissue sarcomas, 42 had somatic alterations in the p53 gene: one-half were gross rearrangements and one-half were subtle missense or nonsense mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/32\">",
"     32",
"    </a>",
"    ]. Nearly all of the rearrangements and nonsense mutations showed no immunostaining for p53, indicating that this technique fails to identify a significant proportion of tumors with p53 alterations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/33\">",
"     33",
"    </a>",
"    ]. Furthermore, there was staining (usually weak) in 29 percent of the cases without detectable alterations in the p53 gene.",
"   </p>",
"   <p>",
"    Somatic loss of the p53 gene appears to be quite variable in soft tissue sarcomas. Some tumors show a loss of both alleles or a loss of one allele with the remaining allele being either normal or with a point mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/37\">",
"     37",
"    </a>",
"    ]. In a case report, a synovial sarcoma metastasis was composed exclusively of cells bearing a distinct p53 mutation. This same mutation was found as a small clone within the primary tumor, indicating that the metastasis resulted from expansion of a mutant p53 clone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models are consistent with a pathogenetic role for p53 defects in sarcoma development, as suggested by the observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mice deficient for p53 develop a variety of neoplasms including bone and soft tissue sarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Irradiated transgenic mice harboring mutant p53 show higher frequencies of sarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transduction of wild type p53 genes into soft tissue sarcomas bearing mutated p53 genes restores enhanced cell cycle control and suppresses sarcoma growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Restoring p53 function in primary sarcomas in mice lacking p53 causes sarcoma regression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Retinoblastoma gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions or mutations of the tumor suppressor retinoblastoma (RB) gene are critical in the pathogenesis of retinoblastoma and a variety of solid tumors. Even before the RB gene had been identified, it was recognized that some sporadic sarcomas had deletions on chromosome 13 similar to those observed in some patients with retinoblastoma. Alterations in the RB gene are common in soft tissue sarcoma, occurring in up to 70 percent of tumors in some series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. It has been proposed that RB alterations are primary events in human sarcomas and may be involved in tumorigenesis or the early phases of tumor progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/48\">",
"     48",
"    </a>",
"    ]. The RB gene is critical for proper entry into DNA replication and transition through the cell cycle, and mutations are believed to perturb normal cell cycle function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of retinoblastoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MDM2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MDM2 (murine double minute 2 homolog) gene, located at 12q15, is overexpressed in a variety of human tumors including soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Its gene product localizes predominantly to the nucleus, where it acts as an inhibitor of the p53 tumor suppressor gene product. The MDM2 product functions by concealing the activation domain of the p53 protein, thereby inhibiting p53 transcriptional activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 24 soft tissue sarcomas, an alteration in p53 was found in eight tumors and MDM2 amplification in another eight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/56\">",
"     56",
"    </a>",
"    ]. No tumor contained alterations in both genes, which is consistent with the hypothesis that p53 and MDM2 genetic alterations are alternative mechanisms for inactivating the same regulatory pathway for suppressing cell growth. In another study, 22 of 211 soft tissue sarcomas showed increased immunoreactivity to both MDM2 and p53 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/57\">",
"     57",
"    </a>",
"    ]. However, the overexpression of p53 and MDM2 proteins in the nuclei of these cells did not always correlate well with gene amplification at the MDM2 locus or mutation at the p53 gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27167098\">",
"    <span class=\"h3\">",
"     CDK4 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDK4 gene, which encodes a cyclin dependent kinase, occurs in an adjacent amplicon at 12q14. Amplification of CDK4 has been found in a variety of sarcomas including liposarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/22,58,59\">",
"     22,58,59",
"    </a>",
"    ]. The frequent association with MDM2 has suggested a synergistic effect in opposing p53 function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/59\">",
"     59",
"    </a>",
"    ]. A role for CDK4 amplification in the pathogenesis of soft tissue sarcomas is suggested by the fact that knockdown of CDK4 in liposarcoma cell lines or treatment of these cells with a",
"    <span class=\"nowrap\">",
"     CDK4/6",
"    </span>",
"    inhibitor inhibits proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of MDM2 and CDK4 overexpression by immunohistochemical staining may be helpful in diagnosing well-differentiated and dedifferentiated liposarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29785380\">",
"    <span class=\"h3\">",
"     YEATS4 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The YEATS4 gene, which is adjacent to MDM2 at 12q15, is amplified along with MDM2 in well differentiated and dedifferentiated liposarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/22\">",
"     22",
"    </a>",
"    ]. YEATS4 functions as a transcription factor and negatively regulates p53 function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/61\">",
"     61",
"    </a>",
"    ]. Therefore, overexpressed YEATS4 may act in concert with amplified MDM2 to block p53 function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29785395\">",
"    <span class=\"h3\">",
"     HMGA2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HMGA2 (High mobility group-at hook 2) gene is not only amplified with MDM2 in liposarcomas, but also frequently undergoes intragenic or close extragenic rearrangements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/22\">",
"     22",
"    </a>",
"    ]. The product of the HMGA2 gene is a high-mobility group protein that can accumulate on the chromatin of senescent cells to form senescent associated heterochromatic foci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/62\">",
"     62",
"    </a>",
"    ]. The ability of HMGA2 to promote senescence (permanent cell cycle arrest) is cancelled by overexpression of MDM2 and CDK4. Overexpression of HMGA2 has been shown to promote anchorage independent growth, a feature of oncogenic transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     SAS gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gene originally called SAS (sarcoma amplified sequence), now designated tetraspanin 31, is also located at 12q14 and often coamplified with CDK4 in some soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/22,64\">",
"     22,64",
"    </a>",
"    ]. SAS encodes a new member of the transmembrane 4 superfamily of proteins that may function in signal transduction and growth control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/65\">",
"     65",
"    </a>",
"    ]. One study of 12q13-14 amplification in 98 sarcomas found, among others, SAS amplification in 10, MDM2 in nine (eight of which had amplification of SAS), and the CHOP gene (also called DNA damage inducible transcript 3 gene, or GADD153) in four (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Myxoid and round cell liposarcomas'",
"    </a>",
"    below); it was suggested that the target of these amplifications may be an unidentified gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other genes have been associated with soft tissue sarcomas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CD34 protein, the product of the CD34 gene (also called hematopoietic progenitor cell antigen CD34 gene), is expressed on the tumor cells of dermatofibrosarcoma protuberans (DFSP), but only on the vascular cells of malignant fibrohistiocytic lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/67\">",
"       67",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link\">",
"       \"Dermatofibrosarcoma protuberans\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The expression of the HER2 (c-erbB-2) oncogene and the epidermal growth factor receptor is frequently and independently increased in bone and soft tissue sarcomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chromosomal translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a number of soft tissue sarcomas display specific nonrandom chromosomal translocations, which now serve as definitive diagnostic criteria for the tumors in which they occur (",
"    <a class=\"graphic graphic_table graphicRef64666 \" href=\"mobipreview.htm?23/27/23997\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/69\">",
"     69",
"    </a>",
"    ]. Furthermore, these chromosomal abnormalities have been characterized at the molecular level, and many of the chimeric genes have been identified as being important to the biology of these tumors, acting as abnormal transcription factors that deregulate the transcription of multiple downstream genes and pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the identification of these molecular signatures has provided clues as to the molecular alterations that are fundamental for the development and often maintenance of sarcoma. Because these translocations generate fusion proteins that are specific to the sarcoma cell, they are attractive targets for sarcoma therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ewing sarcoma family of tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 85 to 90 percent of Ewing sarcomas and peripheral primitive neuroectodermal tumors (PNETs) display a reciprocal exchange t(11;22) (q24;q12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. In this translocation, the EWS gene from chromosome 22q12 is covalently linked to the ETS family member, FLI-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/73\">",
"     73",
"    </a>",
"    ]. A less common translocation t(21;22) (q22;q12) has also been identified and links EWS to a different ETS family member, ERG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/74\">",
"     74",
"    </a>",
"    ]. In one study, t(11;22) (q24;q12) fusion transcripts were identified in 83 of 87 of Ewing sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/72\">",
"     72",
"    </a>",
"    ]. In this series, 6 of 15 tumors classified as undifferentiated (ie, not Ewing sarcoma) showed fusion transcripts indicating that they might have to be reclassified as",
"    <span class=\"nowrap\">",
"     Ewing/PNET",
"    </span>",
"    tumors.",
"   </p>",
"   <p>",
"    It is thought that the chimeric proteins that result from these translocations act as transcriptional regulators. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1701481\">",
"    <span class=\"h3\">",
"     Desmoplastic small round cell tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rare desmoplastic small round cell tumor contains a characteristic translocation t(11;22) EWSR1-WT1, in which the breakpoints are between the Ewing sarcoma breakpoint region 1 (EWSR1) and a second gene on chromosome 11, WT1. This specific translocation differentiates these tumors from Ewing sarcoma and other small round blue cell tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Myxoid and round cell liposarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxoid and round cell subtypes of liposarcomas share the same reciprocal translocation t(12;16)(q13;p11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In this translocation, the CHOP gene (also called DNA damage inducible transcript 3 gene, or GADD153) is inserted adjacent to a novel gene called FUS or TLS (Translocated in LipoSarcoma). The fusion gene, called TLS-CHOP, shows sequence homology to the Ewing fusion gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. It fails to induce",
"    <span class=\"nowrap\">",
"     G1/S",
"    </span>",
"    arrest, which is one of the functions of the nononcogenic form of CHOP (GADD153) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/79\">",
"     79",
"    </a>",
"    ]. Identification of the fusion gene has been used as a diagnostic aid for these subtypes of liposarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Synovial sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of synovial sarcomas are characterized by the translocation t(x;18)(p11.2;q11.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/80\">",
"     80",
"    </a>",
"    ]. The breakpoint of this translocation fuses the SYT gene from chromosome 18 to one of three homologous genes, SSX1, SSX2, and SSX4 on the X chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Coexpression of two forms of SYT messenger RNA, I-SYT and N-SYT, has been described in both normal tissues and synovial sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/84\">",
"     84",
"    </a>",
"    ]. Although both fuse with SSX, N-SYT fusion products predominate in normal tissues, while the I-SYT isoform is consistently overexpressed in synovial sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SYT-SSX gene is thought to function as an aberrant transcriptional regulator. The nature of the chimeric gene appears to be of prognostic importance, as metastasis-free survival is significantly higher in patients with SYT-SSX2 compared to SYT-SSX1 fusion genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/82,85\">",
"     82,85",
"    </a>",
"    ]. SYT-SSX1 is associated with biphasic tumors (glandular epithelial differentiation on a background of spindle tumor cells), while SYT-SSX2 is associated with monophasic tumors that lack glandular epithelial differentiation. However, not all reports support a worse outcome for patients with biphasic as compared to monophasic histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these cytogenetic changes, constitutive overexpression of bcl-2 (an apoptosis inhibitor) has been identified in almost all samples studied, predominantly within the spindle cell component of synovial sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/87\">",
"     87",
"    </a>",
"    ]. Furthermore, B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (bcl-2) is not phosphorylated in patients undergoing chemotherapy or radiotherapy, suggesting an inability of these cells to activate apoptotic pathways. This may provide an explanation for the limited effectiveness of conventional cytotoxic treatments.",
"   </p>",
"   <p>",
"    Others have reported the coexpression of c-kit and its ligand stem cell factor (SCF), and c-met and its ligand, hepatocyte growth factor (HGF) in synovial sarcomas, predominantly in the epithelial cell component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/88\">",
"     88",
"    </a>",
"    ]. It has been hypothesized that the nonrandom SS translocation t(X:18) triggers the transactivation of a cascade of genes such as c-kit, c-met and their ligands, and that the epithelial differentiation process is driven by the c-met gene, paralleling a shift of the anti-apoptotic role from bcl-2 to the c-kit gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Alveolar rhabdomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alveolar rhabdomyosarcomas (ARMS) have a translocation at t(2;13)(q35;q14) or less often t(1;13)(p36;q14); the corresponding chimeric genes are termed PAX3-FKHR (FKHR is also called the FOXO1 A gene) and PAX7-FKHR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These translocations are associated with overexpression of a fusion product, which is thought to be involved in the pathogenesis of ARMS, although the specific mechanisms are incompletely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to PAX3-FKHR tumors, PAX7-FKHR tumors are more often extremity-located and localized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/93\">",
"     93",
"    </a>",
"    ]. Molecular determination of minimal residual disease in ARMS is possible but the clinical significance of this finding is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Clear cell sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clear cell sarcoma has often been classified as a subtype of melanoma because of the presence of melanin; the older term was \"melanoma of the soft parts.\" These tumors stain immunohistochemically for melanoma markers, and gene expression profiling supports their classification as a distinct genomic subtype of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/95\">",
"     95",
"    </a>",
"    ]. Nevertheless, they are more correctly classified as sarcomas.",
"   </p>",
"   <p>",
"    Cytogenetically most clear cell sarcomas exhibit a translocation at t(12;22) (q13-14;q12), which is not seen in melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. This results in the fusion of the EWS gene (EWSR1) with ATF1, a gene encoding a member of the cyclic AMP-responsive element binding protein (CREB) family of transcription factors. A variant translocation (EWS-CREB1) has been described in clear cell sarcomas arising in the gastrointestinal tract; these tumors lack melanocyte differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hemangiopericytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in the 12q13-15 region have been described in a subgroup of hemangiopericytomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Multiple chromosomal abnormalities have also been seen in some of these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Alveolar soft part sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alveolar soft part sarcomas are highly vascular rare malignant soft tissue tumors that tend to arise on the extremities of adolescents and young adults; some series show a female predilection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/101\">",
"     101",
"    </a>",
"    ]. A characteristic nonreciprocal translocation (derivative or der(17)t(X,17)(p11;q25)) has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. The translocation involves the ASPSCR1 (previously called ASPL) gene on chromosome 17 and the TFE3 gene on the X chromosome, and the ASPSCR1-TFE3 fusion gene is postulated to be involved in the pathogenesis of this tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/104\">",
"     104",
"    </a>",
"    ], possibly by upregulating angiogenesis-related genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/105\">",
"     105",
"    </a>",
"    ]. It is hypothesized that the female predominance is due to their possession of an extra X chromosome, and the fusion gene not being subject to X-inactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Extraskeletal myxoid chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraskeletal myxoid chondrosarcoma (EMC) is a tumor of uncertain histogenesis (despite its name suggesting cartilaginous differentiation) that often presents in the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority are characterized by a unique reciprocal translocation t(9;22) that results in the fusion of the EWS gene on chromosome 22 with a novel gene at 9q22 called NOR1 (also called CHN or TEC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/108-111\">",
"     108-111",
"    </a>",
"    ]. NOR1 encodes the NR4A3 nuclear receptor, the biological function of which is not yet elucidated. The fusion protein appears to function as a transcriptional activator and has been shown to induce cellular transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/112-115\">",
"     112-115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small proportion have a different translocation, either t(9;17) which results in a RBP56-NR4A3 fusion gene and neuroendocrine differentiation in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/116,117\">",
"     116,117",
"    </a>",
"    ], or t(9;15), which results in an",
"    <span class=\"nowrap\">",
"     TCF12/HTF4-NR4A3",
"    </span>",
"    fusion gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     DFSP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatofibrosarcoma protuberans (DFSP) is characterized by a specific nonreciprocal translocation t(17;p22)(q22;q13). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link\">",
"     \"Dermatofibrosarcoma protuberans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29785564\">",
"    <span class=\"h2\">",
"     Chromosomal instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although approximately one-third of all soft tissue sarcomas have a defining translocation as described above, the remaining sarcomas often have a complex karyotype. A positive correlation exists between the number of genomic alterations and the histologic grade of soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/119\">",
"     119",
"    </a>",
"    ]. Because high-grade soft tissue sarcomas have worse outcome, genomic complexity is correlated with more aggressive sarcomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227226#H12227226\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Histologic grade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trend of recent advances is that diagnoses will increasingly be made on the basis of immunohistochemistry, cytogenetics, and gene expression. As an example, molecular assays for specific fusion genes can provide a genetic approach to the differential diagnosis of soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene expression profiling (GEP) by means of DNA microarrays is now being applied to soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/121\">",
"     121",
"    </a>",
"    ]. In one report, transcriptional profiling for 5520 different known genes was used to separate 41 soft tissue sarcomas into five distinct groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/122\">",
"     122",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal stromal tumors (GIST) highly expressed a cluster of 125 genes, which separated them from other sarcomas.",
"     </li>",
"     <li>",
"      Synovial sarcomas expressed a specific cluster of 104 genes, among them, molecules involved in retinoic acid pathways, and the epidermal growth factor receptor.",
"     </li>",
"     <li>",
"      Neural tumors (eg, malignant peripheral nerve sheath tumors).",
"     </li>",
"     <li>",
"      One-half of all leiomyosarcomas, in which 24 specific genes were highly expressed.",
"     </li>",
"     <li>",
"      A broad group, containing all of the liposarcomas, MFH, and the remainder of the leiomyosarcomas, in which molecular profiles were not predicted by histologic features or immunohistochemistry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical utility of such a classification system has been realized only for the GISTs, in which tyrosine kinase-activating c-KIT mutations predict responsiveness to targeted therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the potential for future benefit of improved classification of soft tissue tumors includes better prediction of natural history and patient-tailored therapy based upon the specific targets identified by microarray analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/123\">",
"     123",
"    </a>",
"    ]. For example, a prognostic gene expression signature termed the complexity index in sarcomas (CINSARC) has been developed that includes 67 genes related to mitosis and chromosome management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/119\">",
"     119",
"    </a>",
"    ]. In multivariate analysis, CINSARC predicted metastasis outcome in a training set and in a validation set of 127 independent soft tissue sarcomas. CINSARC was validated as a predictor of metastasis in patients with synovial sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/124\">",
"     124",
"    </a>",
"    ]. Interestingly, chromosomal complexity was more prevalent in adult patients with synovial sarcoma who had worse outcome than pediatric patients with synovial sarcoma. The CINSARC signature had already been shown to be a predictor of clinical outcomes in soft tissue sarcomas, GIST, and other cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RT AND CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is recognized as a cause of sarcoma of bone and soft tissue. The most frequent histopathologic type of radiation-induced soft tissue sarcoma arising in soft tissues is MFH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. Some pathologists no longer use the term MFH and instead call these tumors undifferentiated pleomorphic sarcomas, pleomorphic fibrosarcomas, or pleomorphic myofibroblastic sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/128\">",
"     128",
"    </a>",
"    ]. The frequency increases with the RT dose and with the postradiation observation period and decreases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/129-131\">",
"     129-131",
"    </a>",
"    ]. Sarcoma is primarily a complication of high-dose therapy; it is rarely seen after low doses (&lt;40 Gy). The actuarial frequency at 15 to 20 years is approximately 0.5 percent for RT of normal bone and soft tissue in the adult treated with RT alone to full doses and without chemotherapy.",
"   </p>",
"   <p>",
"    Soft tissue sarcomas, particularly angiosarcoma, are increased in frequency in women undergoing RT for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/132\">",
"     132",
"    </a>",
"    ]. In large series of women who received RT for carcinoma of the breast, the rate of development of soft tissue sarcoma is approximately 0.1 to 0.2 percent at ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/127,133\">",
"     127,133",
"    </a>",
"    ]; most tumors develop around the breast area. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Childhood cancer survivors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of secondary sarcomas is even higher following RT in survivors of childhood cancer. The risk is highest in children who receive both RT and chemotherapy (particularly anthracyclines and alkylating agents), and those who are treated for a primary sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/131,134-139\">",
"     131,134-139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These relationships can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from the UK Registry of Childhood Tumors included a cohort of 13,175 pediatric patients, seen from 1940 to 1983, who had survived for at least three years following treatment of a primary tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/134\">",
"       134",
"      </a>",
"      ]. The estimated 20-year risk for developing bone cancer did not exceed 0.9 percent unless the underlying disease was inherited retinoblastoma (7.2 percent), Ewing sarcoma (5.4 percent), or other malignant bone tumors (2.4 percent). The risk increased linearly with RT dose received to the site of the secondary cancer and higher doses of alkylating agents.",
"     </li>",
"     <li>",
"      In a report of 14,372 participants in the Childhood Cancer Survivor Study who were followed for an average of 18 to 20 years after treatment, a secondary sarcoma developed five or more years after treatment in 108 (0.75 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/138\">",
"       138",
"      </a>",
"      ]. The average latency period was 11 years. Only 56 percent had received RT to the primary anatomic site of the secondary sarcoma. Compared to patients who did not develop a secondary sarcoma, those who did were significantly more likely to have received prior RT (RR 3.1), and to have a primary diagnosis of soft tissue sarcoma (RR 10.1), bone sarcoma (RR 5.6), kidney cancer (RR 6.3), a brain tumor (RR 5.5), or Hodgkin lymphoma (RR 5.4). They were also significantly more likely to have received higher cumulative doses of anthracyclines (RR 2.3) or alkylating agents (RR 2.2), and a history of other secondary neoplasms (RR 2.2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary sarcomas have a poorer prognosis than do de novo sarcomas. As an example, in a comparison of 130 patients with radiation-associated soft tissue sarcomas with a matched cohort of sporadic sarcomas, patients with a secondary sarcoma had significantly worse disease specific survival (HR 1.7, range 1.1- 2.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/140\">",
"     140",
"    </a>",
"    ]. For MFH, five year disease specific survival was 44 percent for patients with radiation-associated sarcomas compared to 66 percent for patients with sporadic MFH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these patients warrant aggressive treatment, as secondary sarcomas are potentially curable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/125,141-146\">",
"     125,141-146",
"    </a>",
"    ]. In a report of 80 patients with histologically verified sarcomas within a previously irradiated field, overall survival rates at two and five years were 69 and 39 percent for patients undergoing surgery, versus 10 and 0 percent for those treated with chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     INDUSTRIAL CHEMICALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of inherent problems in occupational epidemiology with small numbers of patients in any given series and the difficulty in isolating a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/147\">",
"     147",
"    </a>",
"    ]. For these reasons, few associations can be considered established and causal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/148\">",
"     148",
"    </a>",
"    ]. As examples, there is a clear association between vinyl chloride or arsenic exposure and hepatic angiosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/149,150\">",
"     149,150",
"    </a>",
"    ] and a probable association between phenoxy herbicides and soft tissue sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/151-153\">",
"     151-153",
"    </a>",
"    ]. The last risk may be greater with exposure to phenoxy herbicides contaminated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or higher chlorinated dioxins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/154,155\">",
"     154,155",
"    </a>",
"    ]. A role for dioxin per se is controversial. A population-based case control study, however, found no increased risk for soft tissue sarcoma among Vietnam veterans, including those exposed to Agent Orange, which contains dioxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High intensity chlorophenol exposure in jobs involving wood preservation, machinists and the use of cutting fluids may increase the risk of soft tissue sarcoma, independent of phenoxy herbicides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/152,157\">",
"     152,157",
"    </a>",
"    ]. However, some studies have not confirmed this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     CHRONIC EDEMA, CHRONIC IRRITATION, AND TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas of soft tissue (primarily lymphangiosarcomas) may be observed following massive and quite protracted edema. This has classically been seen in the postmastectomy, lymphedematous arm (Stewart-Treves syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/158,159\">",
"     158,159",
"    </a>",
"    ]. It has also been described with chronic lymphedema due to filarial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/160\">",
"     160",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link&amp;anchor=H802871855#H802871855\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Lymphangiosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic irritation secondary to foreign bodies also may be a factor in the induction of sarcomas. We have observed one patient in whom a fibrosarcoma appeared at 15 years at the site of a plastic tube insertion through the scalp for control of hydrocephalus. Trauma may also be a factor in the development of soft tissue sarcomas including desmoid tumors. In an occasional patient, there is a history of major trauma to the affected site many months prior to the appearance of local symptoms of tumor. The usual history is of a traumatic incident occurring shortly prior to the awareness of the mass. Clinicians often explain this sequence of events that the trauma merely brought the patient's attention to the presence of the mass. However, injury has been shown to promote sarcoma development in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/161,162\">",
"     161,162",
"    </a>",
"    ]. Therefore, additional study is needed in patients to determine whether injury promotes sarcomagenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15141964\">",
"    <span class=\"h1\">",
"     VIRAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections are rarely associated with the development of sarcomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human immunodeficiency virus and human herpesvirus 8 have been implicated in the pathogenesis of Kaposi's sarcoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link&amp;anchor=H4#H4\">",
"       \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\", section on 'Anti-HHV-8 antibodies and viremia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      EBV-associated smooth muscle tumors have been described in patients with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      and in other immunocompromised hosts (eg, solid organ transplant, NK cell deficiency) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/18/32042/abstract/163-166\">",
"       163-166",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=see_link&amp;anchor=H12#H12\">",
"       \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\", section on 'Classical NK cell deficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91679590\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clearly defined etiology in most cases of soft tissue sarcoma, but a number of associated or predisposing factors have been identified. These include familial predisposition (Li-Fraumeni syndrome, familial adenomatous polyposis, retinoblastoma, and neurofibromatosis), gene mutations, radiation therapy (RT), chemotherapy, chemical carcinogens, chronic irritation, and lymphedema. In addition, viruses, including human immunodeficiency virus and human herpesvirus 8, have been implicated in the pathogenesis of Kaposi's sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=see_link\">",
"     \"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a high incidence of acquired (somatic) gene alterations in soft tissue and bone sarcomas. Somatic mutations in specific genes vary across histological subtypes of soft tissue sarcoma. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Somatic gene mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of soft tissue sarcomas display specific nonrandom chromosomal translocations, which now serve as definitive diagnostic criteria for the tumors in which they occur (",
"    <a class=\"graphic graphic_table graphicRef64666 \" href=\"mobipreview.htm?23/27/23997\">",
"     table 1",
"    </a>",
"    ). Furthermore, the identification of these molecular signatures has provided clues as to the molecular alterations that are fundamental for the development and often maintenance of sarcoma. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Chromosomal translocations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Radiation therapy (RT) is recognized as a cause of sarcomas of soft tissue and bone. The frequency increases with the RT dose and with the postradiation observation period and decreases with age. The risk of a radiation-induced sarcoma is particularly high in survivors of childhood cancer, and highest in children who receive both RT and chemotherapy (particularly anthracyclines and alkylating agents), and those who are treated for a primary sarcoma. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Childhood cancer survivors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sarcomas of soft tissue (primarily lymphangiosarcomas) may be observed following massive and quite protracted edema. This has classically been seen in the postmastectomy, lymphedematous arm, and is termed Stewart-Treves syndrome. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Chronic edema, chronic irritation, and trauma'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/1\">",
"      Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/2\">",
"      Li FP. Cancer families: human models of susceptibility to neoplasia--the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 1988; 48:5381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/3\">",
"      Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/4\">",
"      Hartley AL, Birch JM, Blair V, et al. Patterns of cancer in the families of children with soft tissue sarcoma. Cancer 1993; 72:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/5\">",
"      Carnevale A, Lieberman E, C&aacute;rdenas R. Li-Fraumeni syndrome in pediatric patients with soft tissue sarcoma or osteosarcoma. Arch Med Res 1997; 28:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/6\">",
"      Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997; 3:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/7\">",
"      Varley JM, McGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997; 57:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/8\">",
"      Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 1993; 66:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/9\">",
"      Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012; 118:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/10\">",
"      Hizawa K, Iida M, Mibu R, et al. Desmoid tumors in familial adenomatous polyposis/Gardner's syndrome. J Clin Gastroenterol 1997; 25:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/11\">",
"      DerKinderen DJ, Koten JW, Nagelkerke NJ, et al. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer 1988; 41:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/12\">",
"      Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/13\">",
"      Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/14\">",
"      Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007; 99:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/15\">",
"      Brekke HR, Ribeiro FR, Kolberg M, et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol 2010; 28:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/16\">",
"      Mertens F, Rydholm A, Bauer HF, et al. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer 1995; 61:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/17\">",
"      Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/18\">",
"      Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003; 9:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/19\">",
"      Ladanyi M, Bridge JA. Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol 2000; 31:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/20\">",
"      Mohamed AN, Zalupski MM, Ryan JR, et al. Cytogenetic aberrations and DNA ploidy in soft tissue sarcoma. A Southwest Oncology Group Study. Cancer Genet Cytogenet 1997; 99:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/21\">",
"      Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/22\">",
"      Italiano A, Bianchini L, Keslair F, et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008; 122:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/23\">",
"      Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990; 63:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/24\">",
"      Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990; 63:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/25\">",
"      el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/26\">",
"      Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/27\">",
"      Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/28\">",
"      Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992; 326:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/29\">",
"      Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992; 326:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/30\">",
"      McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994; 12:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/31\">",
"      Vogel KS, Klesse LJ, Velasco-Miguel S, et al. Mouse tumor model for neurofibromatosis type 1. Science 1999; 286:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/32\">",
"      Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52:6194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/33\">",
"      Wadayama B, Toguchida J, Yamaguchi T, et al. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993; 68:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/34\">",
"      Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992; 140:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/35\">",
"      Soini Y, V&auml;h&auml;kangas K, Nuorva K, et al. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J Pathol 1992; 168:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/36\">",
"      Stratton MR, Moss S, Warren W, et al. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 1990; 5:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/37\">",
"      Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A 1990; 87:5863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/38\">",
"      Patterson H, Gill S, Fisher C, et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 1994; 69:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/39\">",
"      Andreassen A, Oyjord T, Hovig E, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993; 53:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/40\">",
"      Blom R, Guerrieri C, St&acirc;l O, et al. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998; 68:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/41\">",
"      Simms WW, Ord&oacute;&ntilde;ez NG, Johnston D, et al. p53 expression in dedifferentiated chondrosarcoma. Cancer 1995; 76:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/42\">",
"      Pollock RE, Lang A, Luo J, et al. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 1996; 12:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/43\">",
"      Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/44\">",
"      Lee JM, Abrahamson JL, Kandel R, et al. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 1994; 9:3731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/45\">",
"      Pollock R, Lang A, Ge T, et al. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res 1998; 4:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/46\">",
"      Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/47\">",
"      Cance WG, Brennan MF, Dudas ME, et al. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990; 323:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/48\">",
"      Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995; 72:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/49\">",
"      Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst 1991; 83:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/50\">",
"      Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/51\">",
"      Fl&oslash;renes VA, Maelandsmo GM, Forus A, et al. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/52\">",
"      Khatib ZA, Matsushime H, Valentine M, et al. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993; 53:5535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/53\">",
"      Nilbert M, Rydholm A, Will&eacute;n H, et al. MDM2 gene amplification correlates with ring chromosome in soft tissue tumors. Genes Chromosomes Cancer 1994; 9:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/54\">",
"      Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/55\">",
"      Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/56\">",
"      Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/57\">",
"      Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/58\">",
"      Kanoe H, Nakayama T, Murakami H, et al. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. Anticancer Res 1998; 18:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/59\">",
"      Pilotti S, Della Torre G, Lavarino C, et al. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol 1998; 185:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/60\">",
"      Aleixo PB, Hartmann AA, Menezes IC, et al. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 2009; 62:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/61\">",
"      Llanos S, Efeyan A, Monsech J, et al. A high-throughput loss-of-function screening identifies novel p53 regulators. Cell Cycle 2006; 5:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/62\">",
"      Narita M, Narita M, Krizhanovsky V, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006; 126:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/63\">",
"      Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/64\">",
"      Smith SH, Weiss SW, Jankowski SA, et al. SAS amplification in soft tissue sarcomas. Cancer Res 1992; 52:3746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/65\">",
"      Jankowski SA, Mitchell DS, Smith SH, et al. SAS, a gene amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of proteins. Oncogene 1994; 9:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/66\">",
"      Forus A, Fl&oslash;renes VA, Maelandsmo GM, et al. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ 1993; 4:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/67\">",
"      Aiba S, Tabata N, Ishii H, et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br J Dermatol 1992; 127:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/68\">",
"      Duda RB, Cundiff D, August CZ, et al. Growth factor receptor and related oncogene determination in mesenchymal tumors. Cancer 1993; 71:3526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/69\">",
"      Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003; 3:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/70\">",
"      Ladanyl M, Heinemann FS, Huvos AG, et al. Neural differentiation in small round cell tumors of bone and soft tissue with the translocation t(11;22)(q24;q12): an immunohistochemical study of 11 cases. Hum Pathol 1990; 21:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/71\">",
"      Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/72\">",
"      Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/73\">",
"      Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993; 12:4481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/74\">",
"      Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/75\">",
"      Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/76\">",
"      Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/77\">",
"      Hisaoka M, Tsuji S, Morimitsu Y, et al. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Diagn Mol Pathol 1998; 7:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/78\">",
"      Aman P, Ron D, Mandahl N, et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992; 5:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/79\">",
"      Barone MV, Crozat A, Tabaee A, et al. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev 1994; 8:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/80\">",
"      dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 2001; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/81\">",
"      Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/82\">",
"      Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/83\">",
"      Agus V, Tamborini E, Mezzelani A, et al. Re: A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 2001; 93:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/84\">",
"      Tamborini E, Agus V, Mezzelani A, et al. Identification of a novel spliced variant of the SYT gene expressed in normal tissues and in synovial sarcoma. Br J Cancer 2001; 84:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/85\">",
"      Inagaki H, Nagasaka T, Otsuka T, et al. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 2000; 13:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/86\">",
"      Paulino AC. Synovial sarcoma prognostic factors and patterns of failure. Am J Clin Oncol 2004; 27:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/87\">",
"      Mancuso T, Mezzelani A, Riva C, et al. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 2000; 80:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/88\">",
"      Tamborini E, Papini D, Mezzelani A, et al. c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases. Br J Cancer 2001; 85:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/89\">",
"      Barr FG, Nauta LE, Hollows JC. Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 1998; 102:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/90\">",
"      Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1997; 94:8047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/91\">",
"      Ginsberg JP, Davis RJ, Bennicelli JL, et al. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 1998; 58:3542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/92\">",
"      Linardic CM, Naini S, Herndon JE 2nd, et al. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res 2007; 67:6691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/93\">",
"      Kelly KM, Womer RB, Sorensen PH, et al. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997; 15:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/94\">",
"      Kelly KM, Womer RB, Barr FG. Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase-polymerase chain reaction method. Cancer 1996; 78:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/95\">",
"      Segal NH, Pavlidis P, Noble WS, et al. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol 2003; 21:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/96\">",
"      Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993; 4:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/97\">",
"      Coindre JM, Hostein I, Terrier P, et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group. Cancer 2006; 107:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/98\">",
"      Antonescu CR, Nafa K, Segal NH, et al. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res 2006; 12:5356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/99\">",
"      Mandahl N, Orndal C, Heim S, et al. Aberrations of chromosome segment 12q13-15 characterize a subgroup of hemangiopericytomas. Cancer 1993; 71:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/100\">",
"      Sreekantaiah C, Bridge JA, Rao UN, et al. Clonal chromosomal abnormalities in hemangiopericytoma. Cancer Genet Cytogenet 1991; 54:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/101\">",
"      Bu X, Bernstein L. A proposed explanation for female predominance in alveolar soft part sarcoma. Noninactivation of X; autosome translocation fusion gene? Cancer 2005; 103:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/102\">",
"      Heimann P, Devalck C, Debusscher C, et al. Alveolar soft-part sarcoma: further evidence by FISH for the involvement of chromosome band 17q25. Genes Chromosomes Cancer 1998; 23:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/103\">",
"      Joyama S, Ueda T, Shimizu K, et al. Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: A case report and review of the literature. Cancer 1999; 86:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/104\">",
"      Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001; 20:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/105\">",
"      Lazar AJ, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007; 13:7314.",
"     </a>",
"    </li>",
"    <li>",
"     WHO: Cartilage tumours. In: World health organization classification of tumours. Pathology and genetics - Tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F (Eds), 2002. p.234.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/107\">",
"      Drilon AD, Popat S, Bhuchar G, et al. Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer 2008; 113:3364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/108\">",
"      Brody RI, Ueda T, Hamelin A, et al. Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma. Am J Pathol 1997; 150:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/109\">",
"      Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 2004; 16:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/110\">",
"      Hirabayashi Y, Ishida T, Yoshida MA, et al. Translocation (9;22)(q22;q12). A recurrent chromosome abnormality in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet 1995; 81:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/111\">",
"      Stenman G, Andersson H, Mandahl N, et al. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer 1995; 62:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/112\">",
"      Labelle Y, Bussi&egrave;res J, Courjal F, Goldring MB. The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. Oncogene 1999; 18:3303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/113\">",
"      Filion C, Motoi T, Olshen AB, et al. The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol 2009; 217:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/114\">",
"      Hisaoka M, Hashimoto H. Extraskeletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. Pathol Int 2005; 55:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/115\">",
"      Filion C, Labelle Y. The oncogenic fusion protein EWS/NOR-1 induces transformation of CFK2 chondrogenic cells. Exp Cell Res 2004; 297:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/116\">",
"      Panagopoulos I, Mertens F, Isaksson M, et al. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer 2002; 35:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/117\">",
"      Attwooll C, Tariq M, Harris M, et al. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma. Oncogene 1999; 18:7599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/118\">",
"      Sj&ouml;gren H, Wedell B, Meis-Kindblom JM, et al. Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21). Cancer Res 2000; 60:6832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/119\">",
"      Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010; 16:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/120\">",
"      Barr FG, Chatten J, D'Cruz CM, et al. Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 1995; 273:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/121\">",
"      Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/122\">",
"      Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002; 359:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/123\">",
"      Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/124\">",
"      Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013; 31:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/125\">",
"      Wiklund TA, Blomqvist CP, R&auml;ty J, et al. Postirradiation sarcoma. Analysis of a nationwide cancer registry material. Cancer 1991; 68:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/126\">",
"      Davidson T, Westbury G, Harmer CL. Radiation-induced soft-tissue sarcoma. Br J Surg 1986; 73:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/127\">",
"      Taghian A, de Vathaire F, Terrier P, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991; 21:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/128\">",
"      Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003; 163:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/129\">",
"      Kim JH, Chu FC, Woodard HQ, et al. Radiation-induced soft-tissue and bone sarcoma. Radiology 1978; 129:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/130\">",
"      Robinson E, Neugut AI, Wylie P. Clinical aspects of postirradiation sarcomas. J Natl Cancer Inst 1988; 80:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/131\">",
"      Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998; 77:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/132\">",
"      Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 2001; 92:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/133\">",
"      Karlsson P, Holmberg E, Johansson KA, et al. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996; 38:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/134\">",
"      Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/135\">",
"      Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/136\">",
"      Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005; 103:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/137\">",
"      Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/138\">",
"      Henderson TO, Whitton J, Stovall M, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2007; 99:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/139\">",
"      Newton WA Jr, Meadows AT, Shimada H, et al. Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 1991; 67:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/140\">",
"      Gladdy RA, Qin LX, Moraco N, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol 2010; 28:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/141\">",
"      Lagrange JL, Ramaioli A, Chateau MC, et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the F&eacute;d&eacute;ration Nationale des Centres de Lutte Contre le Cancer. Radiology 2000; 216:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/142\">",
"      Kalra S, Grimer RJ, Spooner D, et al. Radiation-induced sarcomas of bone: factors that affect outcome. J Bone Joint Surg Br 2007; 89:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/143\">",
"      Cha C, Antonescu CR, Quan ML, et al. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/144\">",
"      Inoue YZ, Frassica FJ, Sim FH, et al. Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue. J Surg Oncol 2000; 75:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/145\">",
"      Chapelier AR, Bacha EA, de Montpreville VT, et al. Radical resection of radiation-induced sarcoma of the chest wall: report of 15 cases. Ann Thorac Surg 1997; 63:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/146\">",
"      Bacci G, Longhi A, Forni C, et al. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. Int J Radiat Oncol Biol Phys 2007; 67:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/147\">",
"      Sathiakumar N, Delzell E. A review of epidemiologic studies of triazine herbicides and cancer. Crit Rev Toxicol 1997; 27:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/148\">",
"      Dich J, Zahm SH, Hanberg A, Adami HO. Pesticides and cancer. Cancer Causes Control 1997; 8:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/149\">",
"      Lee FI, Smith PM, Bennett B, Williams DM. Occupationally related angiosarcoma of the liver in the United Kingdom 1972-1994. Gut 1996; 39:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/150\">",
"      Lander JJ, Stanley RJ, Sumner HW, et al. Angiosarcoma of the liver associated with Fowler's solution (potassium arsenite). Gastroenterology 1975; 68:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/151\">",
"      Hardell L, Eriksson M. The association between soft tissue sarcomas and exposure to phenoxyacetic acids. A new case-referent study. Cancer 1988; 62:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/152\">",
"      Wingren G, Fredrikson M, Brage HN, et al. Soft tissue sarcoma and occupational exposures. Cancer 1990; 66:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/153\">",
"      Vineis P, Faggiano F, Tedeschi M, Ciccone G. Incidence rates of lymphomas and soft-tissue sarcomas and environmental measurements of phenoxy herbicides. J Natl Cancer Inst 1991; 83:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/154\">",
"      Kogevinas M, Becher H, Benn T, et al. Cancer mortality in workers exposed to phenoxy herbicides, chlorophenols, and dioxins. An expanded and updated international cohort study. Am J Epidemiol 1997; 145:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/155\">",
"      Fingerhut MA, Halperin WE, Marlow DA, et al. Cancer mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. N Engl J Med 1991; 324:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/156\">",
"      The association of selected cancers with service in the US military in Vietnam. II. Soft-tissue and other sarcomas. The Selected Cancers Cooperative Study Group. Arch Intern Med 1990; 150:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/157\">",
"      Hoppin JA, Tolbert PE, Herrick RF, et al. Occupational chlorophenol exposure and soft tissue sarcoma risk among men aged 30-60 years. Am J Epidemiol 1998; 148:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/158\">",
"      Stewart FW, Treves N. Classics in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin 1981; 31:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/159\">",
"      Tomita K, Yokogawa A, Oda Y, Terahata S. Lymphangiosarcoma in postmastectomy lymphedema (Stewart-Treves syndrome): ultrastructural and immunohistologic characteristics. J Surg Oncol 1988; 38:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/160\">",
"      Muller R, Hajdu SI, Brennan MF. Lymphangiosarcoma associated with chronic filarial lymphedema. Cancer 1987; 59:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/161\">",
"      Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 1990; 248:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/162\">",
"      Martins-Green M, Boudreau N, Bissell MJ. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res 1994; 54:4334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/163\">",
"      Purgina B, Rao UN, Miettinen M, Pantanowitz L. AIDS-Related EBV-Associated Smooth Muscle Tumors: A Review of 64 Published Cases. Patholog Res Int 2011; 2011:561548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/164\">",
"      Cheuk W, Li PC, Chan JK. Epstein-Barr virus-associated smooth muscle tumour: a distinctive mesenchymal tumour of immunocompromised individuals. Pathology 2002; 34:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/165\">",
"      Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995; 332:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/18/32042/abstract/166\">",
"      McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995; 332:12.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7737 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32042=[""].join("\n");
var outline_f31_18_32042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91679590\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC PREDISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FAP and Gardner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurofibromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GENETICS AND MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Somatic gene mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29785294\">",
"      - NF1 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29785309\">",
"      - PI3KCA gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - p53 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Retinoblastoma gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MDM2 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27167098\">",
"      - CDK4 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29785380\">",
"      - YEATS4 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29785395\">",
"      - HMGA2 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - SAS gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chromosomal translocations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1701481\">",
"      - Desmoplastic small round cell tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Myxoid and round cell liposarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Synovial sarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Alveolar rhabdomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Clear cell sarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hemangiopericytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Alveolar soft part sarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Extraskeletal myxoid chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - DFSP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29785564\">",
"      Chromosomal instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RT AND CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Childhood cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      INDUSTRIAL CHEMICALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      CHRONIC EDEMA, CHRONIC IRRITATION, AND TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15141964\">",
"      VIRAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91679590\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7737|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/27/23997\" title=\"table 1\">",
"      Selected translocations in sarcomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis?source=related_link\">",
"      Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_18_32043="Neuro complications of hypothy";
var content_f31_18_32043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the neurologic manifestations of hypothyroidism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardinal features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myxedema coma",
"       </td>",
"       <td>",
"        Decreased mental status, bradycardia, hypothermia, hypotension, others",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive impairment",
"       </td>",
"       <td>",
"        Slowed mentation, poor concentration and short-term memory",
"       </td>",
"       <td>",
"        Common in overt hypothyroidism; uncertain in subclinical hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellar ataxia",
"       </td>",
"       <td>",
"        Gait most often affected, limb and speech involvement can occur",
"       </td>",
"       <td>",
"        Uncertain; early studies suggest 10 to 30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carpal tunnel syndrome",
"       </td>",
"       <td>",
"        Pain, numbness, weakness in median nerve distribution",
"       </td>",
"       <td>",
"        Common 25 to 33 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"       <td>",
"        Predominantly sensory, often painful",
"       </td>",
"       <td>",
"        Common, but rarely the presenting symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myopathy",
"       </td>",
"       <td>",
"        Ranges from asymptomatic serum CK elevation to cramps and myalgias to more disabling proximal muscle weakness",
"       </td>",
"       <td>",
"        Common in at least one form",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32043=[""].join("\n");
var outline_f31_18_32043=null;
var title_f31_18_32044="Differential diagnosis of pulmonary infiltrate";
var content_f31_18_32044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common radiographic appearances of pulmonary disorders in HIV patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Chest radiograph or CT abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiology by rate of disease progression",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiology by rate of disease progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Acute &lt;24 hrs*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consolidation",
"       </td>",
"       <td>",
"        Any organism (especially bacteria)",
"       </td>",
"       <td>",
"        <p>",
"         Fungi",
"        </p>",
"        <p>",
"         Nocardia spp, Actinomyces spp",
"        </p>",
"        <p>",
"         Mycobacteria",
"        </p>",
"        <p>",
"         Bronchoalveolar cancer",
"        </p>",
"        <p>",
"         Bronchiolitis obliterans organizing pneumonia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse interstitial infiltrate",
"       </td>",
"       <td>",
"        <p>",
"         P. jirovecii",
"        </p>",
"        <p>",
"         Bacteria (especially H. influenzae)",
"        </p>",
"        <p>",
"         Virus (Influenza, CMV)",
"        </p>",
"        <p>",
"         Pulmonary edema",
"        </p>",
"        <p>",
"         Acute respiratory distress syndrome",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mycobacteria",
"        </p>",
"        <p>",
"         Drug toxicity",
"        </p>",
"        <p>",
"         Lymphocytic interstitial pneumonia",
"        </p>",
"        <p>",
"         Metastatic disease",
"        </p>",
"        <p>",
"         Pulmonary alveolar proteinosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nodular infiltrate",
"       </td>",
"       <td>",
"        <p>",
"         Bacteria",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nocardia spp, Actinomyces spp",
"        </p>",
"        <p>",
"         Fungi",
"        </p>",
"        <p>",
"         Kaposi's sarcoma",
"        </p>",
"        <p>",
"         Other tumors (especially lung cancer)",
"        </p>",
"        <p>",
"         Castleman's Disease",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenopathy",
"       </td>",
"       <td>",
"       </td>",
"       <td>",
"        <p>",
"         Lymphoma",
"        </p>",
"        <p>",
"         Kaposi's sarcoma",
"        </p>",
"        <p>",
"         Castleman's Disease",
"        </p>",
"        <p>",
"         Lung cancer",
"        </p>",
"        <p>",
"         Tuberculosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural effusion",
"       </td>",
"       <td>",
"        <p>",
"         Bacteria (parapneumonic)",
"        </p>",
"        <p>",
"         Tuberculosis",
"        </p>",
"        <p>",
"         Empyema",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lymphoma (especially non-Hodgkin's lymphoma and primary effusion lymphoma)",
"        </p>",
"        <p>",
"         Kaposi's sarcoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax",
"       </td>",
"       <td>",
"        P. jirovecii",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Some infections that are typically chronic may appear acutely with immune recovery/reconstitution.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32044=[""].join("\n");
var outline_f31_18_32044=null;
var title_f31_18_32045="Low dose step up gonadotropins";
var content_f31_18_32045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Step-up protocol for ovulation induction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 199px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the low-dose, step-up protocol of gonadotropin administration for ovulation induction. The initial subcutaneous or intramuscular dose of FSH is 37.5 to 75 IU/day; the dose is increased only if, after 14 days, no response is documented on ultrasonography and serum estradiol monitoring. Increments of 37.5 IU then are given at weekly intervals up to a maximum of 225 IU/day. Detection of an ovarian response is an indication to continue the current dose until hCG can be given to stimulate ovulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32045=[""].join("\n");
var outline_f31_18_32045=null;
var title_f31_18_32046="ACC AHA Rx systolic HF";
var content_f31_18_32046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81590%7ECARD%2F80859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81590%7ECARD%2F80859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management of adults with current or prior symptoms of heart failure (HF) and a reduced left ventricular ejection fraction (LVEF) (HF stage C)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Diuretics and salt restriction for fluid retention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Angiotensin converting enzyme (ACE) inhibitors in all patients, unless contraindicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Beta blockers in all stable patients, unless contraindicated. One of the three beta blockers proven to reduce mortality should be used (bisoprolol, carvedilol, and sustained release metoprolol succinate).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Angiotensin II receptor blockers (ARBs) in patients who do not tolerate ACE inhibitors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Drugs that can adversely affect the patient's clinical status should be avoided or withdrawn, if possible. These include nonsteroidal antiinflammatory drugs, most antiarrhythmic drugs, and most calcium channel blockers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Exercise training as an adjunctive approach to improve clinical status in ambulatory patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; An implantable cardioverter-defibrillator (ICD) for secondary prevention to prolong survival in patients with a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; An ICD for primary prevention to reduce total mortality by preventing sudden cardiac death (SCD) in patients with non-ischemic or ischemic heart disease who meet the following criteria: at least 40 days post-myocardial infarction, an LVEF &le;35 percent, New York Heart Association functional class II or III symptoms despite optimal chronic medical therapy, and a reasonable expectation of survival with a good functional status for more than one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Cardiac resynchronization therapy (CRT), with or without an ICD, unless contraindicated, in patients who meet the following criteria: cardiac dyssynchrony as defined by a QRS duration &gt;120 msec, LVEF &le;35 percent, sinus rhythm, and New York Heart Association functional class III or ambulatory class IV symptoms despite optimal medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who can be carefully monitored for preserved renal function and normal potassium concentration. Creatinine should be &le;2.5 mg per dL in men or &le;2.0 mg per dL in women and potassium should be &lt;5.0 mEq per liter. Under circumstances in which monitoring for hyperkalemia and renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone antagonists.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The combination of hydralazine and nitrates is recommended to improve outcomes for patients self-described as African-Americans, with moderate-severe symptoms on optimal therapy with ACE inhibitors, beta blockers, and diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence and/or opinion is in favor of the following approaches being effective in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; It is reasonable to treat patients with atrial fibrillation and HF with a strategy to maintain sinus rhythm or with a strategy to control ventricular rate alone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; ARBs as an alternative to ACE inhibitors as first-line therapy in patients with mild to moderate HF, particularly those already taking an ARB for other indications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Digitalis in patients with current or prior symptoms of HF to reduce hospitalization for HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The addition of the combination of hydralazine and a nitrate in patients with persistent symptoms who are already taking an ACE inhibitor and beta blocker.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; CRT with or without an ICD is reasonable in patients with an LVEF of &le;35 percent, a QRS &ge;0.12 seconds, and atrial fibrillation who have New York Heart Association functional class III or ambulatory class IV symptoms symptoms despite optimal chronic medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; CRT is reasonable in patients with an LVEF of &le;35 percent who have New York Heart Association functional class III or ambulatory class IV symptoms despite optimal medical therapy and who have frequent dependence of ventricular pacing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence and/or opinion is less well established for the following approaches in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The combination of hydralazine and a nitrate in patients who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Addition of an ARB in patients with persistent symptoms who are already being treated with an ACE inhibitor, beta blocker, and diuretics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approaches are not effective and may be harmful in the management of patients with current or prior symptoms of HF and a reduced LVEF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine use of triple therapy with an ACE inhibitor, an ARB, and an aldosterone receptor antagonist is not recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Routine administration of calcium channel blockers is not indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Long-term infusion of a positive inotropic drug may be harmful and is not recommended, except as palliation for end-stage disease that cannot be stabilized with standard medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Nutritional supplements are not indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Hormonal therapies may be harmful and are not recommended unless given to replete hormone deficiencies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management of concomitant diseases in patients with heart failure (HF)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that the following approaches are effective for the management of concomitant diseases in patients with HF.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  All recommendations for HF therapy should apply to patients with concomitant disorders unless there are specific exceptions.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       &bull;  Treatment of concomitant diseases:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Control of systolic and diastolic hypertension according to current guidelines.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. Control of diabetes mellitus according to current guidelines.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. Nitrates and beta blockers for the treatment of angina.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       4. Coronary revascularization for angina according to current guidelines.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       5. Anticoagulation for paroxysmal or persistent atrial fibrillation or a previous thromboembolic event.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       6. Control of the ventricular response in patients with atrial fibrillation with a beta blocker (or amiodarone if the beta-blocker is contraindicated or not tolerated).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       7. Treatment of coronary artery disease according to current guidelines.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       8. Antiplatelet agents for prevention of MI and death in patients with coronary artery disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approaches for the management of concomitant diseases in patients with HF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Control the ventricular response in patients with atrial fibrillation with digitalis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Amiodarone to decrease recurrence of atrial arrhythmias and recurrence of implantable cardioverter-defibrillator discharge for ventricular arrhythmias.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following approaches for the management of concomitant diseases in patients with HF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Restoration and maintenance of sinus rhythm in patients with atrial fibrillation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Anticoagulation in the absence of atrial fibrillation or a previous thromboembolic events.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Enhancing erythropoiesis in patients with anemia.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that the following approaches are not useful or may be harmful for the management of concomitant diseases in patients with HF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Class I or III antiarrhythmic drugs to prevent ventricular arrhythmias.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Antiarrhythmic drugs as primary treatment of asymptomatic ventricular arrhythmias or to improve survival.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32046=[""].join("\n");
var outline_f31_18_32046=null;
var title_f31_18_32047="Common causes pneumonia child";
var content_f31_18_32047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54228%7EPEDS%2F71263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54228%7EPEDS%2F71263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common etiologic agents of pediatric pneumonia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Microbial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Susceptible hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &ge;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydophila pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &ge;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Treponema pallidum",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycoplasma hominis",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Ureaplasma urealyticum",
"        </em>",
"       </td>",
"       <td>",
"        First 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus pyogenes",
"        </em>",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory syncytial virus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza A and B",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parainfluenza 1, 2, and 3",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhinovirus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human metapneumovirus",
"       </td>",
"       <td>",
"        Primarily children &lt;5 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excluding neonatal pneumonia (in infants &lt;28 days of age).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Klein JO, Bacterial pneumonias, In: Textbook of Pediatric Infectious Diseases, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, McIntosh K, N Engl J Med 2002; 346:429, Gaston B, Pediatr Rev 2002; 23:132, Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Disease, Feigin BD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, and Sandora T, Harper MB. Pediatr Clin North Am 2005; 52:1059.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Less common etiologic agents of pediatric pneumonia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Microbial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Susceptible hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        (typeable and non-typeable)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Moraxella catarrhalis",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"        (often group Y)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Klebsiella",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Enterobacter",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Burkholderia cepacia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Achromobacter xylosoxidans",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Stenotrophomonas maltophilia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Legionella pneumophila",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas pseudomallei",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Francisella tularensis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (rabbits) or insect vector; bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Brucella abortus",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (cattle, goats)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydophila psittaci",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (parakeets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Leptospira",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Yersinia pestis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir or insect vector (rats); bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaerobic mouth flora (",
"        <em>",
"         Prevotella",
"        </em>",
"        spp., Fusobacterium,",
"        <em>",
"         Bacteroides",
"        </em>",
"        spp.)",
"       </td>",
"       <td>",
"        Aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas, contact with known TB, homeless, recent immigrants from endemic areas, prisoners, and HIV-infected individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nontuberculous mycobacterium",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Bordetella pertussis",
"        </em>",
"       </td>",
"       <td>",
"        Infants, exposure to adult with a cough illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        (typeable and non-typeable)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Moraxella catarrhalis",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"        (often group Y)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Klebsiella",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Enterobacter",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts, nosocomial pathogen, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Burkholderia cepacia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Achromobacter xylosoxidans",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Stenotrophomonas maltophilia",
"        </em>",
"       </td>",
"       <td>",
"        Cystic fibrosis patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Legionella pneumophila",
"        </em>",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pseudomonas pseudomallei",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Francisella tularensis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (rabbits) or insect vector; bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Brucella abortus",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (cattle, goats)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Chlamydophila psittaci",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (parakeets)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Leptospira",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Yersinia pestis",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir or insect vector (rats); bioterrorist activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaerobic mouth flora (",
"        <em>",
"         Prevotella",
"        </em>",
"        spp., Fusobacterium,",
"        <em>",
"         Bacteroides",
"        </em>",
"        spp.)",
"       </td>",
"       <td>",
"        Aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas, contact with known TB, homeless, recent immigrants from endemic areas, prisoners, and HIV-infected individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nontuberculous mycobacterium",
"       </td>",
"       <td>",
"        Cystic fibrosis patients, immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Bordetella pertussis",
"        </em>",
"       </td>",
"       <td>",
"        Infants, exposure to adult with a cough illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Coccidioides immitis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas (southwest United States)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Histoplasma capsulatum",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas (Ohio and Mississippi River valley)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Blastomyces dermatitidis",
"        </em>",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas (Ohio and Mississippi River valley)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Candida",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Nosocomial pathogen, immunocompromised hosts, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Aspergillus",
"        </em>",
"        spp.",
"       </td>",
"       <td>",
"        Nosocomial pathogen, immunocompromised hosts, cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Pneumocystis jiroveci",
"        </em>",
"        (formerly",
"        <em>",
"         carinii",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Rickettsiae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Coxiella burnetii",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular animal reservoir (sheep)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Rickettsia rickettsii",
"        </em>",
"       </td>",
"       <td>",
"        Exposure to a particular insect vector",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rubeola",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Immunocompromised hosts, first 3 months of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus",
"       </td>",
"       <td>",
"        Immunocompromised hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coronavirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterovirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rubella",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hantavirus",
"       </td>",
"       <td>",
"        Travelers to or residents of endemic areas, exposure to a particular animal reservoir (mouse droppings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mumps",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bocavirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parechovirus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avian influenza",
"       </td>",
"       <td>",
"        Exposure to birds; travel to affected area",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excluding neonatal pneumonia (in infants &lt;28 days of age).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Klein JO, Bacterial pneumonias, In: Textbook of Pediatric Infectious Diseases, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, McIntosh K, N Engl J Med 2002; 346:429, Gaston B, Pediatr Rev 2002; 23:132, Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Disease, Feigin BD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004, and Sandora T, Harper MB. Pediatr Clin North Am 2005; 52:1059.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_18_32047=[""].join("\n");
var outline_f31_18_32047=null;
